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ABSTRACT 
 
The goal of this body of research was to elucidate the mechanism by which CD4+ T cells 
provide help for CD8+ cytotoxic T lymphocyte (CTL) responses in different immunization types. 
The establishment of diseases, such as chronic infections and cancers, is attributed to severe loss 
of or dysfunctions of CD4+ T cells. Even in acute infections, CD4+ T cell deficiency leads to 
poor memory responses. While the role of CD4+ T cells is being increasingly appreciated in 
these diseases, the timing and nature of CD4+ T help and associated molecular mechanisms are 
not completely understood. Growing evidence suggests that, depending on the type of infections 
or immunizations, the requirements of CD4+ T cells can vary for optimal CD8+ CTL responses. 
In order to understand the modulatory effects of CD4+ T cells for optimal CD8+ CTL responses, 
two distinct immunization types were chosen. These include: 1) non-inflammatory dendritic cell 
(DC) immunization, which fails to provide inflammatory/danger signals; and 2) inflammatory 
adenovirus (AdV) immunization, which provides profound inflammatory/danger signals. This 
allowed us to study CD4+ T cell’s participation under different inflammatory conditions.  
The studies described in Chapters 2 and 3 of this thesis were performed to further 
understand the concept of how CD4+ T cells mediate optimal CD8+ CTL responses. This has 
been called the “new dynamic model of CD4+ T helper – antigen (Ag)-presenting cells (Th-
APCs),” proposed in 2005 by our laboratory. The study described in Chapter 2 shows that Th-
APCs participate not only in augmenting CTL-mediated immune responses, perhaps during early 
phase, but also in regulating cellular immunity, perhaps during a later phase. Through enhanced 
IL-2, CD80 and CD40L singnaling, and weaker peptideMHC I (pMHC) signaling, Th-APCs 
stimulated naïve CD8+ T cells to differentiate into effector CTLs, capable of developing into, 
central memory CTLs. Th-APC-stimulated CD4+ T cells behaved like Th cells in function, 
augmenting the overall magnitude of CTL responses. In contrast, Th-APCs were able to kill DCs 
and other Th-APCs, predominantly through perforin-mediated pathway. The experiments 
described in Chapter 3 revealed a novel co-operative role of cognate Th-CTL interactions, 
contrary to previously known immune-regulatory mechanisms among Th-Th or CTL-CTL 
interactions. In our experiments, Th cells, via CD40L, IL-2, and acquired pMHC-I signaling, 
enhanced CTL survival and transition into functional memory CTLs. Moreover, RT-PCR, flow 
cytometry and western blot analysis demonstrate that increased survival of Th cell-helped CTLs 
is matched with enhanced Akt1/NF-κB activation, down-regulation of FasL and TRAIL, and 
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altered expression profiles with up-regulation of prosurvival (Bcl-2) and down-regulation of 
proapoptotic (NFATc1, Bcl-10, Casp-3, Casp-4, Casp-7) genes/ molecules. Finally, helped CTLs 
were also able to induce protection against highly metastasizing tumor challenge, explaining why 
memory CTLs generated under cognate Th1’s help show survival and recall advantages.    
The studies in Chapter 4 showed how the precursor frequency (PF) of CD8+ T cells 
impacts CD4+ T helper requirements for functional CTL responses. At endogenous PF, CD4+ T 
helper signals were necessary for both primary and memory CTL responses. At increased PF, 
CD4+ T help, and its CD40L but not IL-2 signal became dispensable for primary CTL responses. 
In contrast, memory CTL responses required CD4+ T cell signals, largely in the form of IL-2 and 
CD40L. Thus, these results could impact the development of novel immunotherapy against 
cancers, since their efficacy would be determined in part by CD4+ T help and CD8+ T cell PF.                
Finally, the study showed the importance of CD4+ T cells for multiple phases of AdV 
transgene product-specific CTL responses. These include: a) cognate CD4+ T cells enhanced 
CTL responses via IL-2 and CD40L signaling during primary, maintenance and memory phases; 
b) polyclonal CD4+ T environment enhanced the survival of AdV-specific CTL survival, 
partially explaining protracted CTL contraction phase; and c) during the recall phase, the CD4+ T 
environment, particularly memory CD4+ T cells, considerably enhanced not only helped, but also 
unhelped, memory CTL expansion. Thus, these results suggest the participation of both cognate 
and polyclonal CD4+ T cells for multiple phases of AdV-specific CTLs. 
Taken together, the current work delineated the critical roles of CD4+ T cells in different 
stages of CTL responses and in the development of anti-tumor immunity. The results presented 
here will significantly advance our current understanding of immunity to cancers, autoimmunity 
and chronic infections, since pathogenesis of these diseases is largely determined by CD4+ T 
helper functions. As most immunization procedures use the principle that is based on functions 
of memory cells, the knowledge gained from this work will also have a major impact on 
designing vaccines against intractable diseases, including cancers and chronic infections. 
Moreover, in advanced tumors, vaccines developed using this knowledge may act synergistically 
with other cancer treatments such as irradiation, chemotherapy and microsurgery, minimizing 
their side effects and prolonging the lives of patients. 
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CHAPTER 1 
1. Introduction, literature review, hypothesis and objectives  
1.1 General overview 
In this ‘manuscript style’ of thesis, the entire project work is presented in Chapters 2 to 5, 
each of which has its own hypothesis and objectives leading to achieve a common goal of the 
thesis. In the beginning, an introduction and a general literature review pertaining to the subject 
of the thesis leading to hypothesis and objectives of the thesis in its entirety are given. 
Subsequently, each chapter containing relevant literature review, introduction, materials and 
methods, results and discussion is presented. The style of all these chapters has been uniformly 
maintained irrespective of journals considered for publication. At the end, a general discussion of 
the thesis in its entirety is given.    
1.2 Introduction to aspects of the immune system relevant to this thesis  
Following entry of foreign substances, usually infectious pathogens, our body responds in 
a collective and coordinated way to eliminate the foreign substance. This defensive response is 
called the ‘immune response/immunity.’ Our immune system is made up of various immune 
cells and their secretary products. Based on immune cells’ origin, location and functions, 
immune system is broadly divided into three parts (1). It includes primary lymphoid organs (fetal 
liver, thymus and adult bone marrow). These are sites of lymphocyte maturation where pre-B 
and pre-T lymphocytes mature into native B and T lymphocytes, respectively, in the absence of 
foreign antigen (Ag). Immune system also includes secondary lymphoid organs [lymph nodes 
(LNs), spleen, tonsils and mucosal-associated lymphoid tissues]. These organs harbor B and T 
lymphocytes and are strategically located in anatomically distinct areas, where Ag-presenting 
cells (APCs) presenting peptides of invading microbes accumulate and activate rare Ag-specific 
lymphocytes to initiate adaptive immunity and development of long-lived protective immunity. 
Immune system further includes tertiary lymphoid organs (eg. inducible bronchus-associated 
lymphoid tissues). These are ectopic collections of lymphoid cells that generate in non-lymphoid 
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organs when chronic inflammation occurs as a result of autoimmunity, microbial infection, and 
graft rejection (2).  
1.3 Classification of Immunity 
Based on Ag specificity and the nature of different immune responses, our immunity is 
broadly classified into innate and adaptive immunity.  
1.3.1 Innate Immunity 
Innate immunity is a potent non-specific protection that prevents or limits infections 
caused by most pathogens. It provides the immediate line of defense and is targeted towards 
structures that are frequent in related groups of pathogens. Essentially, this immunity responds 
similarly to repeated pathogen invasions. The main components of innate immune system are 
(3): 1) physical and chemical barriers (skin, mucosal epithelia and antimicrobial chemicals); 2) 
cells [phagocytes, mainly neutrophils and Ag-presenting cells [(APCs) – B cells, dendritic cells 
(DCs) and macrophages], and natural killer (NK) cells]; and 3) blood proteins (complements and 
inflammatory mediators, such as cytokines).         
1.3.1.1 APCs: DCs  
The specialized components of innate immunity that play a critical role in the initiation 
and development of adaptive immunity is called ‘APCs’. Among various APCs, DCs are 
regarded as professional APCs since they play a crucial role in induction and control of adaptive 
immune responses. DCs are distinct from other APCs in that they sometimes possess dendritic 
morphology, show elevated expression of major histocompatibility complex (MHC) I and II 
molecules as well as co-stimulatory molecules [cluster of differentiation (CD)40, CD80, CD86 
and CD54], exhibit motility, and most importantly, convert from Ag-capturing status to a T cell 
sensitizing status (called ‘maturation’) (4). After 40 years since their discovery, it is now 
confirmed that DCs possess characteristic T cell sensitizing properties and control many aspects 
of immunity, forming a bridge between the innate and adaptive immune responses.    
DCs form a physical link between skin/mucosae (periphery) and secondary lymphoid 
systems where they capture harmful pathogens in the periphery and induce the immune response 
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in the secondary lymphoid organs by activating T cells. Upon phagocytosing pathogens, DCs 
secrete important cytokines, principally type I interferons (IFNs) and tumor necrotic factor 
(TNF)-α.  They also produce nitric oxide, and mediate antiviral defense mechanisms and NK cell 
activation (5). To achieve these functions, DCs undergo a definitive maturation process where 
they (in immature status) capture invaded pathogens, rearrange cytoskeleton structures to down-
regulate their phagocytic activity, process and present Ags to T cells (6). The functions of DCs 
can vary depending on time, location and type of pathogens involved. For instance, in bacterial 
and parasitic infections, DCs are biased towards inducing the T helper (Th) 2 response and 
humoral immunity (7). In contrast, in intracellular pathogen infections, they mainly induce Th1 
and/or Th17 responses and cellular immunity (7). In addition to acting as a physiological 
adjuvant in initiating innate and adaptive immunity, DCs also play a pivotal role in inducing 
central and peripheral tolerance (8, 9).   
1.3.1.1.1 DC subsets  
DC subsets have different propensities to reside in particular tissues. Their variable 
phenotypes endow them with distinct capabilities to ensure optimal tissue-specific immunity 
although some functions can overlap. The different DC subsets are classified based on their 
phenotype. Their specialized functions are described below. 
A. Conventional DCs (cDCs): These are DCs present in the secondary lympoid organs (also 
called as ‘resident DCs’). Based on the expression of CD4 and CD8α markers, cDCs are divided 
into three subsets (10); CD11c+CD8α+ DCs, CD11c+CD8α-CD4+ DCs and CD11c+CD8α-CD4- 
DCs. All cDCs are derived from a common precursor, reside in the spleen in an immature state, 
and perform screening of blood-born pathogens (11). The composition of these subsets varies 
with the type of lymphoid organs. For instance, LNs do not contain CD4+DCs but largely 
possess CD4-CD8- DCs (12). cDCs in LNs capture Ag either from migratory DCs, or from 
lymphatic conduits.   
a) CD8+ DCs  
These DCs bear the CD8α+, CD205+, CD24+ and CD11b- antigenic markers. They have 
been extensively studied owing to their crucial functions in the immune system. During steady 
 4
state when body is not challenged by foreign entities (such as pathogens), these cells play a 
crucial role in establishing peripheral tolerance to self Ags (9). Unlike other resident DCs, CD8+ 
DCs typically present in T cell areas of the spleen and LN (13), where they get maturation 
(licensing) signals from CD4+ T cells during intracellular pathogen infections and cross-present 
Ags to CD8+ T cells (14). Although most DC subsets cross-present exogenous Ag on MHC I 
molecules, CD8+ DCs possess exceptional ability, suggesting their key roles in viral diseases (14-
16). They express high levels of toll-like receptor (TLR)-3 but not TLR7, suggesting they are 
specialized for protection against dsRNAs viruses (17). Following infection, CD8+ DCs show up-
regulation of MHC Ags and co-stimulatory molecules, and secrete interleukin (IL)-12p70, which 
in turn induces CD4+ Th1, and CD8+ primary and memory cytotoxic T lymphocyte (CTL) 
generation (18). These cDCs are also chiefly responsible for clearing apoptotic bodies from the 
blood (19).  
b) CD8- DCs   
These DCs are characterized by their absence of CD8α and CD24 and the presence of the 
33D1 and CD11b markers. They are the most abundant cDCs in the spleen (~80% of DC 
population) but are only present in low levels in LNs. Unlike CD8+ cDCs, which reside in T cell 
areas, CD8- cDCs reside in the marginal zones of the LN and spleen. CD8- cDC activity is 
dependent on the presence of the C-C chemokine receptor (CCR6) and macrophage 
inflammatory protein (MIP)-3α. They are specialized for Ag-presentation to CD4+ T cells (20). 
In contrast to CD8+ cDCs, CD8- cDCs express principally TLR7 but not TLR3. Following LPS 
or other TLR agonists, CD8- cDCs secrete large amounts of the inflammatory chemokine 
RANTES, MIP-1αβ and MIP-1β and migrate to T cell areas (18).     
B Plasmatoid-derived DCs (pDCs)  
These DCs, in immature status, have a plasmacytoid shape, and contain round eccentric 
nucleus. They also have a distinct gene expression profile compared to cDCs (12). pDCs are 
phenotypically Ly6C/Gr-1+, B220+, CD11clow/int, 120G8+, MHCIlow, MHCII- and CD4+. They 
express low levels of co-stimulatory molecules (21-23). In mice, pDCs are present in the blood, 
 5
thymus, bone marrow, liver and lymphoid organs. pDCs play an important role in pathogen 
surveillance, including against bacterial, viral and certain TLR agonists. 
C Migratory DCs  
These include dermis-derived DCs, epidermis-derived Langerhans DCs (LDCs), and 
CD103+ DCs. The CD103+ DCs usually reside in the periphery (skin and mucosal layers). LDCs 
possess longer processes, contain characteristic Birbeck granules (made of langerin), and express 
the surface marker Ag, CD207+ (langerin). Langerin is a type II transmembrane cell surface 
receptor that known to helps in non-classical Ag-processing pathway (23). LDCs reside in the 
epidermis of skin and stratified squamous epithelia in the pharynx, upper esophagus, vagina and 
external cervix. They have the potential to convert into DCs following Ag encounter (24). 
Dermal-derived Langerin+ DCs are CD103+ and play a crucial role in cross-presentation of self 
and viral Ags (12). Dermal classic DCs are CD11b+ langerin- and reside in the dermis of skin. 
D Resident DCs  
These DCs are CD11chiCD45RAloMHC-IIint, immature steady-state cDCs, and are further 
divided into CD8α+ DCs and CD8α– DCs. CD8α– DCs make up the majority of the CD4+ DC 
population (20). A detailed description of these DC subsets has been described above.  
E Circulating DCs  
These DCs act as circulating sentinels against blood-borne pathogens. These include 
some pre-DCs, such as pDCs and Ly6Chi monocytes, CD11c+B220+ pDCs, and CD11c+MHCII– 
pre-DCs or Ly6Clo monocytes. These DCs are regarded as poor presenters of Ags to T cells 
although some researchers reported otherwise (20). Whether DX5+ NK cells, which are CD11c+, 
also possess DC characteristics is not known. Monocytes are chief components of the circulating 
DCs and possess the capacity to enter from the blood stream to organs to initiate innate immune 
responses. Limited studies have also shown that they can differentiate into CD11c+MHCII+ DCs 
in the presence of granulocyte macrophage- colony-stimulating factor (GM-CSF), with or 
without IL-4 during inflammation (20). However, under steady state, they form important 
sources of DCs in skin (Langerhans cells) and mucosa (lamina propria of the gastrointestinal, 
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respiratory, and urogenital tracts) (25). During inflammation, monocytes also provide defense 
against pathogens by linking both adaptive and innate immune responses (25). They activate 
cognate CD4+ T cells and cross-prime CD8+ T cells during viral, bacterial, and parasitic 
infections. 
F Interstitial DCs   
These comprise of the dermal DCs of skin and DCs of the mucosae. Interstitial DCs are 
similar to LCs with some differences. Upon encountering foreign Ags, these DCs migrate to 
draining lymphoid organs and show as CD11cintMHC-IIhi DEC-205int DCs (26). They play 
important roles in some cutaneous viral infections and in immune-regulation. 
G Inflammatory TNF-α inducible nitric oxide synthase (iNOS)-producing DCs (Tip DCs)  
Under the influence of GM-CSF and CCR2, these DCs develop and produce high levels 
of TNF-α and iNOS. Unlike splenic cDCs, which are CD11chiCD11blowMAC-3–, Tip DCs are 
CD11cintCD11bhiMAC-3+ under steady state. Studies have also shown that CD11c–MHCII–
Ly6Chi monocytes can develop into CD11cintMHCII+Mac3+ DCs (27). Tip DCs play a crucial 
role in variety of infectious diseases, including bacterial, viral and parasitic diseases and they 
have also been implicated in the autoimmune disorders.  
H FL-derived DCs  
Under the influence of Flt3 in cultures, these DCs develop and are analogous to steady-
state CD8–, CD8+, and pDCs (20).  
I Veiled cells  
These DCs are named after their sheet-like processes and reside in afferent lymphatic 
vessels. Veiled cells are thought to form peptide MHC (pMHC) complexes by capturing Ag from 
matured DCs that are undergoing apoptosis, thereby playing an important role in amplifying 
immune responses. 
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1.3.1.1.2 DC vaccines in cancer therapy 
 All currently available cancer therapies, including irradiation and chemotherapy, are 
nonspecific in action and generally kill healthy tissues in addition to tumors. Furthermore, these 
therapies themselves have the potential to induce tumors. Therefore, immunotherapy appears to 
be very promising approach in the treatment of cancers. Studies have shown that people with 
increased Ag-experienced T cell infiltration at the tumor site show an improved clinical outcome 
(28-30). As DCs are extremely potent APCs and robustly activate T cells, they can potentially be 
used as cellular adjuvant in the treatment of cancers. In support of this, DCs loaded with tumor 
Ags have proven to induce T cell-mediated tumor destruction (31, 32). These findings have led 
to clinical trials to understand the protective roles of Ag-loaded DCs as a therapeutic vaccine in 
patients with cancer (33). Although DC vaccination in cancer therapy is a promising approach, 
several factors could potentially influence such vaccination outcomes. These include (34): 1) Ag 
factors - identifying immunogenic non-mutating tumor Ag; 2) DC factors - introducing Ag into 
MHC I and II processing pathways, methods of purifying and maturation of the DCs, and route 
of administration; and 3) T cell factors – precursor frequency (PF). Although optimizing these 
parameters in DC-based vaccination methods is cumbersome, the results of many clinical trials 
with solid tumors, such as melanoma and prostate cancer, imply that DC vaccination may 
eventually prove efficacious and could be applicable to the treatment of other tumors (34).         
1.3.2 Adaptive immunity 
 Following pathogenic invasion, a non-specific innate immune response immediately sets 
in followed by a specific immune response that targets Ags specific for a pathogen. The 
magnitude and protective abilities of specific immunity augment with repeated infections of 
particular pathogen. This definitive immune response is called adaptive immunity. The hallmarks 
of adaptive immunity are discriminating specificity for distinct molecules of a pathogen, 
enormous diversity (can recognize any foreign Ags exist on the earth), and immunological 
memory, the capacity to remember and respond more quickly to repeated invasions of pathogens. 
The main components of adaptive immunity are (3): 1) cellular and chemical barriers [epithelial 
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lymphocytes and antibodies (Abs)]; 2) blood proteins (Abs); and 3) cells (lymphocytes). 
Depending on the types of immune cells involved and their functions, adaptive immunity is 
broadly divided into 1) humoral-mediated immunity (HMI); and 2) cell-mediated immunity 
(CMI).      
1.3.2.1 Humoral Immunity or HMI 
 HMI is mediated by B lymphocytes, which secrete specialized molecules called 
antibodies (Abs). Naïve B cells undergo activation upon encountering foreign Ag under the 
influence of a type of T cell subset, called T follicular helper cells (Tfh), and differentiate into 
Ab-producing plasma cells and memory B cells. Abs principally act against extracellular 
pathogens, such as bacteria, and some parasites, and their toxins (35). Abs form effector arms of 
humoral immunity and provide defense in many ways, depending on the type of Abs involved 
(36): 1) Neutralization – Abs help in neutralization of bacterial toxins, viruses and bacteria, 
preventing the cellular entry; 2) Opsonization – Abs also coat the pathogen and aid the 
phagocytosis by APCs; and 3) Ab-dependent cell-mediated cytotoxicity – Abs also activate 
complement pathway by coating pathogens. This allows complement receptor binding, attraction 
of phagocytic cells, and even the lysis of the target cells.  
1.3.2.2 Cellular Immunity or CMI 
 CMI is principally mediated by T lymphocytes, such as CD4+ Th1 and CD8+ CTLs. Once 
naive T cells develop in thymus, they migrate and re-circulate between blood and peripheral 
lymphoid tissues. T cells are mainly involved in defending our body against intracellular 
pathogens, such as viruses and some bacteria (37, 38). To engage in adaptive immunity, T cells 
have to recognize Ags in the form of short peptide present on MHC of APCs. Ag-recognition 
leads to activation and differentiation of naïve T cells into effector T cells. For instance, naïve 
CD8+ T cells, upon recognition of pathogen peptides presented by MHC I, differentiate into 
CTLs. Naïve CD4+ T cells, upon recognition of pathogen peptides presented by MHC II 
complexes, differentiate into different effector Th cells, including Th1, Th2, Th17, Tfh and 
various regulatory T (Treg)-cell subsets. In typical activation of T cells, 3 signals are very 
essential: 1) signal 1 – comprises antigenic signals derived from the interaction of a specific 
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pMHC with the T cell receptor; 2) signal 2 – are co-stimulatory signals that support the survival 
and expansion of T cells; and 3) signal 3 – are cytokine signals that mediate/direct T cell 
differentiation into the different subsets of effector T cells.  
Th cells confer protection indirectly by activating macrophages to kill phagocytosed 
microbes, B cells to induce Ab production, and DCs or CD8+ T cells to mediate cellular 
immunity (39). On the other hand, CTLs form final effector arms of CMI and confer protection 
by directly destroying virally-infected and cancerous cells that present antigenic peptides of 
pathogens (called target cells) (37). Naïve T cells follow definite kinetics in response to Ag 
recognition, and undergo activation and clonal expansion called primary response/priming. 
During priming, long-lived memory T cells that retain imprints of invaded pathogen generate and 
swiftly respond to subsequent invasion of similar pathogen, the process called 
secondary/memory/recall responses. Although both CD4+ and CD8+ T cells follow definite 
kinetics, the magnitude and timing of each phase as well as its regulatory factors can vary 
depending on the type of pathogen/immunogen involved.  
1.4 Phases of CD8+ CTL responses  
CD8+ T cells, which are regarded as guided missiles of the immune system, provide 
protection against numerous cancers and intracellular pathogens, such as viruses and some 
bacteria. Hence, the induction of an effective CD8+ CTL response is one of the most important 
steps in any vaccination strategy. In general, their response to an acute infection is divided into 4 
phases: (i) ‘effector phase’ – naïve, Ag-specific CD8+ T cells interact with APCs expressing 
foreign Ags, undergo activation and differentiation into effector CTLs; (ii) ‘contraction phase’ - 
more than 90% of effector CTLs undergo activation-induced cell death, leaving behind only 
small proportion of cells as long-lived memory CTLs; (iii) ‘maintenance phase’ - memory CTLs 
maintained for very long period of time, perhaps life-long in some cases; and (iv) ‘recall phase’ - 
memory CTLs undergo rapid proliferation and differentiation into effector CTLs during 
subsequent exposure to similar Ags (40). CD4+ T cells are also known to behave in a similar 
manner but differentiate into different T helper subsets, including Th1, Th2, Th17 and Tfh, 
depending on the microenvironment they receive (41). The factors that control CD4+ and CD8+ T 
cell fates include nature of Ag, duration of exposure to Ag and surrounding microenvironment in 
terms of signaling by cytokines and costimulation. Although both types of T cells follow self 
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program of differentiation, the factors regulating the differentiation, kinetics and efficiency of 
CD8+ T cells differ significantly from that of CD4+ T cells (37). When mounting immunity, 
various factors affect the differentiation process and control the quality and quantity of CD4+ and 
CD8+ T effector and memory cells (42-44). Among various regulatory factors, Th1 cells appear 
to play central role in orchestrating one or several phases of CTL responses in many disease 
conditions.  
1.4.1 Primary or expansion phase  
 Upon pathogen entry, DCs ingest pathogen or pathogen-infected cells, and present 
pathogen-derived peptides on their MHC I (pMHC I). Once naïve, cognate CD8+ T cells 
recognize pMHC I (signal 1), they undergo activation and expansion (priming). As mentioned 
earlier, this process is facilitated by other signals such as stimulations from co-stimulatory 
molecules (signal 2) and cytokines (signal 3) (40). In signal 2, OX40L, 41BBL, and CD80/CD86 
co-stimulatory molecules on DCs respectively binds to OX40, 41BB and CD28 on CD8+ T cell 
surface, which results in increased survival, cytokine production (IL-2) and differentiation into 
effector and memory CTLs (45). Depending on the type of disease involved, primary CTL 
response also requires help from CD4+ T cells, which will be discussed later in detail. In signal 3, 
cytokines, mainly IL-12 and type I IFNs, further drive CD8+ T cell clonal expansion (46, 47). 
During primary response, generation of millions of copies of effector CTLs occurs due to 
repeated divisions of activated CD8+ T cells. Also, some researchers believed that the 
programming of effector and memory responses occurs largely during first 2-3 days of infection 
(48-51) although no consensus has been achieved yet.  
 Differentiated CD8+ CTLs leave lymphoid tissues and find the target cells that display 
pMHC complexes for killing. During differentiation, CD8+ T cells acquire effector functions, 
include cytokine-secreting (IFN-γ, TNF-α and lymphotoxin (LT)-α) and target cell killing (by 
developing membrane-bound cytoplasmic granules containing perforin and granzyme-B) (40, 52, 
53). CD8+ CTLs form an immunological synapse with the target cells to aid signaling and to 
directly release effector molecules. Upon recognizing pMHC I complexes on target cells, CD8+ 
CTLs release perforin, which facilitates the delivery of granzymes. Granzymes are pro-proteases 
that undergo activation in cytoplasm and induce apoptosis in the target cell. CTLs also express 
membrane-bound effector molecule Fas ligand that binds to Fas (CD95) on Fas-bearing target 
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cells and initiates apoptosis. IFN-γ secreted by CTLs inhibit viral replication, increase expression 
of MHC I complexes and Ag presentation in the infected cells, and activate and recruit 
macrophages to sites of infection, or even remove virus from target cells without killing them. 
TNF-α and LT-α can synergize with IFN-γ and induce macrophage activation or apoptosis in 
target cells upon interacting with tumor necrotic factor receptor-1.       
1.4.2 Effector/transitiona/contraction phase  
 Once invaded pathogen gets cleared from the body, which typically takes 1-2 weeks, 
about 90-95% of effector CTL pool undergoes death by a process called apoptosis. At least two 
types of apoptosis have been described in CTL contraction: 1) activation-induced cell death 
(AICD), also called Ag-driven apoptosis, is triggered by Fas-FasL interactions; and 2) activated 
T cell autonomous cell death, also called growth factor withdrawal-induced apoptosis (54). It 
was proposed that inflammation during effector phase determines extent of proliferation and 
directly influences the contraction rate of effector CTLs (55, 56). The availability of growth 
factors (cytokines) during peak of effector phase have also been implicated for contraction of 
CTLs (57). For instance, IL-15 is known to reduce the contraction of effector CTLs by inducing 
expression of antiapoptotic molecules (58). In contrast, the recent study has suggested that 
contraction of effector CTLs is predetermined before the onset of contraction and is postulated to 
be due to epigenetic mechanisms and asymmetric mitotic divisions (56). Interestingly, during 
contraction phase, about 5-10% of effector CTL pool escapes AICD and develops into functional 
memory CTLs, the size of which depends on the extent of effector CTLs that survive contraction 
(58). Although memory development occurs in this phase, whether regulatory factors, 
particularly of CD4+ T helper signals, have any influence on the size and quality of memory T 
cell generation is not completely understood.          
1.4.3 Memory maintenance phase  
 Immunological memory, a hallmark of acquired immunity, is defined as transformed and 
heightened immune response of a vertebrate host to subsequent encounter of same Ags. The 
realistic use of this dynamic process was noted in the earliest periods by Greek historian, 
Thucydides during the outbreaks of Plague in Athens. He pointed that person recovered from the 
 12
disease often immune to the same disease again and thus he can assist the diseased person 
without contracting infection (59). Although the development of long-lived memory CTLs 
programmed reported to occur during first few days of effector phase (48), the growing 
literatures suggest that memory CTL generation occur in the late stage of immune response, and 
is believed to form from a minute fraction of effector cells that have undergone some degree of 
proliferation and differentiation (42). Despite extensive studies, the mechanism by which the 
lineage of memory CTLs forms is not completely understood. Various models have been put 
forward to explain how memory generation occurs. These include: 1) Linear Differentiation 
Model, which states “memory cells are descended directly from the effector cells” (60); 2) 
Modified Linear Differentiation Model, which states that “a brief exposure to antigenic 
stimulation favors the development of central memory CTLs (TCM) cells, whereas prolonged 
exposure to antigenic stimulation lead to development of effector memory CTLs (TEM)” (41); 
and 3) Decreasing Potential Model of Memory CD8+ T cell Development, which states that 
“effector T cells which receive strong and prolonged Ag-induced signals die by apoptosis, 
whereas those effector cells which receive moderate and short duration of antigenic stimulation 
develop into TEM and TCM, respectively (61).”  
Various factors, notably signals from CD4+ T cells, are known to influence both quality 
and quantity of memory T cells generation. These factors are discussed in detail specific to each 
chapter. During the production of T memory cells, various surface markers are either expressed 
or downregulated to fulfill their functions effectively. These markers are often used to 
characterize and distinguish T memory cells from naïve and effector cells. These markers are 
discussed in detail later wherever appropriate. Once memory CTLs are generated, they 
maintained for very long period under the influence of survival signals (62). Even the size of 
memory pool remains fairly constant over extended duration of time. Naïve CD8+ T cells occupy 
distinct location in the secondary lymphoid organs. However, their memory counter parts 
destined to home different non-lymphoid tissues apart from secondary lymphoid organs in order 
to fulfill their functions (63). Such a distinct homing property of memory cells is an outcome of 
interaction of various molecular tools of the immune system, including adhesive molecules, 
chemokines and cytokines. These events are necessary to bring about effective 
immunosurveillence of various re-entries of foreign Ags. Expression of various adhesion 
molecules and chemokine receptors by T memory cells reflects their residence and migrating 
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properties (63). Recent studies have suggested that signals from various cytokines (IL-15 and IL-
7), co-stimulatory molecules, and CD4+ T cells play important role in memory CTL maintenance 
and homeostasis [reviewed in (42)].   
1.4.4 Recall or secondary phase  
  During memory maintenance phase, if our body encounters invasion of similar pathogen, 
memory CTLs respond quickly and robustly compared to their naïve CD8+ T cell counterparts, 
and eliminate pathogens efficiently. It has been shown that memory CTLs possess special 
characters, perhaps epigenetically, enabling them to respond more rapidly and vigorously (64). 
Recall response is contributed by CD8+ memory T cells. Protection has shown to be contributed 
by both resting type of memory cells, TCM, and a more activated type of memory cells, TEM (65, 
66). Although both types exhibit some common functions, they have shown to differ in cytolytic 
and overall cytokine-secreting abilities (67-69). Overall, TCM are characterized by rapid 
proliferative capacity in lymphoid organs whereas TEM are characterized by immediate effector 
functions in the peripheral tissues. Depending on the model system used, investigators have 
reported that CD4+ T cell signals during priming and memory maintenance can influence the 
magnitude and quality of recall responses (49, 62, 70-72). As recall responses represent 
hallmarks of any vaccination regimen, there is a great need to understand mechanisms and 
regulatory factors that influence CD8+ T memory recall responses. In this context, the role of 
CD4+ T cells during recall responses as such is scantily available and needs detailed study. Such 
an understanding would aid better design of vaccines for treating and preventing infectious 
diseases.  
1.5 CD4+ T cells and their subsets  
CD4+ T cells are one of the most versatile immune cell types and exhibit multi-faceted 
roles in regulating diverse immune responses. Generally, both naïve CD4+ and CD8+ T cells live 
for few to several months. During this period, unless they encounter foreign Ags, they inexorably 
migrate through circulation and lymphoid organs; do extensive sampling of self-pMHC, exit 
secondary lymphoid organs, and return to circulation (73, 74). Both CD4+ T cells and lymphoid 
organs work in concert to provide immunity to hosts against dangerous invading pathogens. To 
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fulfill this task, both CD4+ and CD8+ T cells constantly search for foreign Ags in lymphoid 
organs through a mechanism called ‘immunosurveillance’, where they screen DCs in T cell areas 
for foreign pMHC complexes (75). If a pathogen breaks innate immunity, then DCs ingest the 
pathogen, and undergo maturation via both pathogen- (TLR, NOD and C-type lectin) and host-
derived (IFN-γ, IL-1, TNF-α and CD40L) signals (76). If a productive T cell receptor (TCR)- 
pMHC interaction occurs between DCs and cognate CD4+ T cells via immunological synapse, 
activation and proliferation of CD4+ T cells begins. Immunological synapse comprised of central 
T cell signaling molecules (TCR, CD28) encircled by adhesion molecules (LFA-1), and cytokine 
and chemokine receptors (77). Once the pathogen is cleared from the system, a variety of host 
signals, particularly Tregs, control ongoing immune reactions to prevent host tissue damage. 
 Unlike CD8+ T cells, CD4+ T cells, being very sensitive to environmental cues, have 
potential to develop into many subsets, each of which shows distinct phenotype and gene 
expression, and performs different tasks. Depending on the type of pathogens, DCs take 
blueprint of pathogens via combinatorial ligation of pattern recognition receptors and generate 
distinct cytokine microenvironment, which in turn decides the fate of CD4+ T cell choices, 
ensuring immunity specific for different classes of pathogens with diverse life cycles and evasion 
strategies (75, 77). In addition, it is believed that formation of immunological synapse, which 
might determine strength of TCR and co-stimulatory signals, also plays an important role in 
CD4+ T cell lineage commitments. CD4+ T cell subsets can be distinguished based on the 
cytokine secretion and the surface marker expression [reviewed in (78)]. In contrast to 4 distinct 
subsets, Th1, Th2, Th17 and inducible T regulatory (iTreg) cells, which derive from naïve CD4+ 
T cells that are selected from thymus in Ag-dependent manner, some CD4+ T cell subsets, such 
as NKT and natural T regulatory (nTreg) cells, do not derive from naïve CD4+ T cells but rather 
selected directly from thymus as distinct lineages in an Ag-independent manner without the aid 
of cytokines (78). Unlike CD8+ T cells, most of the CD4+ T cell functions are indirect. CD4+ T 
cells play crucial roles in orchestration and/or recruitment of other immune including B cells, 
CD8+ T cells, macrophages, mast cells, neutrophils, eosinophils and basophils and nonimmune 
cells, (79). A summary of these CD4+ T cell subsets, their phenotype and functions is given 
below:  
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1.5.1 Th1 cells  
Upon encountering cognate Ags in the presence of IL-12 and IFN-γ, naïve CD4+ T cells 
express signal transducer and activator of transcription (STAT) 1, STAT4, and T-bet 
transcriptional factors (80) and differentiate into Th1 (81, 82). T-bet in combination with STAT4 
brings about its effects by inducing IFN-γ production and inhibiting GATA3 ie Th2 
differentiation factor. Other factors, interferon regulator factor (IRF)1, Ikaros and Runx3, are 
also required for fine-tuning Th1 differentiation (83). Th1 cells are characterized by the secretion 
of IFN-γ and LT as signature cytokines (78). In addition, Th1 cells also secrete IL-2 and TNF-α 
and also express cytokine receptors, IL-12Rβ2 and IL-18Rα, activation markers, CD25, CD69 
and CD40L, and chemokine receptors, CXCR3 and CCR5 (84-86).  
Th1 cells activate microbicidal activity of macrophages, NK cells and CD8+ T cells by 
secreting IFN-γ, LTα, and IL-2 (87). Th1 cells are chief mediators of inflammation and play a 
crucial role in systemic immunity against various intracellular pathogens. Both IL-2 and CD40L 
costimulation provided by Th1 cells are very critical in the generation of primary and memory 
CTL responses (50, 51, 88-91). Absence of T-bet transcription factor in CD4+ T cells leads to 
diminished IFN-γ and Th1 differentiation, resulting in the reduced protection against Leishmania 
infections (92). T-bet-expressing CD4+ T cells also get reduced in asthmatic patients, suggesting 
the importance of Th1 cells in asthma (93, 94). Recently, another transcription factor, 
Eomesodermin (Eomes), has also been shown to involve in Th1 differentiation, and that the 
absence of this along with T-bet results in poor protection against lymphocytic choriomeningitis 
virus infection (83, 95).   
1.5.1.1 Th1-derived co-stimulatory and cytokine signals in CTL memory development 
 Th1 cells modulate CTL responses in many ways (96). Among many signals provided by 
Th1 cells, two signals, such as CD40L and IL-2, have been frequently studied and implicated in 
the development of memory CTLs although they are reported to be required for primary 
responses in some situations. There are two schools of thought to describe how CD40L signaling 
from Th1 is targeted for memory CTL development. First, during DC interaction, CD4+ T cells 
get activated and license the DCs through CD40-CD40L costimulation such that licensed DCs 
stimulate CD8+ CTLs activation, and differentiation into effector and memory CTLs (97-99); 
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Second, this concept was challenged by the finding that activated CD8+ T cells transiently 
expressing CD40 can directly receive CD40L signaling from Th1 (51, 88), Recently, several 
reports also suggested that CD4+ T cells induce memory CTL development by providing IL-2 
signaling (50). Subsequently, various results suggested that both IL-2 and IL-15 signals 
determine the generation of TCM versus TEM with IL-2 signals promoting TEM cells (96, 100-104). 
Recently, it has been shown that Th1 cells license DCs to secrete IL-12, which in turn act on 
CD8+ T cells to express IL-2Rα for efficient use of IL-2 secreted by Th1 (90).  
1.5.2 Th2 cells  
Th2 cells require IL-4 and to some extent IL-2 for their differentiation, and typically 
secrete IL-4, IL-5, IL-13 and IL-25 as signature cytokines. Evidence of these cells secreting IL-2, 
TNF-α and IL-9 has also been suggested. These cytokines are responsible for up-regulation of 
STAT5, STAT6, and a master transcriptional regulator, GATA3, which in turn influence Th2 
differentiation and functions via induction of IRF4 (83, 95). Absence of this factor leads to 
resistance to autoimmune encephalomyelitis. In addition, c-Maf factor is also shown to induce 
IL-4 secretion from Th2 cells (83). Th2 cells also express surface markers, IL-4Rα, IL-2Rα 
(CD25), IL-33Rα, and chemokine receptors, CCR3, CCR4, CCR8, and CRTh2 (84). Th2 cells 
are critical to provide defense in mucosal and epithelial surfaces against extracellular pathogens, 
including bacterial and helminth infections. 
1.5.3 Th17 cells  
Th17 cells are induced under the influence of IL-6 and transforming growth factor 
(TGF)-β, and can be maintained well in the presence of IL-23 and IL-21 (83). Under these 
cytokine milieus, and in the presence of cognate Ag, naïve CD4+ T cells upregulate STAT3, and 
master regulatory factors, RORγt and RORα, and differentiate into Th17 cells (105). STAT3 
together with RORγt expressions in Th17 cells also down-regulates Foxp3 induction and Tregs 
differentiation. Another factor IRF1 is also required for fine-tuning Th17 differentiation (83). 
Under the influence of these molecules, they also produce IL-17A, IL-17F and IL-22 as signature 
cytokines. In addition, Th17 cells also secrete IL-21, IL-6, and TNF-α and express cytokine 
receptors, IL-23R, IL-1R1, and IL-18Rα, and chemokine receptors, CCR6 and CCR4 (84). Th17 
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cells mainly regulate inflammation and provide antitumor immunity, and in concert with 
neutrophils, provide defense against extracellular bacterial and fungal infections (106, 107). Over 
expression of Th17 cells have been implicated in the pathology of autoimmune disorders, 
particularly experimental autoimmune encephalomyelitis, collagen induced arthritis, 
inflammatory bowel disease and multiple sclerosis, and even in some conditions contribute to 
cancerous status (106, 107). 
1.5.4 Tfh cells  
Although it is controversial, it was thought that IL-6 or IL-21 cytokines together with 
TCR-mediate induce Bcl-6 expression, which in turn determine the differentiation of Tfh cells 
(83). Bcl-6 expression also mediates Tfh-related molecules, including CXCR5, PD-1, IL-6R, and 
IL-21R, and suppresses Th1, Th2 and Th17 differentiation (83). Tfh cells are identified as p-
selectin glycoprotein ligand-1- and CXCR5+, and can secrete IL-4 or IFN-γ depending on the 
priming conditions (108, 109). For instance, in Schistosoma mansoni infections, Tfh cells secrete 
IL-4 to mediate their functions (83). They remain in LNs and spleen, and are responsible for 
mediating Ab responses by activating B cells and inducing germinal centers formation (108, 
110). In addition, they are also responsible for somatic hypermutation and Ab class-switching. 
Th17 cells mediate these functions in germinal centers via CD40 signaling and secretion of Th1- 
and Th2-like cytokines. How far these cells are distinct from Th1 or Th2 lineages is not yet clear.  
1.5.5 Treg cells   
Growing experience in regulatory immune response studies where Treg cells were 
involved suggest that different Treg populations may control the functions of different CD4+ T 
cell subsets. Treg cells express moderate levels of GATA3 although its function is not clear. 
CD4+CD25+FoxP3+ Treg cells are induced by CD103+ DCs in respiratory and gastrointestinal 
tracts following exposure to commensal microorganisms, food proteins, and possibly pathogens, 
and this is required to maintain balance between tolerance and immunity (111).  
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1.5.5a iTreg cells 
These cells derive from naïve CD4+ T cells under the control of distinct transcription 
factors parallel to Th1, Th2 and Th17 lineages (112, 113). For example, IRF4 induces 
differentiation of Tregs that possess the ability to control Th1 functions. Similarly, STAT3 
expression in Tregs controls Th17 cell’s functions. In all these situations, TGF-β and IL-2 
together with TCR stimulation are critically required for iTregs differentiation (114). These 
cytokines mediate STAT5 activation required for Tregs development (115). These Tregs produce 
TGF-β as their signature molecule, and express CD25, IL-2Rα, CTLA-4, glucocorticoid-induced 
TNFR related protein, Folr4 and CD103, which can be used to distinguish naïve conventional 
nTregs (84). Although these cells can develop from naïve CD4+ T cells, their in vivo relevance 
has not been demonstrated yet in humans unlike in mice (116).  
1.5.5b nTreg cells  
In contrast to iTregs, nTregs do not derive from naïve CD4+ T cells but rather selected 
from thymus as distinct lineages (117). nTreg cells naturally express a master transcription 
factor, Foxp3. This factor together with TGF-β, regulate nTregs differentiation and its 
maintenance of suppressive activity. Mutations in the Foxp3 lead to various autoimmune 
disorders, such as immunodeficiency, polyendocrinopathy, and enteropathy, X-linked syndrome, 
in humans. These patients often develop insulin-dependent diabetes, increased serum 
immunoglobulin (Ig)E, eczema and psoriasis. Furthermore, patients also develop 
hypothyroidism, anemia, thrombocytopenia, and neutropenia (83). 
1.6 Costimulation in cellular immunity 
 T cells are stimulated through recognition of Ag-peptide bound MHC I (in CD8+ T cells) 
or MHC II (in CD4+ T cells) molecules on APCs, such as macrophages and DCs. However, as 
discussed earlier, this TCR complex engagement is alone not sufficient for productive T cell 
activation (118). In addition to antigenic stimulation, costimuation-mediated signal 2 and 
cytokine-mediated signal 3 are very important for T cell activation. Signal 2 is mediated by one 
of the many co-stimulatory receptors and transmits independent signals or facilitates the signal 
cascade triggered by the engagement of TCR complex.   
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1.5.1 CD28  
CD28 signal is major costimulus for both CD4+ and CD8+ T cells and is required for 
many functions in T cells. Although many co-stimulatory receptors expressed on the resting T 
cells are able to provide signal 2, CD28 appears to be very much required for activation of both 
CD4+ and CD8+ T cells (119). CD28 is present on all resting T cells and binds to CD80 (B7-1) 
and CD86 (B7-2) expressed on mature professional APCs (45). Uniquely, this binding is known 
to induce enhanced secretion of IL-2 from T cells. This results in the effective T cell response 
due to activation of c-Jun kinase and P13K pathways. These pathways in turn enhance T cell 
activation as well as T cell survival by inhibiting apoptosis and up-regulating anti-apoptotic 
molecules via AKT activation (120-122). CD28 signals also up-regulate CD40L expression on T 
cells, which leads CD40 signaling on APCs and on APCs lead to up-regulation of B7-1 and B7-2 
ligands,       
1.5.2 Inducible costimulators (ICOS) 
 Recently, studies have also shown that ICOS, another member of CD28 family, also 
engages in T cell activation. In contrast to CD28 that express on all resting T cells, ICOS express 
mostly on active T cells, suggesting sequential involvement of these costimulators in productive 
T cell activation (123). Since ICOS ligand express relatively on many cell types (nonlymphoid 
cell types, including epithelial and endothelial cells) in addition to APCs (B cells, DCs and 
macrophages), it is postulated that insufficiently activated T cells can undergo further activation 
in tissues that express ICOS ligand (124). ICOS signals are known to stimulate mainly P13K 
pathway and required for regulating ability of T cells to provide help to B cells for both class-
switching and germinal centers formation (125). The level of ICOS expression has been shown 
to associate with the type of cytokines produced, with ICOShi T cells linked to IL-10 production, 
ICOSmedium T cells linked to IL-4, IL-5 and IL-13 production, whereas ICOSlow T cells are linked 
to IL-2, IL-6 and IFN-γ production (5). ICOS is also known to suppress Tregs in vivo (126). 
1.5.3 TNF/TNFR super family costimulators  
 In addition to the above co-stimulatory molecules, additional accessory molecules also 
provide essential signals required for full activation of T cells. These molecules are TNF/TNFR 
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super family members, such as CD27, 4-1BB (CD137), OX-40 (CD134) and CD30 receptors on 
T cells and their ligands CD27L, 4-1BBL, OX-40L and CD30L, respectively, on APCs. CD27 
acts as costimuatory molecule to induce T and B cell responses. It is present excessively on NK 
cells, on induced B cells, and on CD4+ and CD8+ T cells. It is known to control the size of 
primary and memory T cell responses, particularly in respiratory viral infections by preventing 
the death of activated T cells (5, 127). CD27 ligand, CD70, expresses in DCs only transiently 
during interaction with T cells. Persistent CD27-CD70 interactions in chronic infections lead to 
excessive secretion of TNF-α and IFN-γ, which results in the loss of splenic architecture, 
increased tissue pathology and increased T cell exhaustion and reduced virus-specific 
neutralizing Ab responses leading to lethal immunodeficiency (127). These undesired effects can 
be reverted by blocking this signal. OX40 signaling is required for maintaining T cell numbers. 
In addition, OX40 signal facilitates TNF secretion in CD4+ and CD8+ T cells, and cytotoxic 
functions in CD8+ T cells. This signaling has also been implicated in the IL-12-mediated Th1 
autoimmunity. OX40 is known to express transiently on T cells. 4-1BB expresses on activated 
CD4+ and CD8+ T cells, activated NK cells, and DCs, whereas its ligand expresses on resting B 
cells and activated APCs. 4-1BB costimulation enhances CTL generation and immunity against 
tumors and viruses. Interestingly, 4-1BB costimulation inhibits autoimmunity, suggesting its 
effects can vary with the stages of T cell responses. CD40L (CD154), expresses on activated 
CD4+ T cells, some CD8+ T cells, eosinophils, basophils, and NK cells. Its ligand, CD40, 
expresses on B cells, activated macrophages, DCs, thymic epithelium, and endothelial cells (5). 
Signaling from CD40L is crucial for effective T and B cell responses. Principally, this signaling 
is mediated through activated CD4+ T cells. CD40L-expressing CD4+ T cells binds to CD40 on 
APCs, which on B cells result in B cell expansion, Ig production, and isotype class switching, 
and on DCs result in maturation of DCs, production of cytokines and chemokines, and prolonged 
survival, thereby increasing overall magnitude and quality of CMI responses (5, 128).      
  1.5.4 Inhibitory co-stimulatory molecules  
Cytotoxic T-Lymphocyte Ag (CTLA)-4, programmed death (PD)-1 and B and T 
lymphocyte attenuator (BTLA) are inhibitory receptors that bind to the negative costimulator B7 
family molecules.  
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CTLA-4 (CD152) expressed on activated and memory CD4+ and CD8+ T cells (similar to 
ICOS) (129). Upon T cell activation, CTLA-4 traffics to the sites of TCR engagement and has 
high affinity for B7 molecules than CD28 and thus suppresses the activation of T cell by out 
competing CD28 for B7 binding, which in turn lead to aborting of T cell response (129). 
Mechanistically, CTLA-4 is known to inhibit Akt directly in T cells, transmit suppressive signals 
to DCs via B7 and suppress natural Tregs to maintain tolerance to self-Ags (5).  
PD-1 (CD279), in contrast to CD28 and CTLA-4, inducibly express in wide range of 
cells, including CD4+ and CD8+ T cells, NKT cells, B cells, and monocytes upon activation (5). 
PD-1 transmits signals only when engaged along with TCR ligation. APC ligands for PD-1 
receptor are B7-H1 (PD-L1) and B7-DC (PD-L2). PD-L1 expression is induced by IFN-γ. Both 
PD-L1 and PD-L2 synergistically inhibit T cell activation. Tumor cells often use PD-L1 to evade 
immune recognition. It has been shown that PD-1 also expresses on CD8+ T cells during chronic 
infections, such as LCMV and HIV-1, and blocking PD-1/PD-L1 pathway has shown to increase 
T cell proliferation and effector functions. Similar to CTLA-4, PD-1 has shown to inhibit Akt 
phosphorylation, suggesting both CTLA-4 and PD-1 may regulate T cell activation (130).     
B and T (especially Th1 cells) cells express BTLA (5). Upon binding to its ligand, herpes 
virus entry mediator, BTLA negatively regulates T cell responses (5).  
1.7 Immunity in vaccination  
 Vaccination, by markedly decreasing mortality from infections, forms one of the most 
important contributions to public health in the last century. Vaccines mediate their effects by 
inducing adaptive immunity and immune memory (53). Pre-existing Abs in the blood and tissues 
act as the first line of defense and readily attack the invading pathogen. Abs maintain their levels 
for long period, presumably due to the presence of Ab-secreting long-lived plasma cells. 
Memory B cells act as a source of Abs during pathogen invasion. Similarly, T cell memory is 
contributed by TEM cells, which reside in infected peripheral tissues and provide an immediate 
line of defense by killing pathogen-infected target cells, and TCM cells, which reside mainly in 
LNs and undergo activation and differentiation into effector T cells upon encountering pathogens 
(67, 131, 132). T cell memory is contributed by both CD4+ and CD8+ memory T cells (132).  
Since the discovery of small pox vaccination by Edward Jenner, our understanding of 
immunity as a result of vaccination has tremendously increased, particularly in the last two 
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decades with the advent of modern immunological technologies. The development of vaccination 
began with two empirical approaches (reviewed in (53)): 1) killed or inactivated, in which the 
infective ability of pathogens is destroyed by killing, yet retaining immunogenesity; and 2) live 
or attenuated vaccines, in which the infective ability of pathogen is reduced by modifying the 
organism, yet they retain a natural behavior of an original pathogen. Killed vaccines act mainly 
by inducing humoral immunity. They are often targeted to bacteria and viral infections. In 
contrast, attenuated vaccines act as a larger and more sustained dose of Ags (by pathogen 
replication), and thus can able to induce both Ab and T cell memories. Although attenuated 
vaccines are potent inducers of T memory, they are contraindicated in certain infections, such as 
those which induce immunosuppression or undergo genetic recombination. Though smallpox 
was eradicated without having much knowledge of cellular and humoral (both primary and 
secondary) immune responses, currently we are still struggling to control various chronic 
diseases and cancers even with much immunological background. Still we have not been 
completely able to understand the basic reasons for success or failure of our vaccination 
regimens. Hence, immunologists began to develop novel approaches. One such effective 
approach is the use of microbial vectors in vaccines preparation (133). In this approach, 
attenuated recombinant viral vectors, such as adenovirus (AdV), fowl pox, canary pox and 
modified vaccinia Ankara virus that infect mammalian hosts but are unable to replicate, are used 
to insert genes encoding proteins of pathogen. This approach acts as a powerful vaccination 
strategy since it is endowed with several benefits, including its ability to induce potent humoral 
and cellular immunity (133, 134). These approaches appear to be invaluable especially in the 
treatment of chronic diseases, such as HIV, malaria, tuberculosis and hepatitis.         
1.8.1 AdV vectors  
In the last two decades, the transfer of genetic information that encodes desired proteins 
in target cells using viruses and viral vectors has gained more interest for the prevention or 
treatment of infectious diseases, autoimmune disorders, allergies, and cancers (135). Although 
non-vector systems, such as naked plasmid DNA, DNA complexed with cationic lipids, and 
particles comprising DNA condensed with cationic polymers, are available, viral vectors have 
been commonly used due to their potent ability to transfer genes to broad range of host cells 
(136). In cancer immunotherapy, several of these vectors have been used to stimulate patient’s 
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immune system to destroy tumors. Although several replication-deficient viral vectors derived 
from retroviruses, AdV, adeno-associated virus, semliki forest virus and herpes simplex virus 
families also have been used in gene expression studies. AdV vectors have been most commonly 
used in the treatment of cancers and chronic diseases due to their several inherent features (133, 
137).  
AdVs are non-enveloped viruses and contain linear double-stranded DNA genome. AdV-
based vectors are considered to be the widely-used vectors in clinical studies worldwide, 
representing major part of all the trials (138). AdVs have several advantages, enabling them the 
choice of vector for many preventive and therapeutic applications (136). One of the best traits in 
AdVs is their ability to transiently transfect the therapeutic genes into both dividing and non-
dividing cancer cells (136). Another advantages of using AdVs in vaccine preparation is our in-
depth understanding of lifecycle and immunological effects of adenoviral vector delivery (139). 
Currently, almost all serotypes that infect humans naturally have been identified and 
characterized. AdVs immunological consequences in various doses and routes have also been 
extensively studied. This knowledge is particularly relevant especially when excessive immune 
response in host that needs to be controlled. For instance, in situations where controlled 
immunity is desired, one needs to reduce innate immunity (by reducing dose, avoiding coexisting 
inflammation, etc.) and adaptive immunity (delivery during neonatal immune systems, avoiding 
APC transduction, blocking co-stimulatory molecules, delivery to organs such as liver, eye, 
mucosa and muscle) (138). Characterization of various aspects of AdVs and their genetic 
modification have also now allowed us to modify them for use in a safer and efficacious way 
(140).   
1.7.1.1 Immunity to adenoviral vaccination  
AdV vectors have attracted considerable attention as a platform for eliciting productive 
immunity against intractable diseases, including chronic infectious and cancerous diseases and 
are at the forefront of vaccine development against such diseases. One of the most notable 
characteristics of AdV vectors is their capacity to induce exceptionally high and sustained levels 
of transgene product-specific CD8+ CTL responses (133, 134). They are also regarded as 
exceptionally strong inducers of innate as well as humoral immune responses (133). Transgene 
product-specific Abs are mainly of IgG2a isotype although IgG1 are also known to be induced, 
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suggesting AdV induce a mixed Th1/Th2 response with Th1-type predominance. AdVs have 
shown to induce very quick and persistent immune responses in both adults and neonatal mice 
(133). This potent immunogenicity of AdV vectors appears to be due to their capacity to activate 
innate immune cells, particularly APCs (141). Compared to other vaccine candidates, such as 
poxvirus vectors, DNA vaccines, and alphavirus vectors, AdV vectors perform superiorly in 
terms of inducing transgene-specific Abs and CD8+ T cell responses (142, 143). Hence, AdV are 
being currently considered in treating various infectious diseases, including AIDS, hepatitis, 
Rabies, SARS and Ebola. AdV vectors do not induce potent transgene product-specific CD4+ T 
cell responses (133). However, AdV vectors appear to require CD4+ T help for optimal CD8+ T 
cell responses (144). Although the usage of AdV vectors largely depends on their ability to 
induce CD8+ CTL responses, our knowledge on how CD4+ T cells regulate different phases of 
CTL responses is incomplete. This knowledge is very critical since AdV vectors are currently 
being used in diseases such as AIDS, hepatitis and other chronic diseases, and cancers, which 
often induce CD4+ T cell dysfunctions in the body.  
1.9 Models to explain mechanism of CD4+ T cell help for CD8+ CTL responses  
For the development of effective CMI responses, multiple, at times rare immune cell 
types must communicate within organized lymphoid tissues. Despite our technological 
advancement in the immunology field, the mode by which CD4+ T cells provide help for CD8+ 
CTL responses has been debated frequently. Our perception on where CD4+ T cells participate in 
the CTL responses has been changing gradually. Various models have been proposed to explain 
the development of CD8+ CTLs [reviewed in (145, 146)] (Fig. 1).   
1.9.1 Traditional model of three-cell interactions 
Initial studies in allograft rejection and in vitro studies of allogeneic mixed lymphocyte 
reactions suggested that CD4+ T cell “help” is vital for the clonal expansion of naive CD8+ T 
cells (147-149). Based on these observations and recent studies, researchers thought that both 
CD4+ and CD8+ T cells have to recognize peptide Ag on the same APC simultaneously for 
optimal delivery of CD4+ T cell help (98, 150, 151). Justifications in formulating this model 
include: a) CD4+ T cells were a chief source of IL-2 and its help often thought to occur in 
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paracrine manner (152); and b) neutralization of IL-2 or blockade of the IL-2 receptor in culture 
severely limited CTL proliferation (153-155). Hence, according to this model, CD4+ and CD8+ T 
cells recognize antigenic peptide on the same APC so that IL-2 produced by CD4+ T cells can act 
on neighboring IL-2-receptor-expressing CD8+ T cells (150, 156). Two main limits of this model 
include:   
a) this model cannot explain how two rare Ag-specific cells, CD4+ and CD8+ T cells manage to 
interact on the same Ag-bearing APC.  Such an event has extremely low probability; and  
b) CTL responses can also be elicited without CD4+ T cells in various models, suggesting the 
need for CD4+ T help is conditional rather than absolute.  
1.9.2 Model of sequential two-cell interactions by APC by Polly Matzinger  
The above notion of CD4+ T and CD8+ T cell cooperation raised many questions when 
immunologists came to realize that mature DCs and activated CD8+ T cells can also transiently 
secrete IL-2, questioning earlier notions that CD4+ T cells are unique producers of IL-2 that 
mediates CD4+ T cell help (157-159). Furthermore, CD4+ T cells were not essential in the 
control of acute viral infections, challenging the notion that Th1 help is absolutely required for 
CTL clonal expansion (160). These results led to the belief that Th1 help is only required for 
noninfectious Ags that lack molecular pathogen-derived stimuli [pathogen-associated molecular 
patterns (PAMPs)] for the innate immune cells, whereas it is dispensable for acute microbial 
infections, whose PAMPs acts as potent stimuli for APCs (161, 162). Thus, this model states 
that, in the absence of PAMPs [eg. TLRs, such as dsRNA (TLR3), lipopolysaccharide (LPS) 
(TLR4), and CpG-containing oligonucleotides (TLR9) and type 1 IFNs], CD4+ T cells, during 
activation, recognize APC and deliver all signals required for APC maturation (163). It was 
shown that such activation occur through CD40L and CD40 interactions in immunity involving 
noninfectious Ags (97-99). The licensed APCs (typically DCs) can then directly stimulate CD8+ 
T cells. (97-99). Subsequently, it was also reported that, even in acute infections, memory/recall 
responses require CD4+ T helper signals (51, 62, 72, 164). Furthermore, CD4+ T cell requirement 
was also shown to be required for the clearance of persistent pathogens in chronic infections 
(165-167). 
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This model is supported by the fact that Ag-specific CTL responses can be elicited by 
activating APCs in vitro/in vivo by agonistic anti-CD40 Ab, which mimic CD40L signaling (97, 
99). Limitations to this model include: 
a) very small numbers of Ag-bearing APCs must first be conditioned by a rare and naïve, Ag-
specific CD4+ T cells, and then have to find and activate equally rare and naïve, Ag-specific 
CTLs; 
b) the model does not explain how T cell’s IL-2 precisely targeted to Ag-specific CTLs in vivo; 
and 
c) the experiments used to propose this model may not represent the physiological phenomenon. 
1.9.3 New dynamic model of sequential two-cell interactions by CD4+ Th-APC by Jim Xiang  
Trogocytosis (Greek: trogo; gnaw) is a process through which certain lymphocytes 
interacting with APCs pinch off surface molecules from these cells and express them on their 
own surface. Currently, the transfer of cell surface proteins via trogocytosis among different 
types of cells, and its biological function are becoming the subject of study in immunology (168-
170). Trogocytosis is a wide-spread phenomenon and many immune cells utilize this mechanism 
for cellular communication. Recent studies have shown that CD4+ T cell subsets are particularly 
involved in acquiring APC’s Ag-presenting machinery (APM), attracting the attention of many 
immunologists (88, 146, 169, 171-174). Other correlative studies included Ag-presenting 
functioning of human γδ T cells expressing MHC-II and co-stimulatory molecules, which 
stimulated naive αβ T cell proliferation and differentiation (175), Ag-specific peptide pulsed Th 
lymphocytes which can cross-prime memory CTL responses, and human CD4+ T cells bearing 
viral epitopes which can elicit functional virus-specific memory CD8+ T cell responses (176). 
Consistent with these concepts, Xiang et al. showed the in vivo relevance of Ag-presenting 
nature of CD4+ T cells. This model states that CD4+ T cells while interacting with APCs acquire 
APM and behave like APCs called “Th Ag-presenting cell” (Th-APC) (146). During APC and 
CD4+ T cells interaction, APCs directly transfer pMHC II as well as bystander pMHC I and co-
stimulatory molecules (CD54 and CD80) to expanding populations of IL-2-producing Th1 cells. 
Th-APCs with acquired pMHC I and co-stimulatory molecules can then directly stimulate naïve 
cognate CD8+ T cells for proliferation and differentiation into effector CTLs. Th-APCs are 
efficient in induction of an effective antitumor immunity by triggering CD8+ T cell proliferaftion 
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and differentiation into CTLs through their acquired molecules, pMHC I complexes and CD80, 
and via their inherent ability to secrete IL-2 cytokines (146). These Th-APCs are also known to 
promote CTLs infiltration and survival via IL-2 secretion and targeting effect of pMHC I 
complexes and regression of established tumors in vivo (164). It was found that Th-APCs can 
even stimulate memory CTL proliferation during recall responses via acquired pMHC I 
complexes and CD80 molecules (177-179). Furthermore, it was shown that Th-APC’s 
stimulatory power is independent of endogenous CD4+ T cells. They also have the ability to 
break tolerance and induce autoimmunity. Although these observations provided the evidence of 
CD4+ T cell’s role in CMI responses via direct Ag presentation, many issues associated with this 
model were not understood. These include: 1) whether the acquired pMHC II on CD4+ Th-APC 
are also functional; 2) which type of T cells these CD4+ Th-APC-stimulated CD4+ and CD8+ T 
cells belong to; and 3) what is the molecular mechanism responsible for Th-APC’s stimulatory 
effect on in vivo stimulation of CD8+ CTL responses and antitumor immunity.   
 
 
Figure. 1.  Models to explain development of CTL responses via CD4+ T cell help (146): a) 
Model of three-cell interaction; b) Model of sequential two-cell interactions; and c) New 
dynamic model of two-cell interactions by CD4+ Th-APC. 
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1.10 Rationale, hypothesis and objectives 
Among the various factors that regulate CD8+ T cell responses, CD4+ T cells play a 
predominant role in modulating one or several phases of CTL responses. Studying the 
requirements of CD4+ T cell help is intriguing since this requirement varies with type of disease 
or immunization. Generally, in infectious conditions where inflammatory signals play a 
significant role, it was found that CD4+ T cells have little role in most phases of CTLs with the 
exception of memory phase (62, 180). On the contrary, in immunity associated with minor 
histocompatibility Ags, such as non-inflammatory signals derived from cell-associated foreign 
Ags, transplantation Ags and tumor Ags, it was shown that CD4+ T cells play a crucial role in 
multiple phases of CTL responses (49, 51, 88, 98, 99, 180). These results suggest that the 
requirements of CD4+ T helper cells for effective CTL responses vary with the type of infections 
or immunizations. Furthermore, researchers have also shown that, in addition to inflammatory 
signals, the PF of CD8+ T cells also impact the requirements of CD4+ T-helper signals for CTL 
responses (181, 182). Although at higher PF, CD4+ T cell help is not required (181, 182), how 
higher PF impacts CD4+ T-helper requirements for memory CTL responses is not completely 
known. Hence, keeping in view the above knowledge gap, the main focus of the current work is 
to understand the requirements of CD4+ T cell help and its molecular mechanisms for effective 
CD8+ T cell responses and anti-tumor immunity. As inflammatory signals are known to alter 
CD4+ T cell requirements, two immunization methods were selected to investigate the 
requirements of CD4+ T cell help for CTL responses: 1) the non-inflammatory DC 
immunization; and 2) the inflammatory AdV immunization. To investigate the function of CTLs 
in these immunization methods under CD4+ T-helper influence, the mouse melanoma tumor 
challenge model was used. A detailed rationale and hypothesis specific for each part of the 
project has been further discussed in the introductory part of each chapter.   
In the first part of the project, the study was designed to further characterize the “new 
dynamic model of sequential two-cell interactions by CD4+ Th-APC,” giving particular attention 
to Th-APC’s stimulatory effect on primary and memory CTL responses. Here, the main 
objectives were to investigate: 
1. whether CD4+ Th-APC can acquire co-stimulatory molecules and the pMHC complexes by 
in vivo DCOVA stimulation;  
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2. whether the acquired pMHC II on these CD4+ Th-APC are functional;  
3. which type of  subsets these CD4+ Th-APC-stimulated CD4+ and CD8+ T cells belonged to; 
and 
4. the molecular mechanisms responsible for Th-APC’s stimulatory effect on in vivo 
stimulation of CD8+ CTL responses and anti-tumor immunity.  
In the second part of the project, the study was designed to understand the interaction 
between Th-APCs and differentiated effector CTLs. Here, the main objectives were to 
investigate: 
1. Th1 cells’ signaling during primary and transitional period for memory CTL development; 
2. the nature of CD4+ T-helper requirement for memory CTL development; 
3. the molecular mechanisms of Th1’s help during transitional period for memory CTL 
development; and 
4. genes or molecules that regulate effector CTL’s death or survival under the influence of 
Th1’s signals. 
In the third part of the project, the study was designed to understand the impact of altered 
PF on the requirement of CD4+ T-helper signals for primary and memory CTLs responses. Here, 
the main objectives were to understand: 
1. CD4+ T-helper signals for primary and memory CTL responses at endogenous PF; 
2. CD4+T-helper signals for primary CTL responses at higher PF; 
3. the impact of altered PF on the therapeutic efficacy of DCova immunization; and 
4. CD4+T-helper signals for memory CTL responses at higher PF. 
In the final part of the project, the study was designed to understand the roles of CD4+ T 
cells on different phases of AdV transgene product-specific CTL responses. Here, the main 
objectives were to investigate: 
1. the nature and mechanisms of CD4+ T help for primary CTL responses; 
2. the nature of CD4+ T help for AdV-specific effector and memory CTLs maintenance;  
3. the role of CD4+ T help and its molecular mechanism for functional memory CTL 
responses; and  
4. the role of CD4+ T help for functional recall responses.  
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2.1 Brief introduction to Chapter 2 
 The main goal of the present study is to understand and expand our knowledge on how 
and when CD4+ T cells provide help to CD8+ CTLs for optimal protective responses under 
different immunization conditions. This chapter is mainly focused on understanding how CD4+ T 
cells and their associated signals during priming phase modulate CD8+ CTL effector, survival 
and memory responses. A non-inflammatory DCova immunization model was used in this study. 
Furthermore, this study characterized the “new dynamic model of CD8+ CTL responses via DC-
stimulated CD4+ T helper – Ag-presenting cells (Th-APCs),” proposed recently by our 
laboratory.  
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2.2 Abstract 
T cell-T cell Ag presentation is increasingly attracting attention. We previously showed 
that the in vitro OVA-pulsed dendritic cell (DCOVA)-activated CD4+ Th cells acquired OVA 
peptide/MHC (pMHC) class I and co-stimulatory molecules such as CD54 and CD80 from 
DCOVA and acted as CD4+ Th-APC capable of stimulating OVA-specific CD8+ CTL responses. 
In this study, we further applied the OVA-specific TCR-transgenic OT I and OT II mice with 
deficiency of various cytokines or co-stimulatory molecule genes useful for studying the 
molecular mechanisms underlying in Th-APC’s stimulatory effect. We demonstrated that 
DCOVA-stimulated OT II CD4+ Th-APC also acquired co-stimulatory molecules such as CD40, 
OX40L, and 4-1BBL and the functional pMHC II complexes by DCOVA activation. CD4+ Th-
APC with acquired pMHC II and I were capable of stimulating CD4+ Th1 and central memory 
CD8+44+CD62LhighIL-7R+ T cell responses leading to antitumor immunity against OVA-
expressing mouse B16 melanoma. Their stimulatory effect on CD8+ CTL responses and 
antitumor immunity is mediated by IL-2 secretion, CD40L, and CD80 signaling and is 
specifically targeted to CD8+ T cells in vivo via acquired pMHC I. In addition, CD4+ Th-APC 
expressing OVA-specific TCR, FasL, and perforin were able to kill DCOVA and neighboring Th-
APC expressing endogenous and acquired pMHC II. Taken together, we show that CD4+ Th-
APC can modulate immune responses by stimulating CD4+ Th1 and central memory CD8+ T cell 
responses and eliminating DCOVA and neighboring Th-APC. Therefore, our findings may have 
great impacts in not only the antitumor immunity, but also the regulatory T cell-dependent 
immune tolerance in vivo.  
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2.3 Introduction   
The intercellular transfer of cell surface proteins and the biological function of transferred 
proteins on recipient cells have increasingly attracted great attention for study (1). T cell-to-T 
cell (T-T) antigen presentation, dependent upon CD4+ T cells acquiring major histocampatibility 
complex (MHC) II and CD80 molecules from antigen-presenting cells (APC), has also been 
frequently reported.  However, the role such CD4+ T cells may play have been as yet ill defined, 
and the results of the relevant studies were disparate, in part because multiple experimental 
systems have been used. It has been reported that CD4+ T cells induced T cell apoptosis and 
anergization of CD4+ T cell lines (2, 3) and the transfer of CD4+ T cell line resulted in 
immunosuppression in the context of autoimmune responses (4). In these studies, helper T (Th) 
cells were derived from rather uncharacterized Con A-stimulated allogenic T cells or T cell lines. 
Brandes et al  demonstrated that human γδ T cells expressing MHC II and co-stimulatory 
molecules can stimulate naive αβ T cell proliferation and differentiation (5). Kennedy et al  
reported that the active Th lymphocytes when pulsed with Ag peptides can cross-prime memory 
cytotoxic T lymphocytes (CTL) responses (6). Adamopoulou et al showed that human CD4+ T 
cells displaying viral epitopes elicited a functional virus-specific memory CD8+ T cell response 
(7).  
Recently, we have developed a new concept of  “sequential two-cell interactions by CD4+ 
Th-antigen presenting cells,” a new dynamic model of CD8+ T effector cell responses via CD4+ 
Th cells (8). We demonstrated that the ovalbumin (OVA)-pulsed dendritic cell (DCOVA)-
activated CD4+ Th cells were able to acquire from DCOVA the immunological synapse-comprised 
peptide/MHC (pMHC) II complexes and co-stimulatory molecules (CD54 and CD80) as well as 
the bystander pMHC I since both pMHC I and II as well as co-stimulatory molecules localize in 
the same immunological synapse formed between a DCOVA and a CD4+ T cell (9). These CD4+ 
Th cells with acquired pMHC I and co-stimulatory molecules by DCOVA stimulation termed 
CD4+ Th-APC were able to stimulate naïve OT I CD8+ T cell proliferation and differentiation 
into CTL, and induce effective OVA-specific anti-tumor immunity (8). However, some 
important issues related to this new concept of CD4+ Th-APC remain unclear. These include (i) 
whether CD4+ Th-APC can also acquire the other co-stimulatory molecules and the pMHC 
complexes by in vivo DCOVA stimulation, (ii) whether the acquired pMHC II on these CD4+ Th-
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APC are functional, (iii) which type of  CTLs these CD4+ Th-APC-stimulated CD4+ and CD8+ T 
cells are belonged to, and (iv) what is the molecular mechanism responsible for Th-APC’s 
stimulatory effect on in vivo stimulation of CD8+ CTL responses and antitumor immunity.  
In this study, we applied the OVA-specific T cell receptor (TCR) transgenic OT I and OT 
II mice with or without deficiency of various cytokines or co-stimulatory molecules. This model 
system provides a monoclonal source of OVA-specific CD4+ and CD8+ T cells, which is useful 
for studying cellular interactions between OVA-specific CD4+ and CD8+ T cells at the molecular 
level to address the above questions. We found that both in vitro and in vivo DCOVA-stimulated 
OT II CD4+ Th cells acquired pMHC I and II complexes. CD4+ Th-APC with acquired pMHC II 
and I were capable of stimulating CD4+ Th1 cell and CD8+44+CD62LhighIL-7R+ central memory 
CTL responses, and antitumor immunity against OVA-expressing mouse B16 melanoma. Their 
stimulatory effect on CD8+ CTL responses and antitumor immunity is mediated by IL-2 
secretion, CD40L and CD80 costimulation, and specifically targeted to CD8+ T cells in vivo via 
acquired pMHC I complexes.  
2.4 Materials and methods 
2.4.1 Tumor cells, reagents and animals  
The mouse B16 melanoma BL6-10 and thymoma EL-4 tumor cell lines were maintained 
in DMEM containing 10% FCS, whereas the OVA-transfected BL6-10 (BL6-10OVA) and EL-4 
(EG7) tumor cell lines were maintained in DMEM containing 10% FCS and G418 (0.5 mg/ml) 
(8). The mouse B cell hybridoma cell line LB27 expressing both H-2Kb and Iab was obtained 
from American Type Culture Collection. The mouse T cell hybridoma cell lines RF3370 and 
MF72.2D9 expressing TCR specific for Kb-OVAI and Iab-OVAII peptide complexes, 
respectively, were obtained from Dr. K. Rock (University of Massachusetts Medical Center, 
Worcester, MA) (10). The biotin-labeled and fluorescent dye (FITC, PE, and energy-coupled dye 
(ECD)-labeled Abs specific for CD3 (145-2C11), CD4 (GK1.5), CD11c (HL3), CD25 (7D4), 
CD40 (3/23), CD40L (TRAP1), CD44 (C26), CD45.1 (A20), 4-1BBL (TKS-1), OX40L 
(RM134L), CD62L (MEL-14), CD69 (H1.2F3), CD80 (16-10A), IL-7R (4G3), CD40L (MR1), 
FasL (NOK-1), IL-4 (11B11) and IFN-γ (XMG1.2) Abs from BD Pharmingen and perforin 
(CB5.4) from Alexis Biochemicals were obtained. The recombinant GM-CSF, IL-2, IL-4, IL-7, 
and IL-12 as well as the anti-IL-4 Ab were obtained from R&D Systems. The anti-H-2Kb/OVAI 
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(pMHC I) Ab was obtained from Dr. J. Germain (National Institutes of Health, Bethesda, MD) 
(11). The PE-H-2Kb/OVAI tetramer and FITC-anti-CD8 Ab were obtained from Beckman 
Coulter. The OVAI (OVA257–264, SIINFEKL), OVAII (OVA323–339, ISQAVHAAHAEINEAGR) 
(12), and irrelevant Mut1 (FEQNTAQP) (13) peptides for H-2Kb were synthesized by Multiple 
Peptide Systems. Concanamycin A (CMA) and emetin were obtained from Sigma-Aldrich 
Canada. C57BL/6 (B6, CD45.2+), C57BL/6/B6.1 (B6.1, CD45.1+), OVA257–264, and OVA323–339-
specific TCR-transgenic OT I and OT II mice and IL-2, IFN-γ, TNF-α, CD28, CD40, CD40L, 
OX40L, and CD80 gene knockout (KO) mice on a C57BL/6 background were obtained from 
The Jackson Laboratory. 4-1BBL gene KO mice on a C57BL/6 background were obtained from 
Amgen. Homozygous OT II/H-2Kb−/−, OT II/CD40−/−, OT II/CD40L−/−, OT II/4-1BBL−/−, OT 
II/OX40L−/−, OT II/CD80−/−, OT II/IL-2−/−, OT II/TNF-α−/−, and OT II/IFN-γ−/− mice were 
generated by backcrossing the designated gene KO mice onto the OT II background for two 
generations. Homozygous OT II/B6.1 and OT I/B6.1 mice were generated by backcrossing B6.1 
mice onto the OT II and OT I backgrounds, respectively. The homozygosity was confirmed by 
PCR according to The Jackson Laboratory’s protocols or flow cytometry. All mice were treated 
according to animal care committee guidelines of the University of Saskatchewan.  
2.4.2 Preparation of DC 
Bone marrow-derived DC generated using GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) and 
pulsed overnight at 37°C with 0.3 mg/ml OVA (Sigma-Aldrich) (8) were referred to as DCOVA. 
These DC displayed cell surface H-2Kb, Iab, CD40, CD54, CD80, and pMHC I (14), indicating 
that they are mature DC. OVA-pulsed DC generated from H-2Kb, CD40, 4-BBL, OX40L, and 
CD80 gene KO mice were referred to as (Kb−/−)DCOVA, (CD40−/−)DCOVA, (4-1BBL−/−)DCOVA, 
(OX40L−/−)DCOVA, and (CD80−/−)DCOVA, respectively.  
2.4.3 Preparation of naive CD4+ and CD8+ T cells and active CD4+ T cells  
The naive CD4+ and CD8+ T cells were prepared from splenocytes of OT II mice, OT II 
mice with various gene KO, and OT I mice were enriched by passage through nylon columns 
(C&A Scientific) and purified by negative selection using anti-mouse CD8 (Ly2) and CD4 
(L3T4) paramagnetic beads (Dynal). To generate the in vitro DCOVA-activated CD4+ T cells, 
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naive CD4+ T cells (4 × 106 cells/ml, 100 μl/well) from OT II mice were stimulated for 3 days 
with irradiated (4000 rad) DCOVA (1 × 106 cells/ml, 100 μl/well) in the presence of IL-2 (10 
U/ml), IL-12 (5 ng/ml), and anti-IL-4 Ab (10 μg/ml) (8). These in vitro DCOVA-activated CD4+ T 
cells were then isolated by Ficoll-Paque (Sigma-Aldrich Canada) density gradient centrifugation 
and further purified by positive selection using CD4 microbeads (Miltenyi Biotec). The CD4+ T 
cells derived from OT II mice with respective IL-2, IFN-γ, TNF-α, CD40L, CD40, 4-1BBL, 
OX40L, and CD80 gene KO were referred to as CD4+ (IL-2−/−)T, (IFN-γ−/−)T, (CD40L−/−)T, 
(CD40−/−)T, (4-1BBL−/−)T, (OX40L−/−)T, and (CD80−/−)T cells, respectively. The in vitro 
DCOVA-activated CD4+ T, (IL-2−/−)T, (IFN-γ−/−)T, (TNF-α−/−)T, and (CD40L−/−)T cells were 
referred to as CD4+ Th-, (IL-2−/−)Th-, (IFN-γ−/−)Th-, (TNF-α−/−)Th-, and (CD40L−/−)Th-APC, 
respectively. The in vitro (CD40−/−)DCOVA-, (4-1BBL−/−)DCOVA-, and (OX40L−/−)DCOVA-
activated CD4+ T cells were referred to as CD4+ (CD40−/−)Th-, (4-1BBL−/−)Th-, and 
(OX40L−/−)Th-APC, respectively. The in vitro (Kb−/−)DCOVA-activated OT II/Kb−/− CD4+ T cells 
without acquired pMHC I complexes were referred to as (Kb−/−)Th-APC, whereas the in vitro 
(CD80−/−)DCOVA-activated OT II/CD80−/− CD4+ T cells were referred to as (CD80−/−)Th-APC. 
The phenotypes and cytokine profiles of the above CD4+ Th-APC with various gene KO were 
similar to CD4+ Th cells except for the specifically designed gene deficiency (data not shown). 
To prepare in vivo DCOVA-activated CD4+ Th-APC, the OT II/Kb−/− mice were s.c. immunized 
with irradiated (4000 rad) DCOVA or (Kb−/−)DCOVA (1 × 106 cells/mouse). Three days later, CD4+ 
T cells were purified from immunized mouse draining lymph nodes by positive selection using 
CD4 microbeads (Miltenyi Biotec) and referred to as CD4+ Th-APCvivo and (Kb−/−)Th-
APCvivo, respectively. Con A-stimulated OT II CD4+ T (Con A OT II) cells were generated by 
incubating OT II mouse splenocytes with Con A (1 μg/ml) and IL-2 (10 U/ml) for 3 days. The 
Con A-stimulated CD4+ T cells were then purified on density gradients and then using CD4 
microbeads (Miltenyi Biotec). The cytokine secretion in the supernatants of the above CD4+ Th-
APC was assessed using cytokine ELISA kits (R & D Systems). The phenotypes and cytokine 
profiles of Con A-stimulated CD4+ T cells were similar to in vitro DCOVA-stimulated CD4+ Th 
cells (data not shown).  
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2.4.4 Phenotypic analysis of CD4+ Th-APC  
The BM-derived OVA-pulsed DCOVA and the purified DCOVA-activated CD4+ Th-APC or 
Th-APC with various gene KO were stained with a panel of Abs or with PE-anti-CD4, FITC-
anti-CD11c and ECD-CD3 Abs and then analyzed by flow cytometry (14). For intracellular 
cytokines, cells were restimulated with OVAII-pulsed irradiated (4000rad) LB27, permeabilised 
using Cytofix/CytoPerm Plus reagent (BD Pharmingen) and stained for detecting the expression 
of IL-4, IFN-γ or perforin (14, 35). In another set of experiments, CD4+ Th-APC and Th-
APC(Kb−/−) cells derived from DCOVA and (Kb−/−)DCOVA activation were stained with biotin-anti-
pMHC I Ab and FITC-avidin and then analyzed by confocal fluorescence microscopy.  
2.4.5 Ag presentation 
RF3370 and MF72.2D9 hybridoma cells (0.5 × 105 cells/well) were cultured with 
irradiated (4000 rad) DCOVA, CD4+ Th-APC, Th-APCvivo, and Con A OT II cells (1 × 105 
cells/well) for 24 h. The supernatants were then harvested for measurement of IL-2 secretion 
using an ELISA kit (R & D Systems).   
2.4.6 T cell proliferation assays 
In the in vitro T cell proliferation assays, irradiated (4000 rad) stimulators, DCOVA (0.1 × 
105 cells/well), CD4+ Th-APC, Th-APCvivo, and Con A OT II cells (each 0.4 × 105 cells/well), 
and their 2-fold dilutions, were cultured with a constant number of responders, the naive OT II 
CD4+ or OT I CD8+ T cells (0.5 × 105 cells/well). After 48 h, [3H] thymidine incorporation was 
determined by liquid scintillation counting. In another set of experiments, the purified naive OT I 
CD8+ or OT II CD4+ T cells (0.5 × 105 cells/well) were first labeled with CFSE (final 
concentration, 0.3 μM) and then cocultured with irradiated (4000 rad) stimulators, DCOVA (0. 1 × 
105 cells/well) and CD4+ Th-APC or Con A OT II cells (each 0.4 × 105 cells/well). Three days 
after culture, the cultured cells were purified by Ficoll-Paque density gradient centrifugation 
before determining the number of CFSE-labeled T cell divisions by flow cytometry.  
In the in vivo T cell proliferation assays, C57BL/6 mice (six mice per group) were i.v. 
injected with CFSE-labeled naive OT II CD4+ and OT I CD8+ T cells (4 × 106 cells each mouse). 
One day after the injection, the mice were i.v. immunized with the irradiated (4000 rad) DCOVA 
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(0.5 × 106 cells/mouse) and Th-APC or Con A OT II T cells (3 × 106 cells/mouse). Three days 
after immunization, the mouse splenocytes were analyzed for determination of the number of 
CFSE-labeled T cell divisions by flow cytometry. To assess whether CD4+ Th-APC with 
acquired pMHC I and II can stimulate CD4+ and CD8+ T cell responses, we performed another 
set of in vivo T cell proliferation assays. In the in vivo CD4+ T cell proliferation assay, 
C57BL/6/6.1 (CD45.1+) mice (six mice per group) were i.v. immunized with irradiated (4000 
rad) DCOVA (0.5 × 106 cells/mouse) and CD4+ Th-APC or Th-APCvivo (3 × 106 cells/mouse). 
The tail blood samples derived from mice 4 days after immunization were incubated with PE-
CD45.1, FITC-anti-CD4, and ECD-anti-CD44 Abs (Beckman Coulter) and analyzed by flow 
cytometry. In the in vivo the CD8+ T cell proliferation assay, C57BL/6 mice (six mice per group) 
were i.v. immunized with irradiated (4000 rad) DCOVA (0.5 × 106 cells/mouse) and CD4+ Th-
APC and Th-APCvivo or CD4+ Th-APC with different gene KO (3 × 106 cells/mouse). The tail 
blood samples derived from these immunized mice 6 days after immunization were stained with 
PE-H-2Kb/OVAI tetramer and FITC-anti-CD8 Ab (Beckman Coulter) and analyzed by flow 
cytometry (14).  
2.4.7 Cytotoxicity assays 
In the first in vitro cytotoxicity assay, CD4+ Th-APC were used as effector cells, while 
51Cr-labeled DCOVA, OVAII-pulsed LB27, and Th-APC were used as target cells in a chromium 
release assay (14). For testing the killing mechanisms, the effector cells were preincubated with 
CMA (1 μM) and emetin (5 μM) for 2 h before incubation with the target cells to prevent 
perforin- and Fas-FasL interaction-mediated cytotoxicity (15). In the second in vitro cytotoxicity 
assay, naive CD8+ T cells (4×106 cells/ml, 100 μl/well) derived from OT I/B6.1 (CD45.1+) mice 
were cocultured in 96-well plates with irradiated (4000 rad) DCOVA (1 × 106 cells/ml, 100 
μl/well) and CD4+ Th-APC (2 × 106 cells/ml, 100 μl/well) in the presence of IL-2 (10 U/ml) for 
3 days (8). After incubation, the active OT I/B6.1 CD8+ T cells were harvested and then purified 
on density gradients followed by positive selection using the biotin-conjugated anti-CD45.1 Ab 
and anti-biotin microbeads (Miltenyi Biotec). These purified CD8+ T cells were referred to as 
DCOVA/OT I6.1 and CD4+ Th-APC/OT I6.1, respectively, and used as effector cells. The 51Cr-
labeled EG7 and the control EL-4 tumor cells were used as target cells. Specific killing was 
calculated as: 100 × [(experimental cpm − spontaneous cpm)/(maximal cpm − spontaneous cpm) 
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as previously described (8). In the in vivo cytotoxicity assay, naive C57BL/6 mouse splenocytes 
were stained with either high (3.0 μM, CFSEhigh) or low (0.6 μM, CFSElow) concentrations of 
CFSE at 37°C for 20 min and then pulsed with OVAI and Mut1 peptide (10 μM) for 2 h, 
respectively. After washes with PBS, these target cells (2 × 106 cells each mouse) were i.v. 
coinjected at 1:1 ratio into the above different groups of mice 6 days after immunization. Sixteen 
hours later, the residual CFSEhigh and CFSElow target cells remaining in the recipients’ spleens 
were sorted and analyzed by flow cytometry (8).  
2.4.8 In vivo CD8+ T cell survival  
Naive C57BL/6 mice (six mice per group) were i.v. transferred with the above in vitro 
DCOVA- and CD4+ Th-APC-primed CD8+45.1+ T (DCOVA/OT I6.1 and CD4+ Th-APC/OT I6.1) 
cells (5 × 106 cells/mouse). The tetramer staining assay was performed to examine the presence 
of OVA-specific CD8+ T cells in mouse peripheral blood 6 days and once a week for 3 months 
after the adoptive T cell transfer. The tail blood samples were stained with PE-H-2Kb/OVAI 
tetramer, FITC-anti-CD8, and ECD-anti-CD25, ECD-anti-CD44, ECD-anti-CD45.1, ECD-anti-
CD62L, and ECD-anti-IL-7R Abs, respectively, and analyzed by flow cytometry.  
2.4.9 Animal studies 
Wild-type C57BL/6 mice (eight mice per group) were immunized with irradiated (4000 
rad) DCOVA (0.5 × 106 cells/mouse), the in vitro DCOVA-activated CD4+ Th-APC, (Kb−/−)Th-
APC, (IL-2−/−)Th-APC, (IFN-γ−/−)Th-APC, (TNF-α−/−)Th-APC, (CD40−/−)Th-APC, 
(CD40L−/−)Th-APC, (4-1BBL−/−)Th-APC, (OX40L−/−)Th-APC, and (CD80−/−)Th-APC (3 × 106 
cells/mouse), or the in vivo DCOVA-activated CD4+ Th-APCvivo (5 × 106 cells/mouse), 
respectively. Six days subsequent to the immunization, each mouse was challenged i.v. with 
BL6-10OVA or BL6-10 tumor cells (0.5 × 106 cells each mouse). The mice were sacrificed 4 wk 
after tumor cell challenge and the numbers of lung metastatic tumor colonies were counted in a 
blind fashion (8). Metastases on freshly isolated lungs appeared as discrete black-pigmented foci 
that were easily distinguishable from normal lung tissues and confirmed by histological 
examination. Metastatic foci too many to count were assigned an arbitrary value of >100.  
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2.5 Results 
2.5.1 CD4+ Th cells acquire costimulatory molecules and pMHC complexes by DCOVA activation  
We showed that OVA-pulsed bone marrow-derived DC (DCOVA) expressed CD11c, Iab, 
CD40, CD80, 4-1BBL, OX40L, and pMHC I (Fig. 1a), indicating that they are OVA-specific 
mature DC. The in vitro DCOVA-activated OT II CD4+ T cells expressed CD4, CD40L, and 
CD69 (Fig. 1b), indicating that they are active OVA-specific CD4+ T cells. In addition, they also 
expressed FasL and perforin. These active CD4+ T cells secreted IL-2 (~2.5 ng/ml/106 cells per 
24 h) and IFN-γ (~2 ng/ml/106 cells per 24 h), but not IL-4, indicating that they are Th1 cells. 
We previously demonstrated that these CD4+ Th-APC acquired DC MHC class I and co-
stimulatory molecules (CD54 and CD80) (8). In this study, we showed that the naive OT II CD4+ 
T cells did not express any CD40, CD80, 4-1BBL, OX40L, and pMHC I. However, these in vitro 
DCOVA-activated CD4+ Th-APC did show some expression of CD40, CD80, OX40L, 4-1BBL, 
and pMHC I by using the anti-co-stimulatory molecule Abs and the specific anti-pMHC I Ab 
(Fig. 1b). Therefore, we termed these CD4+ Th cells with acquired pMHC I and co-stimulatory 
molecules the CD4+ Th-APC. Since active CD4+ T cells do not express CD40, OX40L, and 4-
1BBL, but do display some expression of endogenous CD80 by flow cytometric analysis (data 
not shown), the above results indicate that the expression of CD40, OX40L, and 4-1BBL on 
CD4+ Th-APC should be derived from DCOVA by DCOVA activation, whereas CD80 molecules 
on CD4+ Th-APC may be derived from either endogenous CD80 expression of the active CD4+ 
Th cells or acquisition of CD80 from DCOVA or both. This is confirmed by the evidence that 1) 
CD4+ (Kb−/−)Th-APC derived from pMHC I-negative (Kb−/−)DCOVA stimulation did not express 
any pMHC I complex (Fig. 1c and d) and 2) CD4+ Th-APC with various co-stimulatory 
molecule gene KO did not express the respective co-stimulatory molecules such as CD40, 4-
1BBL, and OX40L when these CD4+ Th-APC were derived from the stimulation of 
(CD40−/−)DCOVA, (4-1BBL−/−)DCOVA and (OX40L−/−)DCOVA, respectively (Fig. 1c). CD4+ Th-
APC derived from OT II CD4+ T cells activated by (CD80−/−)DCOVA still expressed some CD80 
molecules (Fig. 1c), but in lower amounts than CD4+ Th-APC derived from DCOVA activation 
(Fig. 1b), indicating that some CD80 molecules expressed on CD4+ Th-APC may be acquired 
from DCOVA. To confirm it, we further analyzed the CD80 expression of the in vitro 
(CD80−/−)DCOVA-activated OT II/CD80−/− CD4+ T cells with deficiency of endogenous CD80 
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expression by flow cytometry. As shown in Fig. 1e, the CD4+ (CD80−/−)Th-APC derived from 
naive OT II/CD80−/− CD4+ T cells activated in vitro by (CD80−/−)DCOVA did not express any 
CD80 molecules, indicating that the CD80 expression on active CD4+ Th-APC is derived partly 
from its endogenous CD80 expression and partly from acquired CD80 molecules from DCOVA. 
To rule out the possibility of irradiated DCOVA contamination in the CD4+ Th cell population, we 
also analyzed them using the anti-CD4 and anti-CD11c Abs specific for CD4+ T cell and DC 
markers, respectively, by flow cytometry. As shown in Fig. 1f, the original DCOVA were 
CD4−CD11chigh. The vast majority (99.98%) of CD4+ Th-APC purified by positive selection 
using CD4 microbeads were CD4highCD11c− T cells, indicating that there is no detectable DCOVA 
in purified CD4+ Th-APC population. This is because that any DCOVA which survived after 
irradiation-induced apoptosis would still be eliminated by the killing activity of CD4+ T cells 
activated by DCOVA (16, 17). We noted that there was a very small amount (0.02%) of cells 
showing CD4highCD11clow within the purified CD4+ Th-APC population. These cells should still 
be considered to be CD4+ Th-APC rather than CD4−CD11chigh DCOVA, because they expressed 
CD4 and the T cell marker CD3. The small amount of CD11c on these CD4+ T cells may be 
derived from its acquisition of DC’s CD11c via a dissociation-associated pathway as we 
previously described (18). To assess pMHC I acquisition by in vivo DCOVA stimulation, CD4+ 
Th-APC were purified from OT II/Kb−/− mice immunized with DCOVA with pMHC I expression 
or (Kb−/−)DCOVA without pMHC I expression and analyzed by flow cytometry. As shown in Fig. 
1g, DCOVA-stimulated CD4+ Th-APCvivo, but not (Kb−/−)DCOVA-stimulated CD4+ (Kb−/−)Th-
APCvivo cells, exhibited pMHC I expression, indicating that CD4+ Th-APC can also acquire 
pMHC I by in vivo DCOVA stimulation.  
2.5.2 The acquired pMHC II complexes on CD4+ Th-APC are functional  
To examine the functionality of acquired pMHC II complexes, we initially assessed their 
ability to stimulate IL-2 secretion of T cell hybridoma MF72.2D9 expressing TCR specific for 
pMHC II. As shown in Fig. 2a, MF72.2D9 cells alone did not secrete any IL-2. However, the in 
vitro DCOVA-activated CD4+ Th-APC with acquired pMHC II, but not Con A-stimulated CD4+ 
OT II T cells without pMHC II expression stimulated MF72.2D9 to secrete IL-2 (320 pg/ml) as 
did DCOVA (770 pg/ml), indicating that CD4+ Th-APC express the functional pMHC II 
complexes. Furthermore, the in vivo DCOVA-stimulated CD4+ Th-APCvivo cells also stimulated 
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MF72.2D9 to secrete IL-2 (180 pg/ml), indicating that the acquired pMHC II complexes on 
CD4+ Th-APCvivo are also functional.  
2.5.3 CD4+ Th-APC expressing TCR negatively modulate immune responses  
To assess whether these CD4+ Th-APC expressing FasL and perforin may kill pMHC II 
expressing DCOVA and Th-APC, we performed an in vitro cytotoxicity assay. As shown in Fig. 
2b, Th-APC exhibited cytotoxicity to OVAII-pulsed LB27 tumor cells expressing pMHC II 
(40% specific killing at E:T cell ratio of 50) and DCOVA expressing endogenous pMHC II (25% 
specific killing at E:T cell ratio of 50), indicating that CD4+ Th-APC after they were activated by 
DCOVA can kill DCOVA, which further supports our above data showing that there is no 
contaminating irradiated DCOVA in the purified CD4+ Th-APC population (Fig. 1f). Because 
CD4+ Th-APC acquired the functional pMHC II, they may also become sensitive to neighboring 
Th-APC expressing TCR. Our data did display that Th-APC killed 51Cr-labeled Th-APC 
(fratricide) (21% specific killing at E:T cell ratio of 50). In addition, they did not kill the original 
DC and LB27 cells, indicating that the killing activity is OVA specific. CTL are able to lyse 
target cells by two mechanistically distinct, but functionally similar mechanisms (19): a Ca2+-
dependent perforin and a Ca2+-independent Fas/FasL mechanism. To assess which type of 
pathway is responsible for the cytotoxicity mediated by Th-APC expressing FasL and perforin, 
CMA and emetin were used to inhibit perforin- and Fas-FasL interaction-mediated cytotoxicity, 
respectively, in a chromium release assay. Our data showed that treatment of Th-APC with CMA 
(1 μM) and emetin (5 μM) resulted in ~85 and ~8% inhibition of its cytotoxicity to either Th-
APC or DCOVA target cells (Fig. 2c), indicating that the perforin-mediated pathway plays a major 
role in in vitro Th-APC-mediated cytotoxicity, which is consistent with some previous reports 
(20, 21). Our data thus indicate that CD4+ Th-APC expressing OVA-specific TCR may 
negatively modulate immune responses by eliminating DCOVA expressing endogenous pMHC II 
and Th-APC expressing acquired pMHC II, when the initial immune responses are too strong.  
2.5.4 CD4+ Th-APC with acquired pMHC II stimulate functional CD4+ Th1 cell responses  
Since CD4+ Th-APC acquired the functional pMHC II complexes, we then assessed their 
ability to induce proliferation of naive OT II CD4+ T cells in vitro and in vivo. Like the positive 
control stimulator DCOVA, CD4+ Th-APC with acquired pMHC II, but not Con A-stimulated 
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CD4+ T cells without acquired pMHC II stimulated in vitro OT II CD4+ T cell proliferation in a 
dose-dependent manner in a [3H]thymidine incorporation assay (Fig. 2d). To confirm it, we first 
labeled the naive OT II CD4+ T cells with CFSE. We then in vitro incubated these CFSE-labeled 
CD4+ T cells with the stimulators or i.v. injected them into the wild-type C57BL/6 mice 
followed by i.v. immunizing the mice with these stimulators 1 day after the injection of CFSE-
labeled T cells. This dye is equally partitioned upon cell division, allowing the generation of 
proliferation profiles. Three days after the incubation or immunization, the CFSE-labeled CD4+ 
T cells in the culture wells or in the immunized mouse spleens were harvested and analyzed by 
flow cytometry. The flow cytometric analysis in Fig. 2e revealed substantial activation of naive 
CD4+ T cells indicated by CFSE dilutions, indicating that DCOVA and CD4+ Th-APC stimulate 
both in vitro and in vivo CFSE-labeled CD4+ T cell divisions. However, CD4+ Th-APC-induced 
stimulations in the above experiments are less efficient than DCOVA, possibly due to 1) fewer 
acquired pMHC II and co-stimulatory molecules on CD4+ Th-APC than on DCOVA and 2) 
lacking the third signal (DC-secreted IL-12) derived from CD4+ Th-APC (22). To further assess 
whether Th-APC can stimulate in vivo OVA-specific CD4+ T cell responses, we immunized 
C57BL/6.1 (CD45.1+) mice with Th-APC and Th-APCvivo and DCOVA derived from OT II and 
C57BL/6 mice (CD45.2+) and then examined the OVA-specific CD4+ T cell responses in these 
immunized mice by flow cytometry. The activation of CD4+ T cells was measured by staining 
for CD44 surface expression as CD44high represents the activated T cell phenotype. As shown in 
Fig. 2f, DCOVA stimulated proliferation of OVA-specific naive CD4+ T cells and differentiation 
into active CD4+44high45.1+ T cells that accounted for 37.5% of the total CD4+ T cell population. 
Interestingly, CD4+ Th-APC and Th-APCvivo with acquired pMHC II, but not Con A-stimulated 
OT II CD4+ T cells without pMHC II expression also stimulated the responses of 
CD4+44high45.1+ T cells that accounted for 35.1 and 26.6% of the total CD4+ T cell population, 
respectively, indicating that both CD4+ Th-APC and Th-APCvivo can stimulate in vivo OVA-
specific CD4+ T cell responses. To characterize Th-APC-activated CD4+ T cells, we purified the 
in vitro Th-APC-activated CD4+ T cells and analyzed them by flow cytometry. As shown in Fig. 
2g, these in vitro CD4+ Th-APC-stimulated OT II CD4+ T cells displayed CD4, CD25, and 
CD69, indicating that they are active CD4+ T cells. These active CD4+ T cells also secreted IFN-
γ (1.4 ng/ml/106 cells per 24 h) and IL-2 (1.9 ng/ml/106 cells per /24 h), but not IL-4, indicating 
that they are Th1 cells. Furthermore, immunization of mice with these CD4+ Th-APC-stimulated 
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CD4+ Th1 cells (Th-APC/OT II) alone did not induce any CD8+ CTL responses (Fig. 2h), 
possibly due to lacking expression of pMHC I on these Th-APC-stimulated CD4+ Th1 cells (Fig. 
2g). However, the cotransfer of these CD4+ Th1 cells into DCOVA-immunized mice significantly 
enhanced the OVA-specific CD8+ CTL responses from 2.0 to 3.1% (p < 0.05; Fig. 2h), 
confirming that these CD4+ Th-APC-stimulated CD4+ Th1 cells are functional.  
2.5.5 The acquired pMHC I complexes on CD4+ Th-APC are functional  
To examine the functionality of acquired pMHC I complexes, we initially assessed their 
ability to stimulate IL-2 secretion of T cell hybridoma RF3370 expressing TCR specific for 
pMHC I. As shown in Fig. 3a, RF3370 cells alone did not secrete any IL-2. However, the in 
vitro DCOVA-stimulated CD4+ Th-APC with acquired pMHC I, but not Con A-stimulated CD4+ 
OT II T cells without acquired pMHC I stimulated RF3370 to secrete IL-2 (100 pg/ml) as did 
DCOVA (220 pg/ml), indicating that CD4+ Th-APC express the functional pMHC I complexes. 
Furthermore, the in vivo DCOVA-stimulated CD4+ Th-APCvivo cells also stimulated RF3370 to 
secrete IL-2 (75 pg/ml), indicating that the acquired pMHC I complexes on CD4+ Th-APCvivo 
are also functional.  
2.5.6 CD4+ Th-APC with acquired pMHC I stimulate CD8+ CTL responses and antitumor 
immunity  
The positive control DCOVA strongly induced in vitro OT I CD8+ T cell proliferation (Fig. 
3a). CD4+ Th-APC and Th-APCvivo with acquired pMHC I also stimulated in vitro OT I CD8+ 
T cell proliferation in a dose-dependent fashion in a [3H]thymidine incorporation assay (Fig. 3b). 
In addition, these CD4+ Th-APC also stimulated both in vitro and in vivo CFSE-labeled CD8+ T 
cell divisions (Fig. 3c). To assess their ability to induce in vivo CD8+ T cell responses, we 
performed an OVA-specific tetramer staining assay (14). As shown in Fig. 3d, the positive 
control DCOVA stimulated in vivo proliferation of OVA-specific CD8+ T cells that accounted for 
3.21% of the total CD8+ T cell population. CD4+ Th-APC and Th-APCvivo also stimulated in 
vivo proliferation of OVA-specific CD8+ T cells that accounted for 2.14 and 1.05% of the total 
CD8+ T cell population, respectively. These data clearly indicate that both CD4+ Th-APC and 
Th-APCvivo can stimulate in vitro and in vivo CD8+ T cell responses. To assess CD4+ Th-APC-
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induced CD8+ T cell differentiation into effector CTL, we performed a cytotoxicity assay by 
adoptively transferring OVAI-pulsed/ CFSEhigh-labeled and Mut1-pulsed/CFSElow-labeled 
splenocytes into the immunized mice. We found that there was substantial loss of the CFSEhigh-
labeled OVA-specific target cells in DCOVA-immunized (95%) and Th-APC-immunized (77%) 
or Th-APCvivo-immunized (52%) mice (Fig. 3e), indicating that both DCOVA and CD4+ Th-APC 
or Th-APCvivo can stimulate CD8+ T cell differentiation into effector CTL with killing activity 
for OVA I-pulsed target cells. To assess the antitumor immunity, we performed animal studies 
by i.v. injecting OVA-expressing BL6-10OVA tumor cells into mice immunized with DCOVA, Th-
APC, and Th-APCvivo. We also found that DCOVA immunization protected all mice (eight of 
eight) from lung tumor metastasis, whereas PBS-injected control mice (eight of eight) all had 
large numbers (>100) of lung BL6-10OVA tumor colonies (experiment 1 of Table I). All mice 
(eight of eight) immunized with CD4+ Th-APC and Th-APCvivo also had no lung tumor 
metastasis. The specificity of protection was confirmed with the observation that CD4+ Th-APC 
did not protect against BL6-10 tumors that did not express OVA, with all mice having large 
numbers (>100) of lung tumor colonies (experiment 1 of Table I).  
2.5.7 CD4+ Th-APCs’ stimulatory effect on CD8+ CTL responses and antitumor immunity is also 
mediated by its endogenous CD40L and acquired CD80 costimulations  
To further elucidate the molecular mechanism of CD4+ Th-APC’s stimulatory effect in 
association with the co-stimulatory molecules, these CD4+ Th-APC with respective co-
stimulatory molecule gene deficiency were used in in vivo T cell proliferation and cytotoxicity 
assays and in animal studies as described above. As shown in Fig. 4a, the stimulation efficiency 
of OVA-specific CD8+ T cell responses significantly decreased in the mice immunized with 
CD4+ Th-APC with CD40L (0.37%) and CD80 (0.23%) gene KO (p < 0.05), whereas the OVA-
specific CD8+ T cell responses remained the same as seen in mice immunized with CD4+ Th-
APC with CD40 (1.87%), 4-1BBL (2.09%), and OX40L (2.05%) gene KO, indicating that the 
CD40L and CD80 costimulations greatly influence the CD4+ Th-APC’s stimulatory effect. To 
further confirm it, we assessed CD4+ Th-APC’s stimulatory effect in CD40 and CD28 gene KO 
mice by immunization of the mice with CD4+ Th-APC. Similar to DCOVA, CD4+ Th-APC also 
failed in stimulating CD8+ T cell responses in CD40 and CD28 gene KO mice (Fig. 4b), thus 
confirming that CD4+ Th-APC-activated CD8+ CTL responses are mediated by signaling derived 
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from CD40L-CD40 and CD80-CD28 interactions. In the cytotoxicity assay, we found that there 
was also a substantial decrease of the killing activity of CFSEhigh-labeled OVA-specific target 
cells from 77% in Th-APC-immunized mice to 12 and 18% in (CD40L−/−)Th-APC- and 
(CD80−/−)Th-APC-immunized mice, respectively (Fig. 4c), whereas the killing activity of 
CFSEhigh-labeled OVA-specific target cells remained the same in (CD40−/−)Th-APC (76%)-, (4-
BBL−/−)Th-APC (74%)-, and (OX40L−/−)Th-APC-immunized mice (73%) as in Th-APC-
immunized mice (77%). In animal studies, we also found that all (eight of eight) (CD80−/−)Th-
APC- and 75% (six of eight) (CD40L−/−)Th-APC-immunized mice lost their antitumor immunity 
(experiment 2 of Table I), whereas all (CD40−/−)Th-APC-, (OX40L−/−)Th-APC-, and (4-
1BBL−/−)Th-APC-immunized mice were alive as did the Th-APC-immunized mice. These data 
indicate that the CD4+ Th-APC’s stimulatory effect on CD8+ CTL responses and antitumor 
immunity is mediated by its CD40L and CD80 costimulations.  
2.5.8 CD4+ Th-APC’s stimulatory effect on CD8+ CTL responses and antitumor immunity is 
mediated by its endogenous IL-2 secretion  
To elucidate the molecular mechanism of CD4+ Th-APC’s stimulatory effect in 
association with cytokines, CD4+ Th-APC with respective cytokine gene deficiency were used in 
in vivo T cell proliferation and cytotoxicity assays and in animal studies as described above. As 
shown in Fig. 4a, the stimulation efficiency of OVA-specific CD8+ T cell responses also 
significantly decreased in the mice immunized with CD4+ Th-APC with IL-2 (0.19%) gene KO 
(p < 0.05), whereas the OVA-specific CD8+ T cell responses remained the same as seen in mice 
immunized with CD4+ Th-APC with IFN-γ (1.95%) and TNF-α (1.92%) gene KO, indicating 
that IL-2 secretion influences CD4+ Th-APC’s stimulatory effect. In the cytotoxicity assay, we 
found that there was also a substantial decrease of the killing activity of CFSEhigh-labeled OVA-
specific target cells from 77% in Th-APC-immunized mice to only 8% in (IL-2−/−)Th-APC-
immunized mice (Fig. 4c), whereas the killing activity of CFSEhigh-labeled OVA-specific target 
cells remained the same in (IFN-γ−/−)Th-APC (75%)- and (TNF-α−/−)Th-APC-immunized mice 
(71%) as in Th-APC-immunized mice (77%). In animal studies, we also found that all (eight of 
eight) (IL-2−/−)Th-APC-immunized mice lost their antitumor immunity (experiment 2 of Table 
I), whereas all (IFN-γ−/−)Th-APC (75%)- and (TNF-α−/−)Th-APC-immunized mice were still 
alive as did the Th-APC-immunized mice. These data indicate that the CD4+ Th-APC’s 
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stimulatory effect on CD8+ CTL responses and antitumor immunity is also mediated by its IL-2 
secretion.  
2.5.9 Targeting CD4+ Th-APC’s stimulatory effect to CD8+ CTL responses and antitumor 
immunity via acquired pMHC I  
To investigate the role of acquired pMHC I, we repeated the above assays using both 
DCOVA-activated CD4+ Th-APC with acquired pMHC I and (Kb−/−)DCOVA-activated CD4+ 
(Kb−/−) Th-APC without acquired pMHC I, respectively. We found that both in vitro and in vivo 
DCOVA-stimulated CD4+ Th-APC with acquired pMHC I stimulated in vivo proliferation of 
OVA-specific CD8+ T cells that accounted for 2.14 and 1.12% of the total CD8+ T cell 
population, whereas CD4+ (Kb−/−)Th-APC without acquired pMHC I complexes completely lost 
their in vivo stimulatory effect (0.02%; Fig. 4a). In addition, the CD4+ (Kb−/−)Th-APC-vaccinated 
mice also displayed little killing activity (5%) for the OVA-specific CFSEhigh-labeled target cells 
in the in vivo cytotoxicity assay (Fig. 4c). Furthermore, all mice (eight of eight) immunized with 
CD4+ (Kb−/−)Th-APC had lost their antitumor immunity against BL6-10OVA tumor cells 
(experiment 2 of Table I). These data clearly indicate that the acquired pMHC I complexes play 
an important role in targeting the CD4+ Th-APC’s stimulatory effect mediated by IL-2 secretion 
and CD40L and CD80 costimulations to the in vivo OVA-specific CD8+ T cell responses and 
antitumor immunity.  
2.5.10 CD4+ Th-APC with acquired pMHC I and costimulatory molecules stimulate CD8+ T cell 
differentiation into CMCTL  
To further investigate the subset of CD8+ CTL derived from in vitro CD4+ Th-APC 
priming, we purified the DCOVA- and CD4+ Th-APC-primed CD8+ T cells derived from OT 
I/B6.1 (CD45.1+) mice using CD45.1 microbeads and then conducted phenotypic 
characterization of these CD8+ CTL by flow cytometry. Our data showed that DCOVA- and CD4+ 
Th-APC-primed CD8+ T cells displayed PE-tetramer staining (Fig. 5a), indicating that they are 
OVA-specific CD8+ T cells. They also displayed the expected expression of CD25, CD44 
(memory T cell marker) (16), and CD62L. Interestingly, CD4+ Th-APC-primed CD8+ T cells 
displayed higher CD62L expression than DCOVA-primed ones, indicating that they may be prone 
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to becoming long-lived memory T (Tm) cells after i.v. transfer. To address this possibility, 
DCOVA- and CD4+ Th-APC-primed CD8+ T cells derived from OT I/B6.1 (CD45.1+) mice were 
i.v. transferred into C57BL/6 (B6, CD45.2+) mice. The number of detected OVA-specific CD8+ 
T cells derived from DCOVA and CD4+ Th-APC priming in the mouse blood accounted for 8.2 
and 9.6% of the total CD8+ T cell population at day 6 after the transfer (Fig. 5b). The majority of 
CD8+ T cells were also CD45.1 positive, indicating that they are previously transferred 
CD8+CD45.1+ T cells. The numbers gradually dropped to 2.32 and 6.10% in the first month 
subsequent to, but stably maintained for at least 3 months after the transfer. Interestingly, 6 days 
after transfer, CD4+ Th-APC-primed, but not DCOVA-primed CD8+ T cells became 
CD44+CD62highIL-7R+ (Fig. 5c), a characteristic of central memory CD8+ T cells (23). We then 
further examined whether CD4+ Th-APC-primed CTL exhibited any other functional traits 
attributed to typical memory cells. These traits include 1) the enhanced survival and proliferation 
in response to IL-7 (24), 2) the capacity to generate Ag-specific CTL, and 3) to expand upon Ag 
stimulation. Our data showed that the in vitro CD4+ Th-APC-primed CTL expanded similarly as 
DCOVA-primed ones in the presence of IL-2. However, they expanded much better than DCOVA-
primed ones in the presence of both IL-2 and IL-7 (Fig. 5d). In the chromium release assay, 
CD4+ Th-APC-primed CTL (Th-APC/OT I6.1) showed cytotoxicity to OVA-expressing EG7 
tumor cells, but at a lower level than DCOVA-primed ones (DCOVA/OT I6.1; Fig. 5e). CD4+ Th-
APC-primed CD8+ CTL expressing TCR also killed Th-APC expressing acquired pMHC I, 
which is consistent with a recent report of Cox et al. (25). In addition, the above in vivo-
transferred CTL can be greatly expanded 3 mo after the transfer upon DCOVA stimulation. As 
shown in Fig. 5f, the expanded CD4+ Th-APC-primed CD8+ Tm cells accounted for almost 95% 
of the total CD8+ T cell population, which is 3-fold more than the expansion of DCOVA-primed 
CD8+ Tm cells (32%). These expanded CD8+ Tm cells are CD25+44+69+ effector CTL. Taken 
together, DCOVA- and CD4+ Th-APC-primed CTL have high and low cytotoxicity, but low and 
high survival capacity, representing the typical effector memory CTL (EMCTL) and CMCTL, 
respectively. Thus, our data indicate that CD4+ Th-APC with acquired pMHC I and co-
stimulatory molecules are capable of stimulating naive CD8+ T cell differentiation into CMCTL.  
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2.6 Discussion 
According to the progressive linear differentiation hypothesis (26), T cell differentiation 
involves a phase of proliferation preceding the acquisition of fitness and effector function. 
Primed CD8+ T cells reach a variety of differentiation stages that contain effector cells as well as 
cells that have been arrested at intermediate levels of differentiation. Thus, they retain a flexible 
gene imprinting. T cells that survive after the retraction phase of an immune response can be 
resolved into distinct subsets of either CMCTL representing cells at the intermediate 
differentiation stage or fully differentiated EMCTL with effector capacity (27). It has been shown 
that a strong Ag presentation stimulates development of effector CTL, whereas a less efficient 
Ag presentation can lead to the generation of CMCTL responses (28). In this study, we 
demonstrated that CD4+ Th cells were able to stimulate naive CD8+ T cell differentiation into 
central memory CD44+CD62highIL-7R+ T cells with less cytotoxicity and longer survival 
capacity, compared with DCOVA-primed CD44+CD62lowIL-7R− EMCTL with high cytotoxicity 
and shorter survival capacity in vivo. This is consistent with another recent report by 
Adamopoulou et al. (7) that human CD4+ T cells displaying viral epitopes elicited a functional 
virus-specific memory CD8+ T cell response. Thus, it seems reasonable to conclude that due to 
the lower level of activation/costimulation signals provided by CD4+ Th-APC as compared with 
DC, CD4+ Th-APC-primed CD8+ T cells would preferentially differentiate into CMCTL, whereas 
DCOVA-primed CD8+ T cells would preferentially differentiate into EMCTL. This finding is 
consistent with some recent reports that the “dilution” of pMHC complexes by DC division may 
regulate T cell fate, with more initial pMHC on DC stimulating the differentiation of T effector 
cells and less pMHC on daughter DC given rise to central memory T cells (29, 30) and that 
enhanced costimulation can lead to reduced Tm cell formation (31).   
Previous experimental evidence showed that a provision of IL-2 dramatically augmented 
the efficiency of CTL expansion (32). However, one important question on how the CD4+ Th-
APC’s IL-2 can be specifically delivered to Ag-specific CD8+ CTL in vivo still remains 
puzzling. In this study, we clearly demonstrated that IL-2 secretion mediates the CD4+ Th-APC’s 
stimulatory effect to CD8+ T cells in vivo, which is consistent with some recent reports showing 
that the help effect of transferred CD4+ Th cells on adoptively transferred CD8+ CTL responses 
and CD8+ memory T cell expansion is mediated by its IL-2 secretion (33-35).  
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Costimulations derived from CD40, CD80, 4-BBL, and OX40L play an important role in 
APC-activated CD8+ CTL responses (36). In this study, we found that CD4+ Th-APC also 
acquired CD40, 4-1BBL, and OX40L by DCOVA activation in addition to the previously reported 
CD80 co-stimulatory molecule (8). To assess the role of these acquired co-stimulatory molecules 
on CD4+ Th-APC, we performed tetramer staining, in vivo cytotoxicity assays, and animal 
studies. We found that CD80, but not CD40, 4-1BBL, and OX40L co-stimulatory signaling on 
CD4+ Th-APC is involved in mediating CD4+ Th-APC-stimulated CD8+ CTL responses and 
antitumor immunity. CD28-CD80 interactions are necessary to sustain late T cell proliferation 
(37). T cell-T cell Ag presentation, dependent upon CD4+ T cells acquiring CD80 molecules 
from APC, has recently been reported. For example, CD4+ T cell acquisition of CD80 from APC 
plays an important role in retaining CD4+ T cell activation in the absence of APC via up-
regulation of NF-κB and Stat5 (38). It has also been reported that CD8+ memory T cells with 
acquired pMHC I and CD80 up-regulated caspase 3, bcl-x, bak, and bax, leading to cell 
apoptosis (39). In this study, we clearly elucidated another important role on CD4+ Th-APC’s 
acquisition of CD80 from DCOVA by demonstrating that the acquired CD80 molecules on CD4+ 
T cells are involved in stimulation of in vivo CD8+ CTL responses by providing the critical 
signal 2 costimulation (40). CD40L-CD40 interactions play an important role in mediating CD4 
helper functions for CD8+ T cell responses. For example, DC present Ags to and activate CD4+ T 
cells with its CD40 costimulation. In addition, when DC stimulate CD4+ T cells, the stimulated 
CD4+ T cells consecutively activate DC through CD40L, allowing DC to become competent to 
drive CD8+ T cell responses (41-43). However, this concept was challenged by the finding that 
CD8+ T cells transiently express CD40 after activation and they could receive CD4 help directly 
via CD40 (44), suggesting that the CD40L signals to CD8+ T cells may be derived from active 
CD4+ T cells. Recently, we have demonstrated that OVA-pulsed DC (DCOVA)-activated OT II 
CD4+ Th cells acquired MHC I and co-stimulatory molecules from DCOVA and acted as CD4+ Th 
cells capable of stimulating OVA-specific CD8+ CTL responses (8). In this study, we further 
demonstrated that CD4+ Th-APC’s CD40L signal plays an important role in initiation of CD8+ T 
cell proliferation and differentiation into CMCTL, clearly elucidating that the CD40L signaling to 
CD8+ T cells is indeed derived from active CD4+ Th-APC.  
More recently, Cox et al. (25) have demonstrated that CD4+ Th cells with acquired 
bystander pMHC I complexes from APC became susceptible to CTL killing in an Ag-specific 
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manner. However, the molecular mechanism for CD4+ Th cell acquisition of the bystander 
pMHC I from DC by DC activation is unclear. We have recently demonstrated that pMHC I and 
II complexes colocalized in the same immunological synapse comprising co-stimulatory 
molecules CD40, CD54, CD80, OX40L, and 4-1BBL between a DC and a CD4+ Th cell (18), 
leading to CD4+ Th cell acquisition of the synapse-comprised bystander pMHC I along with 
pMHC I and co-stimulatory molecules via internalization and the recycling pathway (45, 46). In 
this study, we have further elucidated the critical role of the acquired pMHC I in regulation of 
immune responses. We note that it is the acquired pMHC I complexes on CD4+ Th-APC that 
target the above stimulatory effects derived from IL-2 secretion and CD40L and CD80 
costimulations to the Ag-specific CD8+ T cells in vivo, leading to induction of OVA-specific 
CMCTL responses and antitumor immunity. The targeting role of acquired pMHC I complexes is 
also supported by our recent report showing that the acquired pMHC I complexes on DCOVA-
activated CD4+ Th cells can target its helper effect onto enhancement of adoptive CD8+ Tc cell 
immunotherapy of cancer (26). The targeting role of the acquired pMHC I complexes on CD4+ 
Th-APC may also be applied to interpret the generation of Ag-specific regulatory T (Tr) cells in 
vivo after an encounter with Ag presented by DC (47, 48). Zhang et al. (49) demonstrated that 
double- negative Tr (DN Tr) cells used their TCR to acquire allo-MHC peptides from APC and 
became Ag-specific Tr cells in suppression of graft rejection. Tarbell et al. (50) also showed that 
CD4+25+ Tr expanded in vitro by Ag-specific DC stimulation became 20-fold more efficient in 
suppression of autoimmune diabetes caused by diabetogenic T cells in NOD mice than 
polyclonal unexpanded CD4+25+ Tr cells. However, they did not elucidate the molecular 
mechanism on how the immune-suppressive effect of these Tr cells can be specifically or more 
efficiently delivered to the in vivo T cell-mediated graft rejections or autoimmune diseases. 
Based upon the above principle elucidated in this study, we assume that these CD4+ or DN Tr 
cells may become Ag-specific after acquisition of pMHC I or pMHC II complexes by DC 
stimulation in vivo. This assumption is currently being assessed in our laboratory.   
The molecular mechanism of in vivo CD8+ T cell-mediated cytotoxicity still remains 
controversial although its in vitro cytotoxicity is mainly mediated by the perforin pathway (51). 
Winter et al. (52) demonstrated that the adoptive CD8+ CTL’s cytotoxicity against tumors is 
independent of perforin or Fas-FasL interaction. Later, it has been shown that CD8+ T cells 
exerted its in vivo antitumor effector function via IFN-γ expression (53, 54). Recently, it has 
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been demonstrated that the host-derived TNF-α and IFN-γ were both involved in CD8+ T cell-
mediated tumor eradication (55, 56). Similar to CD8+ T cells, CD4+ T cells were able to kill Ia+ 
target cells (15, 16, 57, 58). In this study, we demonstrated that CD4+ Th-APC expressing OVA-
specific TCR were able to kill pMHC II-expressing DCOVA and Th-APC via the perforin-
mediated pathway in an in vitro chromium release assay, indicating that CD4+ Th-APC may 
negatively modulate in vivo immune responses by eliminating both pMHC II-expressing DCOVA 
and neighboring Th-APC. However, the molecular mechanism of in vivo CD4+ Th-APC-
mediated cytotoxicity is still elusive. It has been previously demonstrated that TRAIL was found 
to be responsible for in vivo CD4+ T cell-mediated cytotoxicity (59, 60).  
Taken together, this study has greatly advanced our new concept of “sequential two-cell 
interactions by CD4+ Th-APC” (8) by further demonstrating that 1) CD4+ Th-APC can acquire 
co-stimulatory molecules (CD40, CD80, OX40L, and 4-1BBL) and functional pMHC I and II 
complexes by both in vitro and in vivo DC activation; 2) CD4+ Th-APC with acquired pMHC I 
and II and co-stimulatory molecules can stimulate CD4+ Th1 and central memory 
CD8+44+CD62LhighIL-7R+ T cell responses, leading to efficient antitumor immunity; 3) CD4+ 
Th-APC’s stimulatory effect on CD8+ T cell responses is mediated by IL-2 secretion and CD40L 
and CD80 signaling; and 4) this stimulatory effect is specifically targeted to the Ag-specific 
CD8+ T cells in vivo via acquired pMHC I complexes (Fig. 6). In addition, CD4+ Th-APC 
expressing OVA-specific TCR, FasL, and perforin may also negatively modulate in vivo immune 
responses by eliminating DCOVA expressing endogenous pMHC II and neighboring Th-APC 
expressing acquired pMHC II, whereas CD4+ Th-APC expressing acquired pMHC I can also be 
eliminated by Th-APC-activated CD8+ CTL (Fig. 6). Therefore, these findings may have great 
impacts in not only the antitumor immunity, but also the regulatory T cell-dependent immune 
tolerance in vivo.  
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2.9 Table 
Table 1 Vaccination with CD4+ Th-APC protects against lung tumor metastases in mice 
 
aIn experiments I and II, C57BL/6 mice (n=8) were immunized with DCOVA and the  in vitro 
irradiated DCOVA-stimulated CD4+ Th-, (Kb-/-)Th-, (IL-2-/-)Th-, (IFN-γ-/-)Th-, (TNF-α-/-)Th-, 
(CD40-/-)Th-, (CD40L-/-)Th-, (OX40L-/-)Th-, (41BBL-/-)Th- and (CD80-/-)Th-APC, and in vivo 
DCOVA-stimulated CD4+ Th-ACvivo and (Kb-/-)Th-ACvivo cells,  respectively. Following the 
immunizations, each mouse was challenged i.v. with OVA transgene-expressing BL6-10OVA or 
wild-type BL6-10 tumor cells. The mice were sacrificed 4 weeks after tumor cell challenge and 
the numbers of lung metastatic tumor colonies were counted. *, P<0.01 versus cohorts of CD4+ 
Th group (Student’s t-test). One representative experiment of two in the above animal studies is 
shown.  
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2.10 Figures 
 
Figure 1 
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Flow cytometric analysis of DCOVA and CD4+ Th-APCs. (a–c) DCOVA, naive CD4+ T cells, 
CD4+ Th-APC, and Th-APC with different gene KO were stained with a panel of Abs (black 
lines) and analyzed by flow cytometry. (d) CD4+ Th-APC and (Kb−/−)Th-APC were stained with 
FITC-anti-pMHC I Ab and examined under differential interference contrast (DIC) by confocal 
microscopy. (e) (CD80−/−)DCOVA-activated CD4+ Th-APC(CD80−/−) cells were stained with anti-
CD80 Ab (solid line) and analyzed by flow cytometry. (f) DCOVA cells and CD4+ Th-APC were 
stained with PE-anti-CD4, FITC-anti-CD11c, and ECD-anti-CD3 Abs and analyzed by flow 
cytometry. The CD4highCD11clow cells in the oval were grouped for ECD-CD3 analysis. The 
value in the panel represents the percentage of CD4highCD11clow cells vs the total CD4highCD11c− 
Th-APC population. The value in parentheses represents the SD. (g) The purified in vivo DCOVA- 
and (Kb−/−)DCOVA-stimulated CD4+ Th-APC and (Kb−/−)Th-APC were stained with anti-pMHC I 
Ab (solid lines) and analyzed by flow cytometry. Irrelevant isotype-matched Ab was used as 
control (gray or dotted lines) in the above experiments. One representative experiment of two in 
the above experiments is shown.  
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Figure 2 
 
 
CD4+ Th-APC with acquired pMHC-II stimulate CD4+ Th1 cell responses. (a) The amounts 
of IL-2 in examining wells containing MF72.2D9 cells and various stimulators were substracted 
by the amount of IL-2 in control wells containing stimulator (DCOVA, CD4+ Th-APC, Th-
APCvivo, Con A OT II cells) alone, and MF72.2D9 alone.*,  P < 0.05 (Student’s t test) vs 
cohorts of Con A OT II cells. (b) In vitro cytotoxicity assay. CD4+ Th-APC were used as effector 
cells, while 51Cr-labeled DCOVA, OVAII-pulsed LB27, Th-APC, and the control DC and LB27 
cells were used as target cells in a chromium release assay. (c) The effector cells were 
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preincubated with CMA (1 μM) or emetin (5 μM) for 2 h and used in the above cytotoxicity 
assay. (d) In vitro CD4+ T cell proliferation assay. Varying numbers of irradiated DCOVA, Th-
APC, Th-APCvivo, and Con A OT II T cells and their 2-fold dilutions were cocultured with 
naive OT II CD4+ T cells. After 2 days, the proliferative responses of the T cells were 
determined by overnight [3H]thymidine uptake assay. *, p < 0.05 (Student’s t test) vs cohorts of 
Th-APC themselves. (e) In the in vitro CFSE-labeled CD4+ T cell proliferation assay, the CFSE-
labeled OT II CD4+ T cells were cocultured with irradiated DCOVA, CD4+ Th-APC, and Con A 
OT II T cells. Three days after culture, the cells were harvested to determine the number of 
divisions by flow cytometry. In the in vivo CFSE-labeled CD4+ T cell proliferation assay, the 
CFSE-labeled OT II CD4+ T cells were i.v. injected into C57BL/6 mice. Twelve hours later, 
each mouse was i.v. given with DCOVA, Th-APC, and Con A OT II cells, respectively. Four days 
later, the number of division cycles of the CFSE-labeled CD4+ T cells in the recipient spleens 
was determined by flow cytometry. Percentages denote the fraction of CD4+ T cells that have 
undergone at least one division. (f) In the in vivo CD4+ T cell proliferation assay, C57BL/6.1 
mice were i.v. immunized with irradiated DCOVA, Con A T, CD4+ Th-APC, and Th-APCvivo. 
Four days after the immunization, the tail blood samples of immunized mice were stained with 
PE-anti-CD45.1, FITC-anti-CD4, and ECD-anti-CD44 Abs and then analyzed by flow 
cytometry. The PE-CD4- and FITC-CD45.1-positive T cells were gated for further analysis of 
ECD-CD44 and PE-CD4 expression. The values in each panel represent the percentage of 
CD44high CD4+ T cells vs the total CD4+ T cell pool. The values in parentheses represent the SD. 
(g) The in vitro CD4+ Th-APC-activated CD4+ Th1 cells (Th-APC/OT II) were stained with a 
panel of Abs (solid lines) and analyzed by flow cytometry. Irrelevant isotype-matched Abs were 
used as controls (dotted lines). (h) Tetramer staining assay. The tail blood samples of mice (six 
mice per group) immunized with irradiated DCOVA, Th-APC/OT II cells, and DCOVA along with 
Th-APC/OT II cells were stained with PE-H-2Kb/OVAI tetramer (PE-tetramer) and FITC-anti-
CD8 Ab (FITC-CD8) and then analyzed by flow cytometry. The value in each panel represents 
the percentage of tetramer-positive CD8+ T cells vs the total CD8+ T cell population. The value 
in parentheses represents the SD. *, representing p < 0.05 vs cohorts of mice immunized with 
irradiated DCOVA (Student’s t test). One representative experiment of two in the above different 
experiments is shown. 
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Figure 3 
 
CD4+ Th-APC with acquired functional pMHC I complexes stimulate CD4+ T cell 
proliferation and the effect is mediated through IL-2 secretion. (a) The amount of IL-2 
secretion in examining wells containing RF3370 cells and various stimulators were substracted 
by the amount of IL-2 in control wells containing various stimulators (DCOVA, CD4+ Th-APC, 
Th-APCvivo, and Con A OT II cells) alone. *, p < 0.05 (Student’s t test) vs cohorts of Con A OT 
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II cells. The in vitro CD8+ T cell (b) and CFSE-labeled CD8+ T cell (c) proliferation assays were 
performed in a similar manner as the above in vitro CD4+ T cell proliferation assays. (d) In vivo 
CD8+ T cell proliferation assay. C57BL/6 mice were i.v. immunized with DCOVA, CD4+ Th-
APC, and CD4+ Th-APCvivo, respectively. Six days after the immunization, the tail blood 
samples of immunized mice were stained with PE-tetramer and FITC-CD8 Ab and then analyzed 
by flow cytometry. The value in each panel represents the percentage of tetramer-positive CD8+ 
T cells vs the total CD8+ T cell pool. The values in parentheses represent the SD. (e) In vivo 
cytotoxicity assay. Sixteen hours after target cell delivery, the residual OVA I-pulsed CFSEhigh 
and Mut1-pulsed CFSElow target cells remaining in the spleens of the above immunized mice 
were sorted and analyzed by flow cytometry. The value in each panel represents the percentage 
of CFSEhigh and CFSElow target cells remaining in the spleens. The values in parentheses 
represent the SD. One representative experiment of three in the above different experiments is 
shown. 
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Figure 4 
 
 
 
Th-APC’s stimulatory effect on OVA-specific CD8+ T cell responses is mediated by CD40L 
and CD80 signaling and acquired pMHC I targeting. (a) In vivo CD8+ T cell proliferation 
assay. The tail blood samples of mice immunized with DCOVA, CD4+ Th-APC, and CD4+ Th-
APC with different gene KO were incubated with PE-tetramer and FITC-CD8 and then analyzed 
 77
by flow cytometry. The value in each panel represents the percentage of tetramer-positive CD8+ 
T cells vs the total CD8+ T cell population. The values in parentheses represent the SD. *, 
Representing p<0.05 vs cohorts of mice immunized with irradiated CD4+ Th-APC (Student’s t 
test). (b) The tail blood samples of mice immunized with DCOVA and CD4+ Th-APC were 
incubated with PE-tetramer and FITC-CD8 and then analyzed by flow cytometry. The value in 
each panel represents the percentage of tetramer-positive CD8+ T cells vs the total CD8+ T cell 
population. (c) In vivo cytotoxicity assay. Sixteen hours after target cell delivery, the residual 
OVA I-pulsed CFSEhigh and Mut1-pulsed CFSElow target cells remaining in the spleens of the 
above immunized mice were sorted and analyzed by flow cytometry. One representative 
experiment of three in the above different experiments is shown. 
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Figure 5 
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CD4+ Th-APC stimulate CD8+ T cell differentiation into central memory T cells. (a) Naive 
CD8+ T cells derived from OT I/B6.1 mice were primed with irradiated DCOVA and CD4+ Th-
APC, purified by using CD45.1 microbeads, stained with PE-tetramer and FITC-labeled Abs, 
respectively, and then analyzed by flow cytometry. PE-tetramer-positive CD8+ T cells were 
gated for further analysis of FITC-CD25, FITC-CD44, and FITC-CD62L expression (solid 
lines). (b) In vitro DCOVA- and CD4+ Th-APC-activated CD8+CD45.1+ T cells derived from OT 
I/B6.1 mice were i.v. injected into C57BL/6 (CD45.2+) mice (six mice per group). Mouse tail 
blood cells were stained with PE-H-2Kb/OVAI tetramer (PE-tetramer) and FITC-anti-CD8 
(FITC-CD8) Ab and analyzed by flow cytometry at indicated time points after CD8+ T cell 
transfer. In addition, 6 days after CD8+ T cell transfer, mouse tail blood cells were also stained 
with PE-tetramer, FITC-CD8, and ECD-conjugated anti-CD25, anti-CD44, anti-CD45.1, anti-
CD62L, and anti-IL-7R Abs, respectively, and analyzed by flow cytometry. The value in each 
panel represents the percentage of PE-tetramer-positive CD8+ T cells vs total peripheral CD8+ T 
cells. The values in parentheses represents the SD. (c) The OVA-specific CD8+ T cells with PE-
tetramer and FITC-CD8 staining were gated, and then assessed for CD25, CD44, CD45.1, 
CD62L, and IL-7R expressions (solid lines). (d) OTI CD8+ T cells (0.4 × 105 cells/well) primed 
on day 0 with DCOVA (▼) or CD4+ Th-APC (■) were maintained in cultures for 1 wk with the 
indicated cytokines (IL-2 (50 U/ml) and/or IL-7 (10 ng/ml)) added on days 3 and 5. Live CD8+ T 
cells with trypan blue exclusion for each culture done in triplicate were counted at the indicated 
time points. (e) The DCOVA-primed and CD4+ Th-APC-primed OT I/B6.1 CD8+ T cells referred 
to as DCOVA/OT I6.1 and CD4+ Th-APC/OT I6.1, respectively, were used as effector cells, while 
51Cr-labeled EG7, Th-APC, and the control EL-4 tumor cells were used as target cells in a 
chromium release assay. (f) Memory T cell expansion. Three months after CD8+ T cell transfer, 
mice were boosted by i.v. injection of DCOVA (0.5 × 106). Four days subsequent to the boost, 
mouse tail blood cells were stained with PE-tetramer, FITC-CD8, and ECD-CD25, ECD-CD44, 
and ECD-CD69 Abs and analyzed by flow cytometry. The value in each panel represents the 
percentage of PE-tetramer-positive CD8+ T cells vs the total peripheral CD8+ T cell population. 
The OVA-specific CD8+ T cells with PE-tetramer and FITC-CD8 staining were sorted and 
assessed for CD25, CD44, and CD69 expression (solid lines). ECD-labeled isotype-matched 
irrelevant Abs were used as controls (dotted lines) in the above experiments. One representative 
experiment of two in the above different experiments is shown.  
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Figure 6 
 
 
 
A new view on the dynamic model of sequential two-cell interactions by CD4+ Th-APC. In 
this model, APC license CD4+ Th cells to act as Th-APC. By activation of CD4+ Th cells, APC 
can also transfer the functional pMHC I and II and the co-stimulatory molecules such as CD80 
onto an expanding population of CD40L-expressing and IL-2-secreting CD4+ Th-APC. The 
CD4+ Th-APC expressing TCR can negatively modulate immune responses by eliminating APC 
expressing pMHC II and neighboring Th-APC with acquired pMHC II. The Th-APC expressing 
acquired pMHC II and I complexes can also positively modulate immune responses by 
stimulating CD4+ Th1 cell and CD8+ CMCTL responses via its endogenous IL-2 secretion and 
CD40L and CD80 signaling, respectively. The stimulatory effect of Th-APC is specifically 
targeted to Ag-specific naive CD8+ T cells in vivo via its acquired pMHC I complexes. The 
CD8+ CMCTL expressing TCR can also eliminate Th-APC with acquired pMHC I complexes. 
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3.1 Brief introduction to Chapter 3 
 
 Although it has been frequently reported that CD4+ T cell signals during priming (where 
CD8+ T cells differentiate from naïve to effector cells) orchestrate memory CTL development, the 
role of these signals during effector/contraction phase (where differentiated effector CTLs 
eliminate invaded foreign Ags and destined to die or develop into memory CTLs) for memory 
CTL responses is less defined. In this chapter, using various monoclonal sources of T cells, and 
DCova immunization model, the study was designed to investigate how Th cell-derived signals 
modulate differentiated effector CTLs’ survival and memory responses. This study showed the 
direct involvement of Th-APCs in modulation of effector CTL fate.  
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3.2 Abstract  
 
Involvement of CD4+ helper T (Th) cells is crucial for CD8+ cytotoxic T lymphocyte 
(CTL)-mediated immunity. However, CD4+ Th’s signals that govern CTL survival and functional 
memory are still not completely understood. In this study, we assessed the role of CD4+ Th cells 
with acquired antigen-presenting machineries in determining CTL fates. We utilized an adoptive 
co-transfer into CD4+ T cell-sufficient or -deficient mice of OTI CTLs and OTII Th cells or Th 
cells with various gene deficiencies pre-stimulated in vitro by ovalbumin (OVA)-pulsed dendritic 
cell (DCova). CTL survival was kinetically assessed in these mice using FITC-anti-CD8 and PE-
H-2Kb/OVA257-264  tetramer staining  by flow cytometry. We show that by acting via endogenous 
CD40L and IL-2, and acquired peptide-MHC-I (pMHC-I) complex signaling, CD4+ Th cells 
enhance survival of transferred effector CTLs and their differentiation into the functional memory 
CTLs capable of protecting against highly-metastasizing tumor challenge. Moreover, RT-PCR and 
Western blot analysis demonstrate that increased survival of  CD4+ Th cell-helped CTLs is 
matched with enhanced Akt1/NF-κB activation, down-regulation of FasL and TRAIL, and altered 
expression profiles with up-regulation of prosurvival (Bcl-2) and down-regulation of proapoptotic 
(Bcl-10, Casp-3, Casp-4, Casp-7) molecules/genes. Taken together, our results reveal a previously 
unexplored mechanistic role for CD4+ Th cells in programming CTL responses. The observed 
CD4+ Th cell-effector CTL cooperation could explain why effector CTLs generated under cognate 
CD4+ Th cell help show survival and recall advantages. This knowledge could also aid in the 
development of efficient adoptive CTL cancer therapy.  
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3.3 Introduction  
CD8+ T cells play a defensive role against viral infections and cancers. Following 
recognition of foreign Ag, they undergo 3 distinct phases (1): (i) a proliferation (primary) phase in 
which naïve CD8+ T cells undergo autonomous clonal expansion and develop into effector 
cytotoxic T lymphocytes (CTLs); (ii) a contraction (transitional) phase, in which ~95% of effector 
CTL undergo activation-induced cell death (AICD) through apoptosis, allowing development of 
~5-10% memory CTLs; and (iii) a maintenance (memory) phase in which memory CTL survive 
for prolonged duration. In subsequent Ag encounters, unlike their naive counterparts, memory 
CTLs respond swiftly by rapid proliferation and heightened effector functions in recall responses.   
CD4+ T cells have potential to influence multiple aspects of CTL responses. Their 
importance in primary CTL responses was first demonstrated in immunizations with non-
inflammatory Ags such as male minor-HY and Qa-1 alloantigen (2). The requirement of cognate 
CD4+ T cell help for different phases of CTL responses is frequently debated and shown to vary 
with type of immunizations. In the absence of inflammation, APCs have to be activated by CD4+ T 
cells through CD40/CD40L interactions to prime CD8+ CTL responses (3). Alternatively, cognate 
CD4+ T cells have also been shown to provide direct signaling on CD40-expressing CD8+ T cells 
through CD40L costimulation (4, 5). Although CD4+ T cell help can be dispensable for primary 
CTL generation, it is prerequisite for programming memory CTLs in most situations (4, 6-8). As 
the effector phase constitute both AICD and memory CTLs development, APC-stimulated Th1 
cells appear to play a critical role in effector CTL survival and functional memory development (9, 
10). Recently, CD4+ T cell help shown to be required for effector CTL survival via regulation of 
TRAIL and Bcl-xL (6, 7, 11). However, the mechanism of CD4+ T cell help which prevents AICD 
of effector CTL is still not completely understood. CD4+ T cell help is also implicated in memory 
CTL recall responses (6). However, whether a cognate (6, 12-14) or heterospecific (15, 16) CD4+ 
T cell help is required is still controversial. Although an important role of IL-2 during CTL 
priming has been suggested for full secondary expansion (17), the timing, and type of CD4+ T cell 
helper-derived signals contributing to optimal recall responses is largely unknown.      
Intercellular membrane transfer through trogocytosis, a wide-spread phenomenon in the 
immune system, plays a crucial role in immunomodulation (18-20). Recently, acquisition of APC’s 
Ag-presenting machineries (APM) by CD4+ T cells has attracted greater attention (1, 19, 21-28). 
Understanding the functional consequences of acquired APM on CD4+ T cells is under intense 
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scrutiny. Although not efficient in soluble-Ag capture, CD4+ T cells acquire APM from APCs, and 
present Ag to other naïve CD4+ T cells, inducing activation and proliferation (20, 22, 28, 29). In 
contrast, their presentation to previously Ag-experienced, activated or memory CD4+ T cells 
inhibits proliferation, thereby maintaining homeostasis of immune responses (1, 21, 22, 26). In 
various studies, we have demonstrated the role of APM on CD4+ T cells in modulating naïve CD8+ 
T cell responses (22, 24, 30). We showed that APC-stimulated CD4+ type 1 helper cells (Th) are 
capable to stimulate naïve CD8+ T cells via acquired peptide-MHC-I complexes (pMHC I), 
inducing central memory CTL stimulation and anti-tumor immunity. However, impact of these 
APM on Th cells in modulating previously Ag-experienced effector CTL responses is not well 
understood, a knowledge that is crucial for successful adoptive CTL therapy of cancers.   
Here, we investigated thoroughly whether Th cells with its acquired APM and helper 
factors, IL-2 and CD40L, have any beneficial effects on adoptively transferred effector CTLs 
generated by in vitro cultivation of transgenic OTII CD4+ and OTI CD8+ T cells with ovalbumin 
(OVA)-pulsed DCs (DCova) into CD4-sufficient [wild-type (WT)] and -deficient [Iab-/-, knockout] 
mice. We demonstrated that Th cells enhanced CTL survival, transition to functional memory pool 
and protection against highly metastasizing tumor challenge. The Th’s inherent ability to provide 
IL-2 and CD40L signals, and presence of low level of acquired pMHC I were found to be critical 
for such helper roles.  
3.4 Materials and methods  
3.4.1 Reagents, tumor cells and animals    
The biotin- and fluorescent dye-labeled (FITC or PE) antibodies (Abs) specific for CD4 
(GK1.5), CD11c (HL3), CD44 (IM7), H-2Kb (AF6-88.5), Iab (KH74), CD80 (16-10A1), CD40 
(3/23), CD40L (MR1), CD54 (3E2), CD62L (MEL-14), CD69 (H1.2F3) and IFN-γ (XMG1.2), 
and streptavidin-PE-Texas-Red or -FITC were purchased from BD-Biosciences. The biotin-anti-
IL-7Rα (A7R34), -CCR7 (4B12) and -pMHC I (25-D1.16) Abs were purchased from eBioscience. 
The FITC-anti-perforin (CB5.4) Ab was obtained from Alexis Chemicals. The recombinant GM-
CSF, IL-2, IL-4 and IL-12 as well as the anti-IL-4 Ab were obtained from R&D Systems. The 
FITC-anti-CD8 (KT15) and PE-anti-CD45.1 (A20) Abs, and H-2Kb/OVA257-264 tetramer were 
obtained from Beckman Coulter. The mouse malignant melanoma (BL6-10) and OVA-transfected 
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BL6-10 (BL6-10OVA) and EL4 (EG7) cell lines were cultured as described previously (22). The 
mouse B-cell-hybridoma cell line LB27 expressing both H-2Kb and Iab was obtained from 
American Type Culture Collection. The age-matched WT [C57BL/6(B6, CD45.2+)], OVA257-264 
and OVA323-329-specific TCR-transgenic OTI and OTII, H-2Kb-/-, and Iab-/- on WT background, and 
C57BL/6.1(B6, CD45.1+) mice were purchased from Jackson Laboratory. The 
OTII/C57BL/6.1(B6, CD45.1+), OTII/CD40L-/- and OTII/IL-2-/- mice were generated by 
backcrossing designated gene-deficient mice with OTII mice, and tested as described previously 
(22). All the experiments were performed as per the guidelines of University Committee on 
Animal Care and Supply.         
3.4.2 Preparation and characterization of mature DCova  
Bone-marrow-derived, DCova from WT mice were generated by culturing bone marrow 
cells for 6 days in medium containing IL-4 (20 ng/ml) and GM-CSF (20 ng/ml) and pulsing with 
0.1 mg/mL OVA overnight at 37°C as described previously (24). OVA-pulsed DCs generated 
from WT B6 and H-2Kb-/- mice were referred as DCova and DCova(Kb-/-), respectively.   
3.4.3 Preparation and characterization of naïve and effector CD4+ or CD8+ T cells       
The naïve CD4+ and CD8+ T cells were isolated from WT, OTII or OTI splenocytes as 
previously described (22). To generate active, OVA-specific CD8+ T (effector CTL) and Th cells, 
the OTI CD8+ or OTII CD4+ T cells (0.75X106cells/mL, 200μl/well) were respectively cultured 
with irradiated (4,000rads) DCova (0.75X106cells/mL, 50μl/well) at 1:4 ratio for three days as 
previously described (24). The proliferated CD8+ or CD4+ T cells were purified using using CD4+ 
and CD8+ MACS microbeads after Ficoll-Paque (Sigma-Aldrich) separation. The naïve, effector 
CTL and Th cells were stained with panel of cell-, naïve-, activation- or memory-specific markers, 
and characterized phenotypically by flow cytometry (Beckman Coulter). The Th cells derived from 
OTII/CD40L-/- and OTII/IL-2-/- mice were termed Th(CD40L-/-) and Th(IL-2-/-), respectively. 
DCova(Kb-/-)-stimulated Th cells without acquired pMHC I molecules were referred as Th(pMHC 
I-/-). For cytokine profiling, effector CTL and Th or Th(IL-2-/-) were respectively re-stimulated 
with irradiated EG7 and OVAII (OVA323–339, Multiple Peptide Systems)-pulsed LB27, and culture 
supernatants were assessed using cytokine ELISA kits (R&D Systems) from previous description 
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with few modifications (31). Non-specifically-stimulated CD4+ and CD8+ T cells were obtained by 
culturing purified B6 mouse CD4+ or CD8+ T populations using ConA (Sigma-Aldrich) as 
previously described (22) followed by Ficoll-Paque separation. In priming studies, OTI CD8+ T 
cells were co-cultured with irradiated DCova as above in the presence or absence of OTII CD4+ T 
cells. Helped orl unhelped effector CTLs were purified by Ficoll-Paque separation and negative 
selection using anti-CD4 (L3T4) paramagnetic beads (Dynal).    
3.4.4 In vivo CD8+ CTL survival and recall studies  
Approximately 5x106 effector CTLs alone that received help during priming period or 
5x106 effectors CTLs with or without 2x106 Th cells (i.e., help after CTL priming) were i.v. 
transferred WT mice. Similarly, effector CTLs alone that received help during priming period or 
effectors CTLs with or without effector Th, Th(IL-2-/-), Th(CD40L-/-), Th (pMHC-I-/-) cells 
(2x106each), naïve monoclonal OTII (naïve-OTII) or polyclonal B6 (naïve-WT) CD4+ T cells 
(15x106  cells), or ConA-stimulated OTII (ConA-OTII) or ConA-stimulated B6 (ConA-WT) CD4+ 
T cells (2x106  cells) were i.v. transferred to Iab-/- mice. After confirming equal engraftment on the 
following day, the effector CTL survival was monitored 6 or 60 days later in peripheral blood by 
staining with H-2Kb/OVA257-264 tetramer and FITC-anti-CD8 Ab (tetramer assay) (22). In recall 
studies, all the groups were boosted i.v. with 1x106 DCova 60 days later and monitored on 4th day 
for the expansion of memory CTL by tetramer assay. To characterize effector or memory CTLs 
phenotypically, the blood samples were collected at 6 or 60 days later, and stained for tetramer 
assay along with panel of biotin-conjugated Abs specific for effector or memory markers, and 
streptavidin-PE-Texas Red.  
3.4.5 Tumor protection studies 
To assess functional effect of memory CTLs, approximately 5x106 effector CTLs alone that 
received help during priming period or 5x106 effectors CTLs with or without 2x106 Th cells (i.e., 
help after CTL priming) were i.v. transferred WT and Iab-/- mice. In addition, to understand 
mechanism of CD4+ T cells, some Iab-/- mice groups were also transferred with effector CTLs with 
effector Th, Th(IL-2-/-), Th(CD40L-/-) or Th (pMHC-I-/-) cells (2x106each). Hundred days later, all 
the groups were i.v. challenged with highly-metastasizing BL6-10OVA tumor cells (0.5x106/mice), 
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monitored for protection as described previously (22), and sacrificed later to determine the 
numbers of surface black tumor colonies in the lungs. The grading was done depending on 
numbers of metastatic tumor colonies as: -, no tumors; +, 1-25; ++, 26-50; +++, 51-75; ++++, 76-
100; +++++, 101-250; ++++++, >250. 
3.4.6 Intracellular IFN-γ staining 
On 24th day of tumor challenge, the splenocytes of helped or unhelped mice were re-
stimulated with OVAI (OVA257-264, Multiple Peptide Systems) and subjected to intracellular IFN-γ 
staining (BD-Biosciences) as described previously (30). 
3.4.7 RT2 profiler PCR array system     
The WT and Iab-/- mice were i.v. injected with effector CTLs (5x106) with or without Th 
cells (2x106). The blood and lymphoid organs were collected 16 days later, and processed to 
remove RBC. The T lymphocytes were enriched in nylon wool columns (C&A Scientific). After 
labeling T lymphocytes with H-2Kb/OVA257-264 tetramer and anti-PE microbeads (Miltenyi Biotec 
Inc), a highly purified population of OVA-specific CTLs was obtained by positive selection by 
passing in 2 separate columns sequentially. The expression of pathway-focused panel of 84 genes 
related to apoptosis in helped or unhelped CTL was examined using RT2 ProfilerTM PCR array 
(SuperArray Bioscience). Total RNA was isolated using RNeasy extraction kit (Qiagen) and 
reverse transcribed using RT2 First Strand Kit (SuperArray Bioscience). The mRNA expression of 
each gene in array system was performed using StepOnePlus thermocycler (Applied Biosystems) 
and analyzed using Hprt1, Gapdh, and β-actin as internal controls in web-based software as per 
manufacturer’s instructions.   
3.4.8 qRT-PCR analysis 
The cDNA samples of helped or unhelped CTL were further subjected to quantitative RT-
PCR (qRT-PCR) for validation of the array results. Sequence-specific primers for β-actin, Bcl-2, 
FasL and Trail were previously described (7, 32), and for Trail receptor, Nfkb1, Bcl10, Akt1, 
Caspase-4 and -7 were given in supplementary information (Table S1). qRT-PCR was performed 
using SYBR Green method following manufacturer’s protocol. Briefly, 20ng of cDNA, 50nM of 
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each primer and 1X Master Mix (Applied Biosystems) were used in 25μl volume. The mRNA 
expressions were analyzed as described for PCR array using β-actin control.    
3.4.9 Western blotting   
Western blotting was performed in helped or unhelped CTL as described previously (22) 
with few modifications. The blots were stained with panel of monoclonal- or polyclonal-rabbit Abs 
specific for Bcl-2 (50E3), β-actin (13E5), Bcl10 (C79F1), Akt1 (2H10), phospho-Akt1 (S473), 
cleaved Caspase-3 (Asp175)(5A1E) and -7 (Asp198) (Cell Signaling Technology), NF-κB-p65 (C-
20), phospho-NFkB-p65 (Ser536) (Santa Cruz Biotechnology) and NFATc1 (7A6) (BD 
Biosciences). The blots were incubated with goat anti-rabbit IRDyeR800/680CW, and band 
densities were quantified using ODYSSEY densitometer (LI-COR Bioscience).       
3.4.10 Statistical analysis 
The statistical analysis was performed using Graphpad Prism-3.0. The results are presented 
as mean ± SD. The statistical significance between two or more groups was analyzed by Student’s 
t-test or analysis of variance, respectively. p<0.05 was considered statistically significant. 
3.5 Results  
3.5.1 Th’s help during priming or transitional period enhance effector CTL survival and its 
transition to memory development    
 In line with the previous results (22), OVA-pulsed bone marrow-derived DCs (DCova) 
expressed all the maturation markers, such as Iab, CD40, CD80, and pMHC I (Supplementory Fig. 
1a). Following in vitro stimulation  of irradiated DCova with OTII CD4+ or OTI CD8+ T cells, the 
active OVA-specific CD4+ or CD8+ T cells were purified using CD4 or CD8 MACS microbeads 
after Ficol separation and the purified Th or effector CTLs had negligible DC contamination [(22, 
33); Supplementory Fig. 1b] DCova-stimulated CD8+ T cells displayed their subset marker (CD8), 
activation marker (CD69) and effector molecule (perforin), but not IL-7Rα or CD62L [(33); 
Supplementory Fig. 1a], and secreted IFN-γ (3.55±0.61ng/mL/106cells/24hrs) and TNF-α 
(1.15±0.13ng/mL/106cells/24hrs), but not IL-4 or IL-10, suggesting a functional effector CTL 
phenotype. DCova-stimulated CD4+ T cells displayed their subset marker (CD4) and activation 
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markers (CD69) [(22); Supplementory Fig. 1a], and secreted IFN-γ 
(2.1±0.35ng/mL/106cells/24hrs) and IL-2 (2.75±0.47ng/mL/106cells/24hrs), but not IL-4 and IL-
10, confirming a Th1 phenotype.     
Initially, we sought to determine the functional consequences of CTL responses upon its 
interaction with Th, particularly focusing on their survival and development into functional 
memory. This interaction can either have immunoregulatory (1, 19, 21, 22, 25, 26, 28) or 
immunopotentiation (11, 22, 28, 31) effects as suggested from previous reports. Here, the equal 
numbers of effector CTLs with or without Th were adoptively transferred to WT or CD4-deficient 
mice where Th cells likely provide help or regulate during effector or transition phase of CTL 
responses (Fig. 1a). Because CD4+ T cell help during priming phase is also shown to be critical for 
programming memory CTLs (4, 7, 8), we also tested this possibility parallelly in the current model 
using a simplified method, where naive OTI CD8+ T cells were stimulated with DCova in the 
presence (allow CD4+ T cell help during priming) or absence of naïve OTII CD4+ T cells. These 
primarily helped or unhelped effector CTLs were adoptively transferred to WT or CD4-deficient 
mice (24). Using tetramer assay, all the mice were monitored for CTL survival at different periods, 
and memory responses after boosting with DCova (Fig. 1b). Primarily helped CTLs significantly 
survived and expanded upon boosting in both WT and CD4-deficient mice (P<0.05 or 0.01 versus 
unhelped CTL), corroborating previous observations (4, 5, 7, 8). Interestingly, transitionally helped 
effector CTLs also significantly survived and expanded both in WT and CD4-deficient mice 
(P<0.05 or 0.01 versus unhelped CTL) up to 3.0 times from their basal levels. Furthermore, 
increasing the dose of Th alone from 2x106 to 5x106 resulted in corresponding increase of memory 
CTL pool in both WT and CD4-deficient mice (P<0.01 versus low Th dose) (Fig. 1c), suggesting 
the dose of Th might directly influence memory pool generation.     
3.5.2 Phenotypic profiling of transitionally helped versus unhelped CTLs during primary and 
memory stage  
Because we observed reduced memory pool without CD4+ T cell help, we compared 
helped versus unhelped CTL’s effector and memory phenotype 6 and 60 days later in peripheral 
blood in an attempt to correlate with differential survival rates. On day 6, both helped and 
unhelped CTLs showed almost equal expression of activation, but not memory, markers although 
IL-7Rα expression was slightly higher in helped CTLs (Fig. 1d). It is possible that a slight increase 
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in the IL-7Rα expression in the effector stage (day 6) might have played some role in subsequent 
survival of helped CTLs as IL-7Rα is known to influence CTL survival. On day 60, memory CTLs 
from both WT and CD4-deficient mice showed almost similar expression of memory-specific 
marker, including CD62L, CD44 and IL-7Rα (central memory CTL phenotype), but not CD25, 
suggesting surface markers expression may not significantly contribute to CTL survival.  
3.5.3 Naïve or non-specifically stimulated CD4+ T cell help is dispensable for effector CTL 
survival and recall responses 
 Next, we assessed the helper roles of other CD4+ T cell types, such as naïve or non-
specifically-stimulated cognate or polyclonal CD4+ T cells on effector CTL fates. ConA-
stimulated OTII and WT CD4+ T cells represent non-specifically stimulated cognate and 
polyclonal CD4+ T cells without acquired pMHC I (not shown) (22). Effector CTLs were 
transferred along with different CD4+ T cell types into Iab-/- or WT mice, and monitored for their 
survival and memory responses. Although the persistent presence of polyclonal CD4+ T cells alone 
supported effector CTL survival and recall responses significantly in WT mice (P<0.01 versus 
effector CTL alone in Iab-/-), the reconstitution of all CD4+ T cell types, except Th, failed to 
enhance effector CTL survival in Iab-/- mice (Fig. 2a), possibly due to their inability to provide 
help, and poor survival in MHC-II deficiency environment. To confirm this, we tracked adoptively 
transferred naïve, Th or ConA-activated polyclonal CD4+ CD45.1+ T cells in the periphery of 
CD45.2+ Iab-/- mice. Interestingly, although the reconstitution was made substantially, the 
transferred CD4+ T cells progressively declined, reaching almost 0.05-0.11% on day 60 (Fig. 2b), 
confirming CD4+ T cells need self-MHC contact for their survival (34). Although Th declined in 
similar fashion (Fig. 2b), their help during transient contraction phase was sufficient to enhance 
CTL survival and recall responses (P<0.01 versus effector CTL alone in Iab-/-). These results 
suggest naïve CD4+ T cell help can act synergistically, but dispensable, for CTL survival and recall 
responses in the presence of cognate CD4+ T cell help.         
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3.5.4 Th cells program effector CTL fates directly via acquired pMHC I, and endogenous CD40L 
and IL-2 signaling  
Because Th’s helper molecules, CD40L and IL-2, and acquired pMHC I are known to 
influence CTL priming (22, 35), survival or memory development (4-6, 17, 22), we sought to 
determine whether these molecular signaling from Th modulate effector CTL fates. From various 
studies including ours, it is increasingly clear that DC-stimulated T cells acquire non-agonistic 
bystander pMHC complexes in addition to agonistic ones (22, 24, 25, 28). Acquisition of DC-
derived bystander pMHC I by Th can facilitate their direct interaction in an Ag-specific manner, 
which tempted us to monitor these bystander complexes on DC-stimulated Th. Consistent with 
previous results (22, 24), we found low to moderate levels of bystander pMHC I molecules during 
DCova interaction (Fig. 3a). The transfer of bystander pMHC I on Th was likely from DCova as 
DCova(Kb-/-)-stimulated Th failed to show expression of these molecules. In contrast to Th, the 
Th(CD40L-/-) and Th(IL-2-/-) respectively fail to show the CD40L expression and IL-2 secretion 
(Fig. 3a and 3b). Effector CTLs were co-transferred with Th, Th(CD40L-/-), Th(IL-2-/-) or 
Th(pMHC I-/-) into CD4-deficient mice and monitored for survival and memory responses. During 
memory stage, effector CTL transferred alone or with Th(CD40L-/-), Th(IL-2-/-) or Th(pMHC I-/-) 
significantly failed to survive, and expand upon boosting (P<0.01 versus Th helped CTL) (Fig. 
3c). In contrast, the helped memory CTLs expanded up to 2 times from their basal levels, reaching 
almost 5.8±1.5% of total CD8+ T population.     
To further assess the impact of Th’s molecular signaling on the functionality of memory 
CTLs, WT or CD4-deficient mice were adoptively transferred with effector CTLs alone or with 
Th(CD40L-/-), Th(IL-2-/-) or Th(pMHC I-/-) and challenged with highly-metastasizing BL6-10OVA 
tumor cells 100 days later (Table 1). In line with recall responses, the lungs of all the unhelped 
mice and those which were transferred with Th(pMHC I-/-), Th(CD40L-/-) or Th(IL-2-/-) developed 
tumor colonies of variable size and numbers considerably compared to mice with transitionally or 
primarily helped CTLs. In contrast, the lungs of mice which received Th did not show any tumor 
colonies with the exception of few mice (4/12) which showed considerably low number of tiny 
colonies. The tumor colonies were further confirmed by histopathology (not shown). To further 
correlate tumor protection, we tracked OVA-specific IFN-γ+ CTLs in spleens by intracellular 
staining. Interestingly, IFN-γ+ helped CTLs were present in significant proportions (P<0.01 versus 
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unhelped CTLs) (Fig. 3d) in both WT and CD4-deficient mice. Unhelped memory CTLs, although 
survived better, almost waned, and completely failed to protect upon lethal tumor challenge.   
3.5.5 Poorly surviving unhelped CTLs show differential expression of genes linked with apoptosis  
Although both helped and unhelped CTLs showed almost similar memory marker 
expressions (Fig. 1d), helped CTLs survived considerably compared to unhelped CTLs. We 
hypothesized that distinct mechanisms under CD4-helper influence might influence CTLs survival. 
To gain mechanistic insights into enhanced survival of helped CTLs, we compared its mRNA 
profiles with that of unhelped CTLs. On days 13-18 of adoptive transfer, we found moderate 
contraction rate in effector CTLs. During this period, we harvested highly purified population (94-
96%) of tetramer+ helped or unhelped CTLs (Supplementary Fig. 2) from blood and lymphoid 
organs of WT or CD4-deficient mice, and subjected to apoptosis pathway-focused PCR array, 
which analyzes TNF ligands and their receptors; members of the Bcl-2, caspase, IAP, TRAF, 
CARD, death domain, death effector domain, and CIDE families; as well as genes involved in the 
p53 and ATM pathways. Strikingly, two distinct patterns of gene expression were observed. First, 
unhelped CTLs generally showed up-regulation of pro-apoptotic and down-regulation of pro-
survival genes (Fig. 4a, 4d, 4e; Supplementary Table 2a and 2b). Among up-regulated genes, 
caspase family genes, Casp-7, -2 and -3, TNF family members, Fas, FasL and Tnfrsf1a, and 
Trp53, which mediate apoptosis induction, were prominent. Interestingly, 34 genes were found to 
be significantly down-regulated, of which 24 were pro-survival and 10 were pro-apoptotic genes. 
Some of the most prominent pro-survival genes down-regulated include Akt1, Api5, Bag1, Bcl-2, 
Birc3 and 5, Nfkb1, Nol3, Pak7, Pim3, Traf1, and Zc3hc1. The down-regulation of some pro-
apoptotic genes, although surprising, may represent compensatory mechanisms that occur in cells 
experiencing various stressors to prevent cell death. Second, in contrast to unhelped CTLs, there 
was a notable shift in the gene-expression profile in helped CTLs, favoring their survival (Fig. 4b-
e, Supplementary Table 2a, 2b). Interestingly, a considerable overlap was observed between up- 
and down-regulated genes in helped CTLs derived from WT and CD4-deficient mice (Fig. 4d and 
4e). Among up-regulated genes, Akt1, Xiap, CD40lg and Traf1, which mediate signals involved 
apoptosis inhibition, were prominent. Additionally, helped CTLs from Iab-/- mice exhibited up-
regulation of an anti-apoptotic gene, Dad1, and pro-apoptotic genes, Casp-2 and Dapk1. Among 
down-regulated genes, caspase superfamily genes, Casp-4, -7 and -3, TNF superfamily members, 
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Fas, FasL and Tnfrsf10b, and Caspase recruitment domain superfamily member, Card6, and Bcl-
10 involved in apoptosis induction were prominent.  
 
3.5.6 Helped CTLs survive better by down-regulating pro-apoptotic and up-regulating pro-
survival molecules  
 
To provide key insights into the above gene-expression studies, some of the key genes 
associated with cell apoptosis or survival, such as TRAIL, TRAIL-rec, FasL, Caspase-4, Caspase-
7, Bcl-10, Bcl-2, Akt1 and Nfκb1, were further analyzed individually in helped and unhelped CTLs 
by qRT-PCR using the same cDNA samples. We found that helped CTLs showed up-regulation of 
the prosurvival (Bcl-2, Akt1 and Nfκb1) and down-regulation of the proapoptotic (FasL, TRAIL, 
TRAIL-rec, Bcl-10, Caspase-4 and Caspase-7) genes (Fig. 4f). To further substantiate the above 
results, some of the key molecules or their active forms, such as Bcl-10, and caspase-3, and -7, 
Bcl-2, NF-κB, Akt1, and NFATc1 transcription factor involved in cell survival or apoptosis were 
analyzed in helped and unhelped CTLs by western blot. Supporting with differential survival and 
gene-expression profiles, unhelped CTLs showed increased expression of activated NFATc1, Bcl-
10, and cleaved caspase-3 and -7, and reduced expression of Bcl-2, and phosphorylated-Akt1 and -
NF-κB when compared to helped CTLs (Fig. 5). Although we could not rule out the discrepancy 
observed in the mRNA and protein levels of NF-κB and Akt1, it possibly represents 
posttranscriptional and posttranslational modifications that may interfere with direct mRNA to 
protein translation (36). Nevertheless, these data reveal striking evidence that Th cells rescue 
effector CTLs from AICD by mediating up-regulation of anti-apoptotic and down-regulation of 
pro-apoptotic genes, and regulation of various pathways involved in cell death or survival.       
3.6 Discussion  
Understanding factors derived from CD4+ T cell help involved in the regulation of effector 
CTL responses is currently one of the most active areas of immunological research. In the last two 
decades, the role of CD40L and IL-2 signaling by Th1 cells for memory CTL development has 
been extensively studied, yet the means by which such signaling occurs is not completely known 
(3, 17). The use of an agonistic antibody to CD40 can substitute CD4+ T cell help for inducing 
optimal primary CTL responses, which led to a conclusion that Th1 cells might license APC via 
CD40-40L signaling (3). Alternatively, Tanchot and his colleagues, and our previous works, 
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suggested that Th1 cells can directly provide CD40L (4, 5, 22) and IL-2 (22) signaling to naïve 
CD8+ CTL for efficient memory CTL development. A more recent study suggested direct 
interaction between DC-stimulated memory CD4+ and CD8+ T cells via CD40-CD40L and/or IL-2 
signaling for optimal recall responses (16, 37). Moreover, a direct cooperative role between Th1 
and effector CTLs has also been frequently reported in the absence of DC (11, 30, 31, 38-40). In 
this study, we demonstrate that cognate CD4+ T cell help required for effector CTL survival and 
memory programming is mediated via direct CD40L and IL-2 signaling, and identify various 
apoptotic pathways and transcription factors involved in CTL survival or apoptosis under helper 
influence, thus providing strong evidence to recently establishing notion that effector phase can be 
altered to enhance both quantity and quality of memory CTLs (9, 10).   
The acquisition of pMHC I appears to be critical for Th to make efficient contact with and 
delivery of CD40L and IL-2 signaling to the effector CTLs in Ag-specific manner due to several 
reasons. First, in the absence of pMHC I, a reduced memory CTL pool exhibiting poor recall 
functions is observed. Second, the transfer of naïve or non-specifically-stimulated CD4+ T cells 
without pMHC I to Iab-/- mice fails to rescue effector CTLs even though they are TCR-specific in 
nature. Finally, the results in this study well support recent emerging evidence that Th cells 
substantially rescue effector CTLs from AICD and promote functional memory generation (6, 11, 
39). Perhaps, even in three-cell interactions, Th cells, after detaching from DCs, might directly act 
on CTLs in the vicinity due to pMHC I and TCR avidity.  
The functional consequences of trogocytosis could vary depending on the situations either 
to prevent self-tissue damage or to protect host from invading pathogens (1, 22, 23). We 
previously demonstrated a 7-fold Ag-specific targeting power of T cell suppression between CD4+ 
Tr1 with acquired pMHC I and CD4+ (Kb-/-)Tr1 without acquired pMHC I (35). Mostbock et al. 
(21) also showed memory CTL with acquired pMHC-1 complexes up-regulate Caspase 3, bcl-X, 
bak and bax, leading to apoptosis. Cox et al. (25) also demonstrated that Th with acquired 
bystander pMHC I complexes from APCs became susceptible to CTL killing in an Ag-specific 
manner, perhaps due to brief period of culturing, and the use of nonprofessional, MHCII-
transfected 293T APCs, which provide poor costimulation, and non-specifically-stimulated CD4+ 
T clones to generate Th cells. In contrast, here we use highly mature, professional APCs to 
stimulate TCR-specific CD4+ T cells for prolonged period (3 days in culture) to generate Th cells. 
Nevertheless, although Th cells, with acquired pMHC I and -II complexes, positively modulate 
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effector CTL responses, they become susceptible to killing by other Th cells (fratricide) (22), 
supporting previous observations (1, 21, 26). Hence, these results provide convincing evidence that 
culturing conditions, extent of stimuli, and nature and type of immune cells might determine 
outcome of trogocytosis in the immune system.    
The gene-expression profiling together with our Western blot results provide mechanistic 
insights into the understanding of CD4+ T cell helper functions in CTL fates. The Fas-FasL–
mediated pathway appears to be the key mediator in the contraction of adoptively transferred 
effector CTLs. Up-regulation of Fas and FasL along with various down-stream signaling 
molecules, such as Tnfrsf1a, Casp-2, -3 and -7, are known to mediate apoptosis by activation of 
caspase-8 and -3 (41), consisting with the present results. Furthermore, unhelped effector CTLs 
also show enhanced expression of NFATc1 transcription factor, a key regulator of FasL expression 
(42), further confirming Fas-FasL pathway in AICD. Interestingly, the helped CTLs show down-
regulation of various pro-apoptotic genes, which mediates not only FasL-, but also Trail-apoptotic 
pathways. These pathways mediate extrinsic-apoptotic pathway that are known to cause 
exhaustion of unhelped CTLs during secondary responses following re-stimulation (7, 43). 
Possibly due to these reasons, unhelped, but not helped, IFN-γ+ CTLs are almost absent in tumor-
challenged mice, irrespective of polyclonal CD4+ T cell help, suggesting cognate CD4+ T cell 
helper signals during the constraction phase can rescue memory CTLs from AICD upon re-
stimulation with Ag. 
Th cells also appear to mediate CTL survival by secreting its survival factors, such as IL-2, 
and by providing its costimulations necessary for survival gene expression. Recently, cognate Th 
cells through secretion of IFN-γ and chemokines were suggested in mobilizing effector CTLs, after 
their differentiation, into infected tissues (40). Perhaps these factors, together with pMHC I and 
TCR interactions with strong affinity, greatly favor Th’s ability to deliver CD40L and IL-2 
signaling directly and efficiently to effector CTLs in vivo. Interestingly, unhelped CTL’s poor 
survival correlated well with significant down-regulation of key survival genes, which mediate 
various signals both at nuclear and cytoplasmic levels required for activation of pro-survival NF-
κB and attenuation of pro-apoptotic JNK pathways (44). Consistently, helped CTLs showed 
decreased Bcl10 expression and increased Akt1 and NF-κB activation, which known to mediate 
transcription of various survival genes (44, 45). TCR together with CD28 and/or IL-2 signaling 
enhance T cell survival via Akt-mediated NF-κB activation and c-jun down-modulation (44, 46). 
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In addition to pMHC I, IL-2 and CD40L signaling, Th cells, with acquired CD80 (22, 23), might 
mediate CD28 signaling as unhelped, but not helped, CTLs show striking down-regulation and 
decreased activation of Akt1 and NF-κB. Interestingly, up-regulation of survival genes is not a 
feature of helped effector CTLs; however, their mRNA profiles are almost similar to those of naïve 
OTI CD8+ T cells predominated by survival genes. The few up-regulated genes above naïve cell 
levels, such as Akt1, Xiap, CD40lg and Traf1 genes, may play leading role in effector CTL 
survival.  
Although cognate CD4+ T cell help during priming is shown to be required for memory 
programming (4, 7, 8), the present results indicate that such help most likely occurs after CD4+ T 
cells polarized to Th following APC stimulation where they acquire ability to secrete IL-2 and 
express CD40L. In support of this, our previous and present results showed that Th, after detaching 
from DCs, can directly stimulate naïve transgenic or endogenous CD8+ T cells (22, 24), and 
effector or memory CTLs (30, 31). In acute infection, Sun et al.(47) showed that naïve, polyclonal, 
but not cognate, CD4+ T cell help, are required to orchestrate size and quality of memory CTLs. In 
their study, effector CTLs are generated in vitro after increasing the precursor frequency by more 
than 50 fold of physiological levels, which likely preclude cognate CD4+ T cell helper 
requirements for memory programming (48), while polyclonal CD4+ T cell help still supporting 
the maintenance of memory CTLs. Our study indicates that non-specific CD4+ T cell help, 
although enhance CTL survival and memory pool, cannot replace cognate Th’s help in improving 
the quality of memories (Fig. 6) as memory CTLs developed under polyclonal CD4+ environment, 
although survived better, completely failed in producing functional IFN-γ+ CTLs, and waned 
following tumor challenge. Recently, de Goer de Herve et al demonstrated that hetero-specific Th 
cells can also rescue effector CTL from AICD, and promote recall responses by direct contact via 
CD40L and IL-2 signaling (16). In contrast, by detailed analysis, here we show that acquired 
pMHC I on Th are required to make direct contact in Ag-specific manner, and to deliver CD40L 
and IL-2 signaling efficiently, thus supporting previously well-appreciated results (6, 12-14, 39, 
40). Perhaps, the discrepancy seen in de Goer de Herve’s report and current study may be derived 
from quantitative differences in the requirement of CD4+ T cells although CD40L and IL-2 
signaling is commonly reported.     
Based upon the present and previous supportive observations (4-6, 11, 12, 17, 22, 31, 38, 
39, 49), we argue that Th interactions with effector CTL might be critical to generate functional 
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memory CTL (Fig. 6). Both CD4+ and CD8+ T cells follow asymmetric immune responses  and 
require different activation signals (50). In contrast to CD8+ T cells, CD4+ T cells need to contact 
with DC multiple times (Ag persistence) to undergo activation and differentiation (51). As a result, 
Th cells might acquire sufficient bystander pMHC I, which not only make them undergo 
exhaustion by fratricide killing (1, 21, 22, 26), but also permit surviving Th cells to precisely target 
effector CTL pool. During the peak effector phase, a majority of the effector CTL which miss Th 
cell contact due to their predominance undergo death by fratricide mechanism (11, 52). As a result, 
only a fraction of the effector CTL pool that receives helper signals might survive and develop into 
a functional memory pool. In support of this hypothesis, we observed a dose-dependent increase of 
the memory CTL pool with Th increase. Williams and Bevan (49), after shortening infectious 
period of recombinant Listeria monocytogenes, observed diminished primary CD4+ and memory 
CTL differentiation although primary CTL expansion was unaltered. Our study could explain these 
observations wherein insufficient Th generation due to shortened infectious period might result in 
poor signaling of effector CTL pool and hence poor memory differentiation. Indeed, during the 
effector phase, the transfer of Th, but not naïve OTII CD4+ T cells into AdVova-immunized Iab-/- 
mice greatly enhanced effector CTL survival and memory differentiation (Unpublished, 
Umeshappa CS and Xiang J). Whether pMHC I acquisition by Th for memory programming is 
common phenomenon in immunity involving to variety of Ags, including pathogen-derived and 
altered self-Ags, needs further detailed study.    
Taken together, our results reveal a previously unexplored mechanistic role of Th in 
programming effector CTL responses. To date, adoptive CTL immunotherapy for cancer using in-
vitro expanded tumor-infiltrating CD8+ T cells has achieved some degree of success (13, 53). 
However, one of the major obstacles in this therapy is their poor survival and development of 
corrupted memories (13, 53) due to AICD and CD4-deficient environment associated with many 
primary therapies. In the present study, unhelped CTL’s poor survival and their incomplete 
protection against lethal tumor challenge re-emphasize the importance of using Th in adoptive 
CTL therapy. Finally, this form of Th-effector CTL cooperation could explain why memory CTLs 
generated under cognate Th help show survival and recall advantages (4-8, 11, 12, 17), a 
phenomenon frequently observed in cancers, and could aid in development of efficient vaccines 
against cancers, perhaps by inclusion of T helper epitopes in the therapy.  
 105
3.7 Acknowledgments  
This study was supported by Research Grant MOP 79415 from the Canadian Institute for Health 
Research. 
3.8 Disclosures 
The authors have no financial conflict of interest 
 
 
 106
3. 9 Tables 
Table 1 Adoptive transfer of Th with effector CTLs leads to functional memory CTL 
development and protection against lethal tumor challenge.  
 
Micea Adoptive transfer % tumor-bearing mice 
Tumor 
grading 
PBS     10/10 (100)      (++++++) 
Effector CTL     12/12 (100)          (+) 
Effector CTL(In vitro helped)     00/12 (0)            0 WT 
Effector CTL+Th     00/12 (0)            0 
PBS     10/10 (100)      (++++++) 
Effector CTL     12/12 (100)         (++) 
Effector CTL(In vitro helped)     05/12 (42)         (+/-) 
Effector CTL+Th     04/12 (33)         (+/-) 
Effector CTL+Th(CD40L-/-)     12/12 (100)          (+) 
Effector CTL+Th(IL-2-/-)     12/12 (100)         (++) 
Iab-/- 
 
Effector CTL+Th(pMHC-1-/-)     12/12 (100)          (+) 
 
 
aApproximately 5x106 effector CTLs were i.v. transferred with or without Th, Th(IL-2-/-), 
Th(CD40L-/-) or Th(pMHC I-/-) cells (2x106each) to WT or Iab-/- mice as indicated. After 100 
days, all the mice were challenged i.v. with highly metastasizing BL6-10OVA tumor cells. The 
mice were sacrificed on 24th day of challenge, and the numbers of metastasized tumor colonies in 
lungs were counted and graded depending on numbers of metastatic tumor colonies. The data are 
cumulative of three independent experiments with three to four mice per group.  
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Table S1, related to Figure 4 
 
Primers Tm          Sequence (5’ – 3’) GeneBank ID
58.0 F - CTTCTATGGTGCGGAGATTGTG Akt1 59.0 R - CCCGGTACACCACGTTCTTC NM_009652 
59.0 F - GAAAGCTGCCGACACACTCA Bcl-10 59.0 R - CCCGACGGCTTCTCAGAAC NM_009740 
60.0 F - CAATGGCCGTACACGAAAGG Casp-4 58.0 R - GCCCCATACCTCAGTGAGAGAT NM_007609 
59.0 F - CCACCAGCGCCTTATAATTCC Casp-7  58.0 R - ATGGTCCCTAGGCCCTCACT NM_007611 
59.0 F - CCAGCTTCCGTGTTTGTTCAG Nfkb1  60.0 R - TCAGGGTAGTAGAGAAAGGGTTTCG NM_008689 
59.0 F - GGGCCTCACAGACAATCAAATC Trail-rec (Tnfrsf10b) 60.0 R - GCCTCACGTGTGACCAGTGT NM_020275 
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Table S2A, related to Figure 4. Top genes uniquely up-regulated above three fold 
 
Gene Symbol Fold Regulation Key functions 
Helped CTL in CD4-sufficient mice 
Akt1 4.212 Inhibit apoptosis via phosphorylation of components of apoptosis pathway  
Xiap 9.412 Inhibit apoptosis via inhibition of caspase 3, 7 and 9 
Prdx2 3.462 Antioxidant protective role in cells 
Cd40lg 6.537 Expressed on activated T cells, exerts diverse effects depending on type of cells involved 
Traf1 3.838 
Activates MAPK8/JNK and NF-κB and mediates anti-
apoptotic signals by inhibiting inhibitor-of-apoptosis 
proteins  
Helped CTL in CD4-deficient mice 
Akt1 3.524 Inhibit apoptosis via phosphorylation of components of apoptosis pathway 
Xiap 3.164 Inhibit apoptosis via inhibition of caspase 3, 7 and 9 
Casp2 6.674 Induce apoptosis by associating with several pro-apoptotic proteins   
Dad1 9.983 Inhibits apoptosis possibly by interacting with Mcl-1 (a bcl-2 family member) (54) 
Dapk1 3.013 Positive mediator of IFN-γ-induced programmed cell death 
Cd40lg 6.215 Expressed on active T cells, exerts diverse effects depending on type of cells involved 
Traf1 4.424 
Activates MAPK8/JNK and NF-κB and mediates anti-
apoptotic signals by inhibiting inhibitor-of-apoptosis 
proteins  
Unhelped CTL in CD4-deficient mice 
Casp2 7.114 Induce apoptosis by associating with several pro-apoptotic proteins   
Casp3 3.246 Mediates apoptosis in both extrinsic (death ligand) and intrinsic (mitochondrial) pathways (41) 
Casp7 9.764 Executioner protein of apoptosis 
Fas (CD95) 3.275 Induces apoptosis on binding by FasL. 
FasL (CD95L) 4.056 Induce apoptosis by binding to Fas receptor (Regulate immune system via inducing apoptosis) 
Tnfrsf1a 3.193 Activate transcription factor NF-κB, mediate apoptosis, and function as a regulator of inflammation. 
Trp53 (p53) 3.014 Mediate apoptosis following activation by myriad of stressors 
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Table S2B, related to Figure 4. Top genes uniquely down-regulated below three fold  
 
Gene Symbol Fold Regulation Key functions 
Helped CTL in CD4-sufficient mice 
Bcl10 -14.122 
Interact with CARD domain containing proteins including 
CARD9, 10, 11 and 14, and mediate apoptosis via NF-κB 
activation (45) 
Card10 -8.342 Interact with Bcl10 and activate NF-κB to induce apoptosis (45) 
Card6 -7.297 Interacts with Cardiac and Nod1 and specifically impairs their ability to induce the transcription factor NF-κB (55) 
Casp3 -5.025 Mediates both extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic pathways(41) 
Casp4 -59.804 Inflammatory caspase, implicated in endoplasmic-reticulum stress-induced apoptosis  
Casp7 -11.942 Executioner protein of apoptosis 
Fas -5.964 Induces apoptosis upon binding by FasL (11) 
FasL -13.781 Induce apoptosis by binding to Fas receptor (Immune regulation) (11) 
Pycard -10.111 Involved in inflammatory and cell death pathways in concert with Caspase-1 
Tnfrsf10b  
(Trail-rec) -7.399 Mediate apoptosis following activation by TRAIL (7) 
Tnfrsf11b -3.017 Exhibit paracrine survival functions on cells (56) 
Helped CTL in CD4-deficient mice 
Bcl10 -3.059 
Interact with CARD domain containing proteins including 
CARD9, 10, 11 and 14, and mediate apoptosis via NF-
kappaB activation (45) 
Birc5 3.01 Prevent apoptosis by inhibiting Caspase activation 
Card6 -3.708 Interacts with Cardiak and Nod1 and specifically impairs their ability to induce the transcription factor NF-κB (55) 
Casp3 -5.231 Mediates apoptosis in both extrinsic (death ligand) and intrinsic (mitochondrial) pathways (41)  
Fas -3.914 Induces apoptosis on binding by FasL (11) 
FasL -3.681 Induce apoptosis by binding to Fas receptor (Regulate immune system) (11) 
Unhelped CTL in CD4-deficient mice 
Akt1 -14.993 Inhibit apoptosis via phosphorylation of components of apoptotic pathway (44, 46)  
Api5 -9.923 Promote cell survival by inhibiting apoptosis 
Atf5 -3.695 Promote cell survival by inhibiting apoptosis 
Bad -4.491 Involved in initiation of apoptosis 
Bag1 -7.675 
Enhances the anti-apoptotic effects of BCL2 and represents 
a link between growth factor receptors and anti-apoptotic 
mechanisms. 
Bcl2 -11.071 Prevent apoptosis (57) 
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Bcl2l1 -10.706 
Prevent apoptosis by controlling the production of reactive 
oxygen species and release of cytochrome C by 
mitochondria 
Bcl2l2 -8.651 Prevent apoptosis 
Birc3 -9.627 Prevent apoptosis by interfering with caspases activation  
Birc5 -17.175 Prevent apoptosis by inhibiting Caspase activation 
Bnip2 -5.851 Prevents apoptosis 
Bnip3 -4.653 Exhibits pro-apoptotic functions 
Bnip3l -19.677 Promotes cell-death 
Bok -7.359 Pro-apoptotic molecule involved in regulation of cell cycle 
Nod1 -5.493 Involved in triggering innate immune response that drives development of adaptive immune responses 
Casp1 -3.262 Inflammatory caspsae involved in triggering apoptosis owing to pro-inflammatory cytokines 
Cidea -3.747 Involved in activation of apoptosis 
Cideb -3.602 Involved in activation of apoptosis 
Dapk1 -3.833 Positively mediate IFN-γ induced programmed cell death 
Ltbr -3.132 Mediate apoptosis; involved in development and organization of lymphoid tissue and transformed cells 
Mcl1 -7.914 A critical anti-apoptotic factor for the survival of T cells at multiple stages in vivo 
Nfkb1 -28.496 
Anti-apoptotic to T cells. MKP-1 is a NF-kappaB-mediated 
prosurvival effector in attenuating JNK-mediated pro-
apoptotic response (44, 46) 
Nol3 -9.897 Prevents apoptosis  
Pak7 -7.727 Regulation of cytoskeletal dynamics, proliferation, and cell survival signalings 
Pim2 -9.293 Promote the growth and survival of nontransformed hematopoietic cells 
Polb -4.186 
Performs base excision repair (BER) required for DNA 
maintenance, replication, recombination, and drug 
resistance (anti-apoptosis) 
Rnf7 -8.467 Anti-apoptosis (antioxidant) 
Cd40 -4.395 Immunomodulation - exhibit diverse functions  
Tnfsf12 -4.526 Known to mediate both apoptosis induction and suppression  
Cd70 -6.649 
CD27/CD70 interactions at the T cell/DC interface prime 
CD8(+) T cells to become tumor-eradicating cytolytic 
effectors and memory cells 
Traf1 -18.465 
Activates MAPK8/JNK and NF-κB and mediates anti-
apoptotic signals by inhibiting inhibitor-of-apoptosis 
proteins (44) 
Traf3 -4.016 
TRAF3 potently suppresses canonical (p50-dependent) NF-
κB activation and gene expression in vitro and in vivo (anti-
apoptosis) (44) 
Trp73 (p53) -3.988 Induce apoptosis in mammalian cells (58) 
Zc3hc1 -10.101 Anti-apoptotic role in NPM-ALK-mediated signaling events 
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3.10 Figures 
Figure 1 
 
 
Th’s help during priming or transitional period enhance effector CTL survival and 
transition to memory development. (a) Experimental Design. To determine direct impact of Th 
on effector CTL fates, effector CTLs and Th with or without specific gene deficiency were 
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adoptively transferred to WT or CD4-deficient mice. All these mice were monitored for CTL 
survival at different intervals and memory recall responses by boosting with DCova or challenging 
with highly metastasizing BL6-10OVA. (b) Approximately 5x106 OVA-specific transitionally 
helped effector CTLs with (2x106) or without Th were adoptively co-transferred to WT or CD4-
deficient mice and monitored 6 and 60 days later in the peripheral blood by tetramer assay. OVA-
specific effector CTLs generated in presence or absence of cognate CD4+ T cells during priming 
(primary help) were also transferred and analyzed. On 60th day, all the groups were boosted with 
1x106 DCova and monitored for memory CTL expansion after 4 days. The values represent 
mean%±(SD) of tetramer+ CTLs in total CD8+ T cell population, and are cumulative of three 
independent studies with three to five mice per group. * or **, p < 0.05 or 0.01, respectively, 
versus unhelped CTLs. (c) Influence of Th’s dose on effector CTL survival and memory CTL 
development. Approximately 5x106 effector CTLs with 2x106 (low) or 5x106 (high) Th cells were 
adoptively transferred to WT or CD4-deficient mice and monitored 60 days later in peripheral 
blood. The values represent mean%±SD of tetramer+ CTLs in total CD8+ T cell population, and are 
cumulative of two independent studies with four to five mice per group. * or **, p < 0.05 or 0.01, 
respectively, versus low Th dose. (d) The blood samples from WT mice which were transferred 
with effector CTLs and Th cells or from CD4-deficient mice which were transferred with effector 
CTLs alone were collected 6 and 60 days later. The samples were stained with H-2Kb/OVA257-264 
tetramer and FITC-anti-CD8 Ab along with panel of biotin-conjugated Abs specific for effector or 
memory markers, and streptavidin-PE-Texas Red. The marker expressions (histogram grey filled 
overlays) were analyzed in tetramer+- and CD8+-specific double population. Irrelevant isotype-
matched Abs were used as control (dotted thin lines). One representative of the two independent 
experiments is shown.    
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Figure 2 
 
 
 
Nature of CD4+ T cell help for CTL survival and recall responses. (a) Naïve or non-
specifically-stimulated CD4+ T cell help is dispensable for CTL survival and recall responses. 
Approximately 5x106 effector CTLs were i.v. transferred along with naïve-monoclonal or -
polyclonal (15x106) or ConA-stimulated-monoclonal or -polyclonal (2x106) CD4+ T cells, or Th 
cells (2x106) as indicated to WT or CD4-deficient mice and analyzed for survival 6 and 60 days 
later, and recall responses on 4th day of boosting with DCova (1x106). The values represent 
frequencies of tetramer+ CTL in total CD8+ T cell population, and are cumulative of three 
independent studies with three to four mice per group. The horizontal bars indicate means. * or **, 
p < 0.05 or 0.01, respectively, versus WT or Th-helped CTLs in Iab-/-. (b) Poor survival of CD4+ T 
cells in CD4-deficient mice. Naïve (15x106), ConA-stimulated (10x106)-polyclonal  or DCova-
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stimulated Th cells on CD45.1+ background were i.v. transferred to congenic CD4-deficient mice 
and analyzed 3, 30 and 60 days later by flow cytometry. One representative figure from each group 
is shown in dot plot. The values represent mean%±SD of tetramer+ CTLs in total CD8+ T cell 
population, and are cumulative of two independent studies with two to three mice per group.  
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Figure 3 
 
 
 
 
Molecular mechanisms of cognate Th’s help for effector CTL survival and recall responses. 
(a) DCova(Kb–/–)-stimulated Th(pMHC I–/–) with anti-pMHC I Ab and DCova-stimulated 
Th(CD40L–/–) with anti-CD40L Ab (solid thick lines; bottom panels) were stained, keeping 
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DCova-stimulated Th as positive control (solid thick lines; top panel) and analyzed by flow 
cytometry. One representative of the three independent experiments is shown. Irrelevant isotype-
matched Abs were used as control (dotted thin lines) in the above experiments. (b) Both Th and 
Th(IL-2–/–) were also re-stimulated with OVA323-329-pusled LB27 cells and the extent of IL-2 
secretion were analyzed in supernatants. The values represent mean%±SD of tetramer+ CTLs in 
total CD8+ T cell population, and are cumulative of two independent studies with four to five mice 
per group. (c) Approximately 5x106 effector CTLs were i.v. transferred with or without Th, 
Th(CD40L-/-), Th(IL-2-/-) or Th(pMHC I-/-) (2x106 each) to CD4-deficient mice, and analyzed for 
survival 6 and 60 days later, and recall responses on 4th day of boosting. The values represent 
frequencies of tetramer+ CTLs in total CD8+ T cell population, and are cumulative of three 
independent studies with three to four mice per group. The horizontal bars indicate means. * or **, 
p <0.05 or 0.01, respectively, versus Th-helped CTLs in Iab-/-. (d) OVA-specific helped IFN-γ+ 
CTLs infiltrate efficiently in tumor-challenged mice. Approximately 5x106 effector CTLs with or 
without Th cells (2x106) were adoptively co-transferred to CD4-sufficient or -deficient mice. On 
100th day, all the groups were challenged with BL6-10OVA tumor cells, and monitored for tumor 
colonies development. On 24th day, the spleen samples were analyzed by intracellular IFN-γ+ 
staining. The data represent cumulative frequencies of Ova-specific IFN-γ+ CTL in total CD8 T 
cell population and are derived from three independent experiments with two to four mice per 
group. **, p < 0.01 versus unhelped CTLs in Iab-/-.     
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Figure 4 
 
 
 
The provision of Th help causes distinct changes in expression of genes that regulate 
apoptosis, favoring effector CTL survival. (a-c) Apoptosis pathway-focused gene expression in 
helped versus unhelped CTLs. Total RNA from purified population of helped or unhelped CTLs 
was isolated, reverse transcribed to cDNA, and subjected to PCR array. Heat map showing relative 
gene expression in helped or unhelped CTLs where intensity of color towards red indicates up-
regulation and green indicates down-regulation. One representative figure from each group of two 
independent experiments, each run on duplicates using pooled cDNA samples derived from two to 
four mice per group, is shown. (d-e) Statistically significant genes (a three-fold mRNA difference 
compared to naïve OTI CD8+ T cells) that were up- (top) or down-regulated (bottom) and their 
overlapping between helped or unhelped CTLs purified from CD4-sufficient or -deficient mice are 
shown as indicated. See Table S2A and S2B for gene-expression data. (f) Validation of PCR array 
results by qRT-PCR. cDNA samples of helped or unhelped CTLs used for PCR array were further 
subjected to qRT-PCR using SYBR Green detection protocol. The genes up- or down-regulated in 
helped or unhelped CTLs purified from CD4-sufficient or -deficient mice are shown as indicated.  
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Figure 5 
 
 
 
Immunoblot analysis of pro-survival and pro-apoptotic protein expressions or 
phosphorylations. The proteins in helped or unhelped CTL lysates were separated by SDS-PAGE, 
and the protein bands were transferred to nitrocellulose membrane blots. The blots were then 
stained with panel of Abs specific for β-actin, Bcl-2, Bcl10, Akt1, NF-κB-p65, phosphorylated-
Akt1 and -NF-κB-p65, cleaved Caspase-3 and -7, or NFATc1 transcription factor and analyzed in 
ODYSSEY densitometer. Densitometric values normalized to β-actin expression as well as n-fold 
changes in normalized target molecule expression in the helped CTLs purified from WT or CD4-
deficient mice are shown below the corresponding lanes. Data are mean derived from triplicate 
values and are representative of four to six mice in each group pooled from two independent 
experiments. 
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Figure 6 
 
 
 
Fate of adoptively transferred effector CTLs under the influence of Th cells and/or naïve 
CD4+ T cells. (a) Specific signals such as pMHC I, CD40L and IL-2 from Th cells alone program 
effector CTLs significantly for both survival and functional memory development. (b) Without 
specific or non-specific signals, effector CTLs survive poorly, possibly due to fratricide killing, 
and develop into defective memory. (c) Upon adoptive transfer, effector CTLs receive specific 
signals such as pMHC I (signal 1), CD40L (signal 2) and IL-2 from Th cells, and survive 
significantly. Non-specific signals from naïve, polyclonal CD4+ T cells could also provide 
synergistic help for the survival. Furthermore, these signals in concert program development of 
fully functional memory CTLs. 
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Supplementary Figure 1 
 
 
 
Phenotypic characterization of DCova, Th cells and effector CTLs. (a) DCova, naïve and 
DCova-stimulated CD4+ (Th) and CD8+ (effector CTL) T cells (solid thick lines) were stained with 
a panel of Abs specific for cell types, acquired pMHC I, and naïve, activation/maturation or 
memory status as indicated, and analyzed by flow cytometry. One representative of the two 
independent experiments is shown. (b) DCova and Th cells or effector CTLs were stained with PE-
anti-CD11c and FITC-anti-CD4 or FITC-anti-CD8 Abs. The value in the panel represents the 
mean%±(SD) of CD4highCD11clow (left) or CD8highCD11clow (right) cells in the total population of 
CD4high Th or CD8high effector CTLs, respectively. One representative figure of three independent 
experiments is shown. 
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Supplementary Figure 2 
 
 
Purity of tetramer-enriched CTLs. Approximately 5x106 effector CTLs with or without Th cells 
(2x106) were adoptively co-transferred to CD4-sufficient or -deficient mice. On 16th day, the 
transferred helped or unhelped effector CTLs were purified from blood and lymphoid organs of 
CD4-sufficient or -deficient mice by positive selection using PE-H-2Kb/OVA257-264 tetramer and 
anti-PE microbeads. The purified CTLs were stained with FITC-anti-CD8 Ab and analyzed for 
purity by flow cytometry. The data represent mean% ±(S.D) and are cumulative of three 
independent experiments with two to six mice per group. 
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4.1 Brief introduction to Chapter 4  
 
 Recent studies have shown that natural differences in the size of Ag-specific CD8+ T cell 
precursors can influence the magnitude of primary and memory CTL responses, suggesting altered 
PF could modify the requirement of regulatory factors for CTL responses. Since Th cells are 
considered to be the most important cells that regulate one or several phases of CTL responses, 
here we studied how altered PF impact CD4+ T-helper signal requirements for functional primary 
and memory responses. 
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4.2 Abstract  
  
CD4+ T cell-derived help is dispensable for primary cytotoxic T lymphocyte (CTL) responses at 
increased CD8+ T cell precursor frequency (PF). However, it remains unclear what role CD4+ T 
cell action and related signals play in the development of memory CTL responses at higher PF. We 
addressed these questions using immunization with ovalbumin (OVA)-pulsed dendritic cells 
(DCOVA) both at endogenous and increased PF, utilizing various gene-knockout and transgenic 
mice. We found that at endogenous PF, CD4+ T-helper signals were required for both OVA-
specific primary and secondary CTL responses. At increased PF, CD4+ T cell help and associated 
CD40L, but not IL-2, signalling became dispensable for primary CTL responses. Furthermore, 
increased PF considerably enhanced DCOVA-induced therapeutic immunity in mice with 
established OVA-expressing tumors independent of CD4+ T cell help. In contrast, CD4+ T cell 
help and related signals were indispensable for functional memory CTL development. Without 
these helper signals, memory CTLs failed in inducing efficient immune protection against tumor 
challenge, even when developed at increased PF. Our results demonstrate that alterations in CD8+ 
T cell PF influence dependence of primary and secondary CTL responses on CD4+ T helper factors 
and could impact the development of novel immune-based cancer therapies, since their efficacy 
would be determined in part by CD4+ T-helper signals and partially by CD8+ T cell PF.               
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4.3 Introduction 
 A hallmark of the cell-mediated immunity is the generation of millions of copies of effector 
CD8+ cytotoxic T lymphocytes (CTLs) and a small fraction of memory CTLs arising from the 
proliferation of extremely low number of naïve CD8+ T cell precursors (~10 of  3000) (1-3). This 
dynamic event is largely regulated by a multitude of factors during priming and effector phases of 
CTL responses (4). Among these factors, CD4+ T cells are known to mediate helper effects either 
indirectly by inducing maturation signals to APCs via CD40L signaling (5-7), or directly by 
modulating CD8+ T cell responses via cytokine (IL-2) and co-stimulatory (CD40L) signals (8, 9).    
 Recently, several studies have indicated that natural differences in the size of CD8+ T cell 
precursor population for a given antigenic epitope can affect the magnitude of effector and 
memory CTL responses (2, 10-14). Even in genetically identical twins, variations in CD8+ T cell 
repertoires impact the development of autoimmune diseases, such as type-I diabetes and multiple 
sclerosis (15). These observations inspired researchers to investigate, whether altered precursor 
frequency (PF) modifies the requirement for specific regulatory factors in the development of 
CD8+ T cell responses. Studies in several models, have recently suggested that primary CTL 
responses at higher PF could occur independent of CD4+ T cell help, even against minor-H Ag (11, 
12, 16). We have recently demonstrated that, at higher PF, the primary CTL responses derived 
from ovalbumin (OVA)-pulsed dendritic cell (DCOVA) stimulation occur in absence of CD4+ T cell 
help (unhelped) in Iab knockout (Iab-/-) mice (17). However, whether these unhelped CTLs are 
functional effectors is unknown. While most of the studies have focused on the effect of PF on the 
primary CTL responses, its potential relation to the requirement of CD4+ T-help and its helper 
signals mediated by CD40L for functional memory CTL development at higher PF is poorly 
understood. In addition, the situation is further complicated by observations that show significant 
differences in the requirement for CD4+ T cell help in different types of infections or 
immunizations (5, 8, 9, 11, 12, 18, 19).   
 In our previous work, we demonstrated that, at higher PF, the primary CTL responses 
derived from DCOVA stimulation occur in absence of CD4+ T cell help in the gene knockout (KO) 
(Iab-/-) mice, lacking CD4+ T cells, while also bypassing self-immune tolerance with the induction 
of type-1 diabetes in the transgenic RIP-mOVA mice (17). In this study, effects of  immunizations 
with DCOVA derived from wild-type (WT) or gene-KO (CD40-/- or CD40L-/-) mice on primary and 
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memory CTL responses were assessed in CD4+ T cell-sufficient WT mice or in CD4+ T cell-
deficient Iab-/-, or in help-signalling-deficient CD40-/- or CD40L-/- mice at endogenous PF, or at 
increased PF, assured by the transfer of OVA-specific naïve CD8+ T cells derived from (WT)OTI-
Ova Transgenic, (CD40-/-)OTI or (CD40L-/-)OTI mice. These experimental approaches allow us to 
monitor the requirement for specific CD4+ T-helper signals in the primary and memory CTL 
responses at both endogenous and increased PFs.  
4.4 Materials and methods 
4.4.1 Reagents, tumor cells and animals    
The biotin- or fluorescent-labeled (FITC or PE) Ab specific for CD11c (HL3), H-2Kb 
(AF6-88.5), Iab (KH74), CD80 (16-10A1), CD40 (3/23), CD4 (GK1.5), CD44 (IM7), CD127 
(A7R34), CD62L (MEL-14), CD69 (H1.2F3), Vβ5·1,5·2 TCR (MR9-4), IFN-γ (XMG1.2) and IL-
2 (JES6-5H4), purified rat anti-mouse IL-2 (JES6-1A12), streptavidin-PE-Cy5 and streptavidin-
FITC were purchased from BD-Biosciences (San Diego, CA). The PE-anti-CD8 (KT15) Ab from 
Serotec (Burlington, Ontario, Canada), and FITC-anti-CD8 (KT15) and H-2Kb/OVA257-264 
tetramer from Beckman Coulter (Miami, FL) were purchased. The recombinant GM-CSF, IL-2 
and anti-IL-4 Ab were obtained from R & D Systems (Minneapolis, MN). The OVAI (OVA257-264, 
SIINFEKL) peptide was synthesized by Multiple Peptide Systems (San Diego, CA). The OVA was 
obtained from Sigma-Aldrich Canada (Oakville, Ontario, Canada). The mouse malignant 
melanoma (BL6-10) (20) and OVA-transfected BL6-10 (BL6-10OVA) (18) cell lines were cultured 
as described previously (8). The C57BL/6J (WT), OVA257-264-specific TCR-transgenic OTI, IL-
2Rα-/-, CD40-/-, CD40L-/- and Iab-/- mice on C57BL/6 background were purchased from Jackson 
Laboratory or bred in University’s animal resource center. The OTI/CD40-/- and OTI/CD40L-/- 
mice were generated by backcrossing designated KO mice with OTII mice, and tested as described 
previously (8). All the animal experiments were performed as per the guidelines approved by the 
University Committee on Animal Care and Supply, University of Saskatchewan.        
4.4.2 Preparation of mature DCOVA  
Bone-marrow-derived DCOVA from C57BL/6 mice were generated by culturing bone 
marrow cells for 6 days in medium containing IL-4 (20 ng/ml) and GM-CSF (20 ng/ml) and 
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pulsing with 0.1 mg/mL OVA overnight at 37°C as described previously (18). DCOVA generated 
from CD40-/- and CD40L-/- mice were referred as (CD40-/-)DCOVA and (CD40L-/-)DCOVA, 
respectively.     
4.4.3 Isolation of mononuclear leukocytes from lung 
The lungs were finely minced and digested for 30 min with collagenase D (1mg/ml) at 
37oC. The cell suspension was incubated with 0.01M EDTA for 5 min and subjected to gradient 
centrifugation using Histopaque (Sigma, St. Louis, MO). The white buffy coat at the suspension 
and histopaque interface was collected for analysis.   
4.4.4 Assessment of primary and memory CTL responses  
C57BL/6 mice were i.v. immunized with DCOVA (1x106/mice). In experiments involving 
endogenous PF, following DCOVA immunization, blood samples from all the groups were collected 
6 and 30 days later, stained with H-2Kb/OVA257-264 tetramer and FITC-anti-CD8 Ab, and analyzed 
for CTL proliferation or survival (8). The naïve CD8+ T cells were isolated from OTI, (OTI)CD40-
/- or (OTI)CD40L-/- mouse splenocytes by enriching T lymphocytes in nylon wool columns (C&A 
Scientific, Manassas, VA), and negative selection using anti-CD4 (L3T4) paramagnetic beads 
(DYNAL, Lake Success, NY) as previously described (8). In experiments involving increased  PF, 
the endogenous PF of mice was increased by i.v. transfer of 1x106 OTI CD8+ T cells one day 
before DCOVA immunization. 6 and/or 90 days after DCOVA immunization, the blood samples were 
collected, re-stimulated with OVAI and subjected to intracellular IFN-γ or IL-2 staining (BD-
Biosciences) (21). Experiments were also performed to determine the presence of tetramer+ or 
IFN-γ+ CTL in lung or spleen during effector stage or 24th day of tumor challenge.  
4.4.5 In vivo cytotoxicity assay  
The targets were prepared as described previously (8) by labeling splenocytes differentially 
with high (3.0 µM) or low (0.6 µM) concentrations of CFSE and by pulsing with OVAI or Mut1 
peptide, respectively, and co-injected i.v. (2x106 cells/mouse) at 1:1 ratio into immunized or 
unimmunized mice. Sixteen hours later, the relative proportions of target CFSEhigh (H) and 
CFSElow (L) cells remaining in the spleens were analyzed by flow cytometry.   
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4.4.6 In vitro and in vivo CFSE proliferation assays  
Both in vitro and in vivo CFSE proliferation assays were described previously (8). Briefly, 
for in vitro assay, OTI CD8+ T cells were labeled with CFSE and co-cultured with irradiated (4,000 
rad) DCOVA at 1:4 ratios for 3 days. To study IL-2 requirements for priming, the culturing was 
done in IL-2 presence (20 U/ml) or absence of IL-2 but with different concentrations of 
neutralizing anti-IL-2 Ab (high, 200 ng/ml; medium, 50 ng/ml and low, 5 ng/ml) or isotype-
matched control Ab. The cultured cells were purified by Ficoll-Paque (Sigma-Aldrich Canada) 
separation and analyzed for % labeled-cell division in flow cytometry. In in vivo assay, the WT or 
Iab-/- mice were i.v. injected with CFSE-labeled OTI CD8+ T cells (2-3x106cells/mouse) one day 
before immunizing with DCOVA (1x106cells/mouse). The mice splenocytes were analyzed four 
days later for % labeled-cell division after labeling with PE-anti-CD8 Ab.    
4.4.7 Phenotypic characterization of memory CTL 
To phenotypically characterize memory CTL, the blood samples were collected 60 days 
after DCOVA immunization, and stained with PE-tetramer, FITC-anti-CD44, a panel of biotin-
conjugated antibodies (Abs) specific for effector or memory T cell markers and subsequently with 
streptavidine-PECy5. The relative expressions of surface markers were analyzed in 
tetramer+CD44hi cell population.  
4.4.8 Tumor protection studies   
All the immunized mice were challenged with BL6-10OVA or BL6-10 (0.5x106 cells/mice) 
on 30th or 90th day of immunization as shown in Table 1 and monitored for protection up to 24 
days or earlier if the mice become moribund as described previously (8). The tumor grading was 
done depending on mean numbers of metastatic tumor colonies in lungs: -, no tumors; +, 1-24; ++, 
25-49; +++, 50-74; ++++, 75-99; +++++, 100 to 250; ++++++, >250. 
4.4.9 Statistical analysis 
 The statistical analysis were performed using Student’s t or Mann–Whitney U test (Graphpad 
Prism-3.0); *P<0.05 and **P<0.01.    
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4.5 Results 
4.5.1 Primary CTL responses require CD4+ T cell help and associated CD40L signaling at 
endogenous PF 
 We investigated the roles of the CD4+ T cell help and of the  CD40L-initiated signal at 
endogenous PF by immunizing WT, Iab-/-, CD40-/- or CD40L-/- mice with mature DCOVA 
expressing all the maturation markers, such as Kb, Iab, CD40 and CD80 (Fig. 1a and 1b). All these 
mice were analyzed for primary CTL proliferation in the peripheral blood using H-2Kb/OVA257-264 
tetramer staining and for CTLs’ lytic functions in spleen using in vivo cytotoxicity assay. 
Compared to WT mice (Fig. 1c, panel b), all the other animals, deficient in CD4+ T cell help or 
CD40L-induced signalling (Fig. 1c, panels c-e), showed significantly reduced CTL proliferation 
(P<0.01). To further assess the impact of CD40 or CD40L expression on DCs, we immunized WT 
mice with DCOVA lacking these molecules. Compared to Iab-/- and CD40L-/- mice, CD40-/- mice 
receiving wild-type DCOVA (Fig. 1c, panel d), and WT mice receiving either (CD40-/-)DCOVA or 
(CD40L-/-)DCOVA (Fig. 1c, panels f and g) showed significantly higher CTL proliferation (P<0.01). 
Consistent with the results in blood (Fig. 1c, panel b), spleens and lungs of WT mice had 
considerably higher levels of primary CTLs compared to Iab-/- mice (Fig. 1d; P<0.01). Correlating 
with the above tetramer-staining data (Fig. 1c), substantially stronger loss of the CFSEhigh-labeled 
OVA-specific target cells was observed in the WT group (Fig. 1e, panel b), compared to all other 
groups, as determined by the in vivo cytotoxicity assay (Fig. 1e; panel c-g P<0.01). Collectively, 
these observations suggest that CD40L expression by host CD4+ T cells is a prerequisite for 
optimal primary responses, and that the partial immune responses observed upon (CD40-/-)DCOVA 
or (CD40L-/-)DCOVA immunizations, or in CD40-/- mice may be due to compensatory mechanisms, 
as CD40-CD40L signaling can occur among CD8+ T cells, DC and/or CD4+ T cells since all these 
immune cells are known to express CD40 and/or CD40L molecules at least during some stages of 
immune responses (5, 9, 22-24).   
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4.5.2 The absence of CD4+ T cell help and CD40L-derived signals lead to functionally defective 
memory CTL responses at endogenous PF    
To assess the role of CD4+ T cell-mediated help and the importance of the related CD40L-
triggered signaling, we analyzed the size and quality of the memory CTL population generated at 
endogenous PF. Thirty days following immunization, all the groups were monitored for memory 
CTL survival by the tetramer assay and later assessed for anti-tumor protection (Fig. 1a; Table-1, 
Exp-I). Compared to WT mice (Fig. 2a), all the mouse groups (Iab-/-, CD40-/- and CD40L-/-) 
deficient in CD4+ T cell help and/or CD40L signalling showed significantly reduced memory CTL 
survival (P<0.05 or 0.01) (Fig. 2a). Although CD40-/- mice or WT mice receiving (CD40-/-)DCOVA 
had comparable primary CTL levels, they had lower memory CTL frequency, perhaps due to their 
poor survival rate. Furthermore, upon challenging with highly metastatic BL6-10OVA tumor cells, 
Iab-/-, CD40-/- or CD40L-/- mice completely failed to provide anti-tumor protection, in contrast to 
the efficient tumor suppression in WT animals (Table-1, Exp-I). The complete protection observed 
in WT mice also correlated with high levels of CTLs in their lungs (Fig. 2b; P<0.05). On the other 
hand, WT mice receiving (CD40-/-)DCOVA or (CD40L-/-)DCOVA gave some degree of protection, 
particularly in the latter group, correlating with memory CTL levels in the blood. These results 
suggest the relative importance of CD40-CD40L signaling among DC, CD4+ and CD8+ T cells in 
modulating memory CTL survival and/or development. For instance, the reduced CTL survival 
and anti-tumor protection in CD40-/- mice could be due to lack of direct CD40L signaling to 
CD40-deficient CD8+ T cells by DCova-stimulated Th1 cells (8, 9, 25). Similarly, the reduced 
anti-tumor protection in (CD40-/-)DCOVA-immunized mice compared to WT mice could be due to 
lack of CD40L signaling by endogenous Th1 cells to CD40-deficient DCova (5-7). It is possible 
that synergistically enhanced responses can occur by the combination of Th1-derived CD40L-
initiated signaling triggered within CD40-expressing DCs and CD8+ T cells; however, this 
intriguing possibility requires further investigation.   
4.5.3 At higher PF, primary CTL response does not depend on CD4+ T cell help and on associated 
CD40L stimulation, while requiring local CD8+ T cell-derived IL-2 signals    
In previous studies, we and others showed that CD4+ T cell-independent CTL priming 
occurs not due to high-affinity CTLs, but possibly due to some unidentified cell-intrinsic or cell-
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extrinsic factors resulting from higher PF (17, 26). Consistent with earlier reports (3, 17, 26), we 
observed an optimal CD4-independent primary CTL response upon transfer of 1x106 naïve OTI 
CD8+ T cells expressing TCR and CD62L, but not CD69 (activation marker) (Fig. 3a) to Iab-/- 
mice. This optimized OTI CD8+ T cell number was used to enhance endogenous precursor CD8+ T 
cell populations in all the studies involving higher PF, unless otherwise indicated (Fig. 3b). In 
agreement with earlier reports (3, 17, 26), an efficient CD4+-independent priming without obvious 
intraclonal competition was observed at this precursor level. To better understand memory CTL 
generation and its requirements at higher PF, we performed two different experiments after 90 
days of DCova immunization as shown in Fig. 3b and Table-1, Expt-IIa and -IIb: one in the 
absence of CD4+ T cell help and/or CD40L-induced signaling, by transferring Iab-/- mice with 
(WT)OTI, (CD40-/-)OTI or (CD40L-/-)OTI CD8+ T cells before immunizing with DCOVA; and 
another in the presence of endogenous CD4+ T cells, but in the absence of CD40L signaling by 
transferring WT, CD40-/- or CD40L-/- mice with (WT)OTI, (CD40-/-)OTI or (CD40L-/-)OTI CD8+ 
T cells prior to immunizing with (WT)DCOVA, (CD40-/-)DCOVA or (CD40L-/-)DCOVA. The initial 
experiment allowed us to determine whether CD4+ T cell help and/or accompanying CD40L 
signaling were required for memory generation, whereas the latter experiment precluded possible 
CD40L signaling among CD4+ T, DC and/or CD8+ T cells (5, 9, 22-24), while allowing other 
CD4+ T-helper signals. Initially, we performed both in vitro and in vivo CFSE proliferation assays 
as shown in Fig. 3c and 3d. Under both in vitro and in vivo conditions, in the complete absence of 
CD4+ T cell help, DCOVA stimulated proliferation of CFSE-labeled OTI CD8+ T cells with almost 
equal efficiency (Fig. 3c and/or 3d) as in the presence of CD4+ T cell help (Fig. 3d). Moreover, 
even in the complete absence of CD40L signaling, DCOVA efficiently stimulated proliferation of 
CFSE-labeled OTI CD8+ T cells, disregarding the presence or absence of CD4+ T cell and its 
CD40L signals (Fig. 3c and 3d). Recently, it was shown that IL-2 signaling from CD4+ T cells is 
very critical for primary CTL proliferation (27, 28). Consistent with these reports, IL-2Rα-/- mice 
with endogenous PF failed to show CTL proliferation upon DCova immunization (data not 
shown), suggesting IL-2 signaling may be indispensable for primary CTL proliferation. To 
ascertain this phenomenon at higher PF, we performed a simple in vitro study by co-culturing 
CFSE-labeled OTI CD8+ T cells with DCOVA in the presence of IL-2 or different concentrations of 
neutralizing anti-IL-2 Ab (Fig. 3e). Interestingly, although OTI CD8+ T cells proliferated 
efficiently in the absence of both IL-2 and CD4+ T cells, their proliferation was inhibited in a dose-
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dependent manner when anti-IL-2 Abs were added to the cultures, suggesting attainment of local 
threshold levels of CD8+ T cell-derived IL-2 and its role in driving primary response in an 
autocrine or paracrine fashion.     
To further assess the proliferation and functionality of effector CTLs generated without 
CD4+ T cell help and/or related helper molecules, we performed OVA-specific intracellular IFN-γ 
staining and in vivo cytotoxicity assays. At higher PF, intracellular IFN-γ-, rather than tetramer-
staining, was used since it detects mostly Ag-experienced CTLs derived from transferred OTI as 
well as endogenous CD8+ T cells, providing complete picture of overall CD8+ T cell repertoire 
responses. In the absence of CD4+ T cell help (Fig. 3f, panel c-e) and/or CD40L costimulation 
(Fig. 3f, panel f and g), DCOVA immunization induced considerable proportions of IFN-γ+ effector 
CTLs comparable to the induction in WT mice (Fig. 3f, panels a and b). Similarly, CD4+ T cell-
independent IFN-γ+ CTL response was also observed in CD4+ T cell-depleted WT mice (Fig. 3g, 
left panel). As in vitro assay revealed IL-2 requirement at higher PF (Fig. 3e), and Iab-/- mice 
without CD4+ T cell-derived IL-2 source and WT mice showed comparable IFN-γ+ CTL 
proliferation in vivo at increased PF (Fig. 3f), we hypothesized that the attainment of local 
threshold levels of IL-2 could drive primary CTL proliferation in the absence of CD4+-T cell-
secreted IL-2 source. To verify this hypothesis in vivo, we tested IL-2 secretion at higher PF in 
vivo by assessing IL-2+ CTLs in WT mice, Iab-/- and CD4+ T cell-depleted WT mice. Indeed, at 
higher PF, both Iab-/- and CD4+ T cell-depleted WT mice (Fig. 3e) showed the presence of IL-2+ 
CTLs comparable to their presence in WT animals (Fig. 3g, right panel). We also did not observe 
any significant differences in the presence of IFN-γ+ CTL levels in spleens and lungs of WT and 
Iab-/- mice (Fig. 3h). Furthermore, correlating with the levels of IFN-γ+ CTLs (Fig. 3f), the results 
from in vivo cytotoxicity assay also showed a substantial loss of the CFSEhigh-labeled OVA-
specific target cells in CD4+ T cell-deficient mice (Fig. 3i, panels c-e) and in mice lacking CD40L-
dependent signaling (Fig. 3i, panels f, g), similar to the situation observed in the WT mice (Fig. 3i, 
panel b). Collectively, these results suggest that, following DCOVA immunization, effector CTLs 
generated at a higher PF, retain normal proliferative, cytokine-secreting and cytolytic functions, 
irrespective of the availability of CD4+ T cell help.   
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4.5.4 Memory CTL responses are compromised by the absence of CD4+ T cell help and/or CD40L-
triggered signal even at increased PF  
To better understand the functions of memory CTLs that generate at higher PF under CD4+ 
T-helper influence, the intracellular staining assay was used to track the survival of IFN-γ+ 
memory CTL population ninety days following immunization. Interestingly, when compared to 
WT animals, mice missing CD4+ T cells and/or CD40L signaling showed significant decrease in 
the number of IFN-γ+ memory CTLs in blood (Fig. 4a; P< 0.01). Furthermore, this decrease in the 
IFN-γ+ memory CTL population was even strongly pronounced in Iab-/- compared to the CD40-/- or 
CD40L-/- mice, lacking exclusively CD40L signaling. As there were considerable differences in 
memory CTL survival in Iab-/- mice compared to WT mice, we sought to determine whether altered 
surface-marker expression correlates with survival rates. In both WT and Iab-/- mice, the tetramer+ 
population expressed high levels of CD44. Furthermore, the analysis of tetramer+CD44+ 
population revealed the central memory (TCM) phenotype, showing considerable expression of 
CD62L and IL-7Rα, but not CD69 (Fig. 4b). However, there was no drastic difference in the 
expression of these markers between WT and Iab-/- mice, suggesting other factors might influence 
the survival of helped versus unhelped memory CTLs.  
To further analyze the survival and functionality of memory CTLs generated at higher PF 
under CD4+ T-helper influence, all the immunized mice were challenged with BL6-10OVA at ninety 
days following immunization and assessed for anti-tumor protection, as shown in Table-1, Exp-II. 
Interestingly, our preliminary attempts to challenge mice at 30 to 45 days post immunization 
induced anti-tumor protection irrespective of CD4+ T cell help (data not shown), perhaps due to 
the prolonged maintenance of the transferred un-stimulated naïve (29) and stimulated effector 
CTLs or effector memory CTLs derived from higher PF. It was previously shown that the presence 
of pre-existing effector CTLs can boost responses of other naïve CD8+ T cells in certain situations 
(26, 30). Consequently, survived residual DCOVA might receive additional signals to prime 
remaining naïve OTI CD8+ T cells, which escaped priming during early stage, and thus, prolong 
anti-tumor protective ability of primary CTLs. However, during later stages, the residual naïve 
OTI CD8+ T cells, which escape DCOVA priming, are unlikely to participate in protection against 
lethal tumor challenge, as we observed complete failure to protect against tumor challenge in both 
WT and Iab-/- mice transferred with OTI CD8+ T cells alone (Table-1, Exp-II). Challenging all the 
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immunized mice groups on the 90th day post-immunization revealed a strong requirement of CD4+ 
T-helper signals for memory CTL responses. Thus, in contrast to WT, all the Iab-/- mice, 
irrespective of the state of CD40L signaling, completely failed to protect against tumor challenge 
(Table-I, Exp-IIA). Consistent with these results, WT animals displayed much higher recruitment 
of IFN-γ+ CTLs in lungs, compared Iab-/- mice (P<0.01) (Fig. 4c). Similarly, although CD4+ T cells 
were present in the experiment IIB, all mice missing exclusivelyCD40L developed tumors (Table-
I, Exp-IIB). However, these mice had 2 to 5 fold lowered tumor burden, when compared to mice 
with the complete absence of CD4+ T-helper signals. This implies that although CD4+- and 
CD40L-independent primary responses occur, CD40L-induced signal alone or in concert with 
other CD4+ T-helper signals appears to be essential for programming of memory CTLs for both 
survival and anti-tumor functions, even at higher PF.    
4.5.5 Higher PF augments therapeutic efficacy of DCOVA immunization in the CD4+ T cell-
deficient environment   
 As the success of cancer immunotherapy heavily depends upon its ability to induce 
protection against established tumors, we asked whether the functional CD4+ T cell-independent 
primary responses observed at higher PF can be exploited to treat established tumors in DCOVA 
immunization protocols. This approach could also be very beneficial in HIV patients, who suffer 
from CD4+ T cell deficiency and often develop tumors. We challenged two groups of mice with 
BL6-10OVA, as shown in Fig. 5a. In the first group, three days after challenge (early tumor burden), 
PF was increased prior to immunizing with DCOVA. In the second group, similar procedures were 
performed on the sixth day of challenge (established tumor burden). When compared to WT and 
Iab-/- mice with endogenous PF, 3rd-day-tumor-bearing WT and Iab-/- mice with increased PF 
showed nearly complete protection (Fig. 5b), which also correlated with efficient recruitment of 
IFN-γ+ CTLs into lungs (Fig. 5c; P<0.01). Furthermore, even on day six of challenge, higher PF 
significantly decreased the tumor burden and incidence in both WT and Iab-/- mice (Fig. 5d). In 
contrast, increasing PF (as high as 2-5×106 precursor cells/mice) alone, without DCOVA 
immunization, failed to provide anti-tumor protection (data not shown). Collectively, these results 
suggest that it is possible to considerably enhance anti-tumor therapeutic efficacy of DCOVA 
immunization by increasing PF even in the absence of CD4+ T cell help.   
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4.6 Discussion    
It has been demonstrated that altered CD8+ T cell PF could affect effector and memory 
responses (2, 10-12, 15, 31-33). However, its relative contribution to the requirement for CD4+ T 
cell help and for the related CD40L, and IL-2 helper signals for memory CTL responses, including 
survival, and anti-tumor functions, is still largely unknown. In this study, we report that it is 
possible to achieve primary CTL responses independent of CD4+ T cell help by increasing PF in 
DC immunization protocol, which is consistent with some previously published observations in 
other models (11, 12, 17, 26). Mintern et al. showed that CD40L-deficient CD8+ T cells 
proliferated well and exhibited cytotoxicity, when stimulated with Ag-coated splenocytes (26). 
Similarly, functional effector CTLs were observed in tissue transplantation model, even when 
CD40L or CD28 costimulation was blocked using specific Abs (11, 12). In the present study, we 
prevented any compensatory mechanisms that may occur in the absence of a single co-stimulatory 
molecule among DC, CD4+ and/or CD8+ T cells (5, 9, 22-24, 34) by using KO mice, and their 
immune cells, and confirmed that, even in the complete absence of CD40L costimulation, the 
primary CTL response occurs efficiently at higher PF. Interestingly, our work with in vitro IL-2 
blocking assay and in vivo studies that demonstrated IL-2 secretion by CD8+ T cells revealed that 
similar to the responses seen at endogenous PF, IL-2 signal may still be required for primary CTL 
responses at higher PF (27). However, it appears that the threshold IL-2 signal derived from CD8+ 
T cells alone, which is capable of driving primary CTL proliferation, may still not be sufficient for 
programming memory CTL generation and survival, as Iab-/- mice with higher PF failed to protect 
mice against tumor challenge during the CTL memory phase. Also, in relation to this response, a 
potential role of the deficient CD4+ T cell-mediated CD40L signaling in Iab-/- mice needs a further 
detailed investigation, since CD40L signaling can enhance IL-2 utilization in CD8+ T cells by up-
regulating IL-2Rα (19).   
To date, factors that govern CTL memory development at higher PF has not been 
established. We demonstrate here that CD4+ T-helper signals are indispensable for the 
development of the functional memory CTL population, even at increased PF. It has been recently 
reported that higher PF controls memory lineage development in infectious models, favoring the 
generation of the inter-convertible TCM vs effector memory T cells (14). Our previous study 
showed that DC-stimulated Th1 cells with acquired Ag-presenting machinery can stimulate naïve 
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CD8+ T cells, which in turn prone to become TCM (8, 18), thus possibly explaining why skewing of 
TCM generation occurs at higher PF. Various studies have suggested that primary and memory CTL 
responses are likely to operate within certain thresholds at higher PF. It is believed that above these 
threshold levels, diminished immune responses occur, since Ag-specific CD8+ T cells compete for 
limited resources, such as antigenic stimulation by APC, costimulations, cytokines, and various 
CD4+ helper factors (3, 35-37). Our results are indirectly suggestive of a model, where the 
provision of additional CD4+ T cell help may decrease intraclonal competition for CD4+ T-helper 
factors, and thus further enhance CTL immunity.   
CD4+ T cells contribute to memory CTL generation either indirectly, by modulating APCs 
(5, 19), or directly, by modulating cognate CD8+ T cells (8, 9, 18) via CD40L signaling. Consistent 
with these data, we observed poor memory responses with inability to provide anti-tumor 
protection in the absence of CD40L signaling even at higher PF, though endogenous CD4+ T cells 
retaining other helper factors were ensured. Nevertheless, the lack of CD40L signal alone resulted 
in a relatively low tumor burden, compared the situation with the complete absence of CD4+ T 
cells, suggesting other CD4+ T-helper factors are likely to contribute to memory generation. 
Whether the reduced protection in Iab-/- mice or in mice without CD40-40L signaling alone is due 
to actual decrease of CTL survival rate as reported previously (29) or due to loss of memory 
functions needs further investigation. It is intriguing however, that anti-tumor protection retained 
for longer periods at higher PF in the absence of CD4+ T helper signals, a phenomenon that can be 
utilized in therapeutic use in CD4-deficient conditions. It has recently been shown that Th1 license 
DCs to secrete IL-12, which in turn acts on CD8+ T cells to boost IL-2 receptor expression for 
efficient IL-2 utilization (19). Consequently, IL-2-induced signaling might be able to reach 
threshold levels required for functional memory development only in the presence of endogenous 
CD4+ T cells. 
 DC-based vaccines have been widely applied to induce therapeutic anti-tumor immunity 
(5-7, 19). Unfortunately, they often fail in treatment of malignancies due to inefficient CTL 
responses, resulting from tolerance induction, inhibitory receptor expression, lower-reactive PF 
and lack of Ag immunodominance (3, 38, 39). The present results are particularly relevant in the 
development of effective DC-based vaccines against established malignant tumors. For example, 
the frequency of pre-existing tumor-specific CTL precursors in mice represents a critical 
determinant of the quality of anti-tumor responses, in accordance with the already recognized role 
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that initial T cell numbers have in the functional immune response against pathogens (14, 40). 
Their cumulative frequency was found to be significantly higher in cancer patients and vary widely 
in relation to various tumor-Ag peptides (10). The detection of these CTLs in cancer patients is 
currently applied for evaluating tumor Ags for vaccination (41). Recent evidence suggests that Ag 
presentation by DCs and PF levels also determine the immunodominance, and, thereby, protection 
against foreign pathogens (42, 43). In support of this, we also observed an increase in the 
therapeutic anti-tumor efficacy of DCOVA immunization for prolonged periods at higher PF, even 
in the absence of CD4+ T cell help. Based on our current findings, we expect that it should be 
possible to achieve a robust therapeutic immunity for extended periods in chronic diseases with 
compromised CD4+ T cell functions, including AIDS and malignancy, by increasing CD8+ T cell 
PF in combination with immunization with mature DCs.  
Taken together, our results demonstrate that altered PF influences the dependence of 
functional primary and memory CTL responses upon CD4+ T cell help, and may thus, impact the 
development of novel cancer immunotherapies, whose efficacy is determined in part by CD4+ T-
helper signals and alterations in CD8+ T cell PF. Based on the current findings, prolonged robust 
anti-tumor immune responses should be achievable through increasing CD8+ T cell PF and 
immunizing with mature DCs, presenting both CD8+ T cell and CD4+ T-helper epitopes. 
Moreover, as this approach is also known to give prophylactical effectiveness in the lymphopenia-
induced environment (3), it may potentially act as an excellent adjuvant in combination with other 
cancer therapies, such as chemotherapy and irradiation, which often deplete host lymphocytes. 
Finally, our observations imply that selective CD4+ Th1 depletion or blockade of associated helper 
molecules may also potentially facilitate organ transplantations and support treatment of 
autoimmune disorders, which are often CD4+ T cell help and costimulation dependent. 
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4.9 Tables  
Table 1. CD4+ help and its CD40L signaling are critical for functional memory 
development, irrespective of PF. 
Micea Adoptive  transfer (106) Immunization 
Tumor 
challenge 
Tumor-
bearing 
mice (%) 
Lung 
tumor 
scoring 
Experiment-I 
WT PBS BL6-10OVA 8/8 (100) ++++++ 
WT DCOVA BL6-10 8/8 (100) ++++++ 
WT DCova BL6-10OVA 0/12  (0) - 
WT (CD40-/-)DCOVA BL6-10OVA 5/10 (50) ++ 
WT (CD40L-/-)DCOVA BL6-10OVA 2/10 (20) + 
Iab-/-  DCOVA BL6-10OVA 10/10 (100) ++++++ 
CD40-/- DCOVA BL6-10OVA 10/10 (100) ++++ 
CD40L-
/- 
Endogenous-PF 
DCOVA BL6-10OVA 10/10 (100) ++++++ 
Experiment-II 
a)  In the absence of endogenous CD4+ T cells 
WT OTI CD8+ T   DCOVA BL6-10OVA 0/12 (0) - 
Iab-/-  OTI CD8+ T    DCOVA BL6-10OVA 10/10 (100) +++++ 
Iab-/-  (CD40-/-) OTI CD8+ T    DCOVA BL6-10OVA 10/10 (100) +++++ 
Iab-/-  (CD40L-/-) OTI CD8+ T  DCOVA BL6-10OVA 10/10 (100) +++++ 
b)  In the presence of endogenous CD4+ T cells 
WT OTI CD8+ T   DCOVA BL6-10OVA 0/12 (0) - 
CD40-/- (CD40-/-) OTI CD8+ T   (CD40-/-)DCOVA BL6-10OVA 10/10 (100) +++ 
CD40L-
/- (CD40L
-/-) OTI CD8+ T  (CD40L-/-)DCOVA BL6-10OVA 10/10 (100) ++++ 
 
aWT, Iab-/-, CD40-/- or CD40L-/- mice with endogenous- (Expt-I) or increased-PF (Expt-II) were 
immunized with DCOVA as indicated. After thirty (Expt-I) or ninety (Expt-II) days, all the groups 
were i.v. challenged with highly metastasizing BL6-10OVA or BL6-10. Twenty-four days later, 
the lung tumor colonies were counted and graded. The data are cumulative of two independent 
experiments, each comprising four to six mice per group.  
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4.10 Figures  
 
Figure 1 
 
 
 
Primary CTL responses require CD4+ T cell help and associated CD40L signaling at 
endogenous PF. (a) A schematic protocol. WT or KO mice were i.v. immunized with DCOVA 
followed by assessment of CTL proliferation and/or its function at six and thirty days of 
immunization. During memory stage, all the groups were challenged with BL6-10OVA tumor 
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cells and assessed for tumor protection. (b) DCova were stained with a panel of Abs specific for 
DC and maturation markers (solid black lines), and analyzed by flow cytometry. Irrelevant 
isotype-matched Abs were used as control (dotted grey lines). (c) Six days after DCOVA 
immunization, the proliferated CTLs were measured by tetramer staining in the peripheral blood. 
The values in each figure represent mean%±SD of tetramer+ CTLs in total CD8+ T cell 
population, and are cumulative of two independent studies with five to six mice per group. 
**P<0.01, versus WT. (d) To determine recruitment/presence of tetramer+ CTLs in spleens and 
lungs, WT- and Iab-/--immunized mice were immunized and monitored by tetramer assay six 
days later. The values represent frequencies of tetramer+ CTLs in total CD8+ T cell population, 
and are cumulative of two independent experiments with two to three mice per group. The 
horizontal bars indicate means. **P<0.01, versus WT mice. (e) In the above immunized groups 
shown in (c), the proportions of CFSEhigh-OVAI-pulsed target cells lysed by effector CTLs were 
determined in the spleens by in vivo cytotoxicity assay seven days later. The values in each 
figure represent mean %±SD of targets remaining in the spleen relative to the controls. 
**P<0.01, versus WT mice.     
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Figure 2 
 
 
The absence of CD4+ T cell help and CD40L-derived signals lead to functionally defective 
memory CTL responses at endogenous PF. (a) Thirty days after immunization, the blood 
samples were analyzed for the memory CTL survival by tetramer staining. The values represent 
mean %±SD of tetramer+ CTLs in total CD8+ T cell population, and are cumulative of two 
independent studies with four to six mice per group. *P<0.05 and **P<0.01, versus WT mice. 
(b) To determine infiltration of tetramer+ CTLs in lungs of challenged mice, the WT- and Iab-/--
immunized mice were challenged thirty days later, and the lungs were monitored by tetramer 
assay after twenty-four days. The values represent frequencies of tetramer+ CTLs in total CD8+ T 
cell population, and are cumulative of two independent studies with two to three mice per group. 
The horizontal bars indicate means. **P<0.05, versus WT mice.   
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Figure 3 
 
At higher PF, primary CTL response does not depend on CD4+ T cell help and on 
associated CD40L stimulation, while requiring local CD8+ T cell-derived IL-2 signals. (a) 
Naïve OTI CD8+ T cells (solid black lines) were stained with a panel of Ab specific for naïve or 
activated status, and analyzed by flow cytometry. Irrelevant, isotype-matched Ab were used as 
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control (grey solid lines). (b) A schematic protocol. WT or KO mice were adoptively transferred 
with OTI CD8+ T cells (with or without CD40 or CD40L molecules) and i.v. immunized with 
DCOVA (with or without CD40 or CD40L). All the groups were monitored for the CTL 
proliferation, survival and/or its function after six and ninety days. During memory stage, all the 
groups were challenged with BL6-10OVA and assessed for protection. (c and d) The extent of 
division of OTI CD8+ T cells by DCOVA in the absence of CD4+ T cell help and/or CD40L 
signaling is shown by both in vitro (c) and in vivo (d) CFSE proliferation assays. (e) To 
determine IL-2 role in primary responses, the CFSE-labeled OTI CD8+ T cells were co-cultured 
with DCOVA in the presence of IL-2, or in the absence of IL-2 but with different concentrations of 
anti-IL-2 Ab (high (H), 200 ng/ml; medium (M), 50 ng/ml and low (L), 5 ng/ml), and percent 
proliferation of CFSE-labeled cells were determined. In experiments (c-e), the data are 
cumulative of three independent experiments, and presented as mean %±SD. (f and g) After 
immunizing mice with higher PF, the blood samples were analyzed by intracellular IFN-γ 
staining assay six days later. The values in each figure or bar diagrams represent mean %±SD of 
IFN-γ+ CTLs in total CD8+ T cell population, and are cumulative of two independent 
experiments with five to six mice per group. *P<0.05 and **P<0.01, versus WT. (h) The 
infiltration of IFN-γ+ CTLs were also determined in spleens and lungs of WT- and Iab-/--
immunized mice. The values represent frequencies of IFN-γ+ CTLs in total CD8+ T cell 
population, and are cumulative of two independent studies with two to three mice per group. The 
horizontal bars indicate means. (i) In the above immunized groups shown in (f), the proportions 
of CFSEhigh-OVAI-pulsed target cells lysed by effector CTLs were determined in the spleen 
seven days later. The values each figure represent mean %±SD of targets remaining in the spleen 
relative to the controls. *P<0.05 and **P<0.01, versus WT mice.       
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Figure 4 
 
Memory CTL responses are compromised by the absence of CD4+ T cell help and/or 
CD40L-triggered signal even at increased PF. (a) 90 days after DCOVA immunization, the 
peripheral blood samples were analyzed for IFN-γ+ memory CTL survival by intracellular 
staining assay. The values represent mean %±(SD) of IFN-γ+ CTLs in total CD8+ T cell 
population, and are cumulative of two independent experiments with five to six mice per group. 
**P<0.01, versus WT. (b) Sixty days following immunization, the blood samples were stained 
for triple markers, and the expression of activation (CD69) and memory (CD62L and IL-7Rα) 
markers were analyzed in tetramer+CD44hi population (histogram grey filled overlays). Irrelevant 
isotype-matched Ab were used as controls (open black lines). (c) To determine recruitment and 
expansion of IFN-γ+ memory CTLs in lungs of challenged mice, the WT- and Iab-/--immunized 
mice were challenged ninety days later, and the lungs were assessed by intracellular IFN-γ assay 
after twenty-four days. The values represent frequencies of IFN-γ+ CTLs in total CD8+ T cell 
population, and are cumulative of two independent experiments with two to three mice per 
group. The horizontal bars indicate means. **P<0.01, versus WT mice.  
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Figure 5 
 
 
Higher PF augments therapeutic efficacy of DCOVA immunization in the CD4+ T cell-
deficient environment. (a) An experimental design. WT or Iab-/- mice were first challenged with 
BL6-10OVA three (early tumor burden) or six (late tumor burden) days before DCOVA 
immunization. One day before immunizing, the endogenous PF of all these mice was increased 
by transferring OTI CD8+ T cells. Twenty-four days after challenge, all the groups were assessed 
for tumor protection. (b) Impact of higher PF on the efficacy of DCOVA immunization in early 
established tumors. Gross pathology of lungs showing relative surface tumor burden. (c) To 
determine whether protection is due to effector CTLs recruitment, the IFN-γ+ CTLs in the lungs 
of some immunized mice were determined by intracellular staining assay. The values represent 
frequencies of IFN-γ+ CTLs in total CD8+ T cell population, and are cumulative of two 
independent studies with two to three mice per group. The horizontal bars indicate means. 
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**P<0.01, versus Iab-/- with endogenous PF. (d) Impact of higher PF on the efficacy of DCOVA 
immunization in late-established tumors. Gross pathology of lungs showing relative surface 
tumor burden. The data in b and d are cumulative of two independent studies with four mice per 
group.    
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5.1 Brief introduction to Chapter 5 
 
 AdV vectors are at the forefront of vaccine development against cancers and chronic 
diseases, where the establishment of these diseases often reflected with poor functions or loss of 
CD4+ T cells. Currently, how CD8+ CTL responses are modulated by CD4+ T cells following 
AdV immunization is less defined area although such an understanding is very critical for 
successful designation of AdV vaccines. Thus, while the above studies discussed in Chapter 2 to 
4 addressed the importance of CD4+ T cells in DC immunization model, the present study 
investigated the role of these cells in different phases of AdV transgene product-specific CTL 
responses following AdV immunization.  
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5.2 Abstract  
Adenoviral (AdV) vectors represent most commonly utilized viral vaccines in clinical 
studies. While the role of CD8+ cytotoxic T lymphocyte (CTL) responses in mediating AdV-
induced protection is well understood, the involvement of CD4+ T cell signals in the 
development of functional CD8+ CTL responses remain unclear. To explore CD4+ T helper 
signals required for AdVova-stimulated CTL responses, we established an adoptive transfer 
system by transferring CD4+ T cells derived from various knock out and transgenic mice into 
wild-type and/or CD4-deficient animals immunized with recombinant ovalbumin (OVA)-
expressing AdVova vector. Without CD4+ T help, the survival of both primary and memory 
CTLs was greatly reduced, and memory CTLs were associated with increased PD-1 expression. 
The transfer of naïve OVA-specific CD4+ T cells to CD4+ T-deficient mice restored primary 
responses, and fairly supported survival and recall responses of memory CTLs. Furthermore, this 
help was specifically mediated by CD4+ T cell-derived IL-2 and CD40L signals. Poor survival of 
adoptively transferred effector or memory CTLs in naïve CD4+ T-deficient mice further revealed 
an additional role for polyclonal CD4+ T cell environment  in  the survival of AdVova-stimulated 
CTLs, partially explaining protracted CTL contraction phase. Finally, during recall responses, 
CD4+ T cell environment containing memory CD4+ T cells greatly enhanced expansion of 
memory CTLs. Collectively, these results suggest a critical role for CD4+ T help in multiple 
phases of AdVova-stimulated OVA-specific CTL responses, and could partially explain certain 
failures in AdV-based immunization trials against tumor and chronic diseases that are often 
associated with compromised CD4+ T cell effect.      
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5.3 Introduction 
CD8+ T cells play a defensive role against viral infections and malignancies. Following 
recognition of a specific Ag, naïve CD8+ T cells undergo 3 distinct phases (1): (i) a proliferation 
(or primary) phase in which naïve CD8+ T cells undergo autonomous clonal expansion and 
develop into functional effector cytotoxic T lymphocytes (CTLs); (ii) a contraction (or effector) 
phase in which 90-95% of effector CTLs undergo activation-induced cell death (AICD) through 
apoptosis, allowing development of  remaining effector CTLs into memory CTLs; and (iii) a 
maintenance (or memory) phase in which memory CTLs survive for prolonged duration. Upon 
subsequent Ag encounter, these memory CTLs respond swiftly by rapid proliferation and 
heightened effector functions leading to recall responses.   
It is becoming increasingly clear that requirements for CD4+ T cell help at different phases of 
CTL responses can vary, depending on a specific type of infection or immunization involved (2, 
3). Primary CTL responses to infectious agents, such as Listeria montocytogenes (Lm), influenza 
and Lymphocytic choriomeningitis virus (LCMV), occur independent of CD4+ T-helper signals 
(4-6). In contrast, primary CTL responses induced in noninfectious conditions by minor-H Ags, 
and cell-associated and protein-triggered immunizations (7, 8), and also CTL responses in 
infectious diseases, such as Herpes simplex (HSV), Viral encephalitis and Vaccinia virus (2, 3, 8, 
9), heavily depend on CD4+ T cell-produced signals. Requirement for cognate CD4+ T cell 
signals during priming in functional memory CTL development has been frequently suggested 
(5, 6, 10). It has also been shown that signaling induced by CD4+ T cell-expressed CD40L is 
needed for the generation of memory CTLs in the courses of the Lm or LCMV infections (11, 
12), while it is not essential in influenza infections (13, 14). In AdV-mediated immunity, Yang et 
al have initially observed the importance of CD4+ T cells in primary CTL responses in AdV 
immunization (15, 16). Subsequently, others also showed the importance of CD4+ T cells in 
AdV-specific primary CTL expansion (17-19). However, the role of CD4+ T cells in priming that 
modulates secondary CTL responses is still controversial. Yang et al (17, 20) reported that CTLs 
generated in CD4+ T cell-deficient environment are less functional yet retain their proliferating 
ability during recall responses. On the other hand, Holst et al (18) showed generation of 
dysfunctional memory CTLs that neither provided the protection against a lethal virus challenge 
nor retained the ability to proliferate during recall responses in the absence of CD4+ T cells. Mu 
 163
et al (19) reported that respiratory mucosal, which is in contrast to intravenous (i.v.) or 
intramuscular, route of AdV immunization can preclude CD4+ T helper dependence for effective 
CTL responses. The molecular mechanisms involved in CD4+ T-helper effects in the primary 
response that modulate different stages of CTL action are still unknown. Furthermore, the 
relative contributions of CD4+ T cells during maintenance and recall phases respectively for CTL 
survival and expansion are yet to be determined. In this study, we addressed these issues by 
systematically investigating the requirement for CD4+ T cells in multiple phases of ovalbumin 
(OVA)-specific CD8+ CTL responses induced by recombinant OVA-expressing adenovirus 
(AdVova) vaccination. 
5.4 Materials and methods 
5.4.1 Reagents, tumor cells and animals    
The biotin- or fluorescent-labeled (FITC or PE) Ab specific for CD4, CD44 (IM7), 
CD62L (MEL-14), CD69 (H1.2F3) and IFN-γ (XMG1.2), and streptavidin-PE Texas Red and 
streptavidin-PECy5 from BD-Biosciences, and PD-1 (J43) from ebiosciences were purchased. 
The FITC-anti-CD8 (KT15) and H-2Kb/OVA257-264 tetramer from Beckman Coulter were 
purchased. The OVAI (OVA257-264, SIINFEKL) and OVAII (OVA265-280, 
TEWTSSNVMEERKIKV) peptides were synthesized by Multiple Peptide Systems. The OVA-
transfected mouse malignant melanoma (BL6-10OVA) cell lines were cultured as described 
previously (10, 21). The WT C57BL/6J, OVA323–339-specific TCR-transgenic OTII, 
C57BL/6/B6.1 (B6.1, CD45.1+), CD80-/-, IL-2-/-, CD40L-/- and Iab-/- mice on C57BL/6 
background were purchased from Jackson Laboratory or bred in University’s animal resource 
center. The OTII/B6.1, OTII/CD80-/- and OTII/CD40L-/- mice were generated by backcrossing 
designated KO mice with OTII mice, and tested as described previously (10). All the animal 
experiments were performed as per the guidelines approved by the University Committee on 
Animal Care and Supply.     
5.4.2 Generation of AdVova and mature DCova  
The recombinant AdV-expressing OVA (AdVova) construction and its amplification 
were previously described (22). Bone-marrow-derived, OVA-pulsed dendritic cells (DCOVA) 
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from C57BL/6 mice were generated by culturing bone marrow cells for 6 days in medium 
containing IL-4 (20 ng/ml) and GM-CSF (20 ng/ml) and pulsing with 0.1 mg/mL OVA 
overnight at 37°C as described previously (21).  
5.4.3 Animal studies - Adoptive transfer and AdVova immunization      
In most experiments, CD4+ or CD8+ T cells were isolated from splenocytes and/or blood 
by enriching T lymphocytes in nylon-wool columns (C&A Scientific), and negative selection 
using anti-CD8 (L3T8) or anti-CD4 (L3T4) paramagnetic beads (DYNAL) as previously 
described (10). For immunization or boosting, 1x107 pfu of AdVova was used for i.v. injection. 
The CD11c+ DCs and, in some cases, CD4+ T cells devoid of CD11c+ CD4+ DCs were purified 
from splenocytes of WT mice as per manufacturer’s instructions (Miltenyl Biotec). In adoptive 
studies, to understand CD4+ T-helper roles, ~15-20x106 polyclonal CD4+ T cells or ~1.5x106 
OTII CD4+ T cells with or without designated gene deficiency and 0.5-1x106 CD11c+ DCs were 
transferred to Iab-/- mice one day before immunization. For generating memory CD4+ T cells, 
B6.1/OTII CD4+ T cells were stimulated with DCova and resulting Th cells were adoptively 
transferred to congenic WT B6.2 mice. After 45 days, polyclonal CD4+ T cells containing CD4+ 
T memory cells were purified and transferred (15-20x106/mouse) to Iab-/- mice for recall studies. 
In memory maintenance or recall studies, polyclonal CD8+ T cells containing effector or memory 
CTLs (~15x106/mouse) were transferred to Iab-/- mice.     
5.4.4 Primary and memory CTL kinetics study by tetramer or intracellular IFN-γ staining assays 
Following AdVova immunization, the blood and/or spleen samples were collected at 
different intervals, stained with H-2Kb/OVA257-264 tetramer and FITC-anti-CD8 Ab, and analyzed 
for CTL proliferation or survival (21). For intracellular staining, the samples were collected, re-
stimulated with OVAI or OVAII and subjected to intracellular IFN-γ assay (BD-Biosciences) for 
analysis of OVA-specific CD8+ and CD4+ T cell responses, respectively as described previously 
(23).  
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5.4.5 In vivo cytotoxicity assay  
The targets were prepared as described previously (10) by labeling splenocytes 
differentially with high (3.0 µM) or low (0.6 µM) concentrations of CFSE and by pulsing with 
OVAI or Mut1 peptide, respectively, and co-injected i.v. (2x106 cells/mouse) at 1:1 ratio into 
immunized or unimmunized mice. Sixteen hours later, the relative proportions of CFSEhigh and 
CFSElow cells remaining in the spleens were analyzed by flow cytometry (10).   
5.4.6 Phenotypic characterization of effector and memory CTLs, or memory CD4+ T cells 
To characterize memory CTLs phenotypically, the blood and spleen samples were 
collected 75 days after AdVova immunization, and stained with tetramer and Ab specific for PD-
1 surface marker. The percentage of tetramer+ CTLs that express PD-1 marker were determined 
by flow cytometry. To characterize memory CD4+ T cells, the blood samples were collected 45 
days of adoptive transfer, stained with PE-anti-CD4, FITC-CD45.1 and biotin-conjugated Abs 
specific for active or memory phenotype. The relative expression of surface markers in 
comparison to isotype control levels was determined in CD4+CD45.1+ population.      
5.4.7 Tumor protection studies   
All the immunized mice were challenged with BL6-10OVA (0.5x106 cells/mice) on 120th 
day of immunization as shown in Table 1 and monitored for protection up to 24 days or earlier if 
the mice become moribund as described previously (21). The tumor grading was done depending 
on mean numbers of metastatic tumor colonies in lungs: -, no tumors; +, 1-25; ++, 26-50; +++, 
51-75; ++++, 76-100; +++++, 101-250; ++++++, >250. 
5.4.8 Statistical analysis 
The statistical analysis were performed using Student’s t or Mann–Whitney U test (Graphpad 
Prism-3.0); *P<0.05 and **P<0.01.   
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5.5 Results  
5.5.1 AdVova stimulates persistent CD4+ and CD8+ T cell responses 
Initially, we assessed the kinetics of CD4+ and CD8+ T cell responses at different time 
points following AdVova stimulation by flow cytometry after staining cells with FITC-
CD4/nonspecific PE-CD44 or FITC-CD8/OVA-specific PE-tetramer, respectively. In line with 
previous findings, upon AdVova immunization, we observed a peak of OVA-specific CD8+ T 
cell responses on day 10 (21.2±3.7% of total CD8+ CTLs) and a long-term maintenance of high 
levels of OVA-specific CTLs (as much as 6.5±1.1% of total CD8+ CTLs) even 4 months later 
(Fig 1a), indicating that CD8+ CTLs persist for prolonged period of time, consisting with earlier 
reports (17, 24). In contrast to the situation in blood, assessment of spleen samples revealed 
earlier responses, and was associated with relatively lowered levels (3 to 5 fold) of CTLs (data 
not shown). These results indicate that CD8+ CTLs may persist for a very prolonged period of 
time, which is consistent with previously published reports (17, 24). In addition, our experiments 
also showed that AdVova-stimulated CD4+ T cells persist in both peripheral blood and spleens. 
Strikingly, in contrast to CTL population that showed greater than 60% contraction 4 months 
later, AdVova-stimulated poly-specific CD4+ T cells gradually increased their levels with time, 
representing 21.5±3.2% and 23.4±3.5% of total blood CD4+ T cells as early as on 5 and 10 days 
post-immunization, respectively, and 42.2±5.7% in 4 months (Fig 1b). However, their levels in 
spleen leveled off by 4 months. In addition, we also demonstrated that frequency of IFN-γ-
secreting CD4+ T cells is significantly higher in the immunized mice than in control animals on 
both 5 and 10 days after immunization (P<0.05) (Fig 1c), confirming that AdVova immunization 
also triggered  transgene-specific CD4+ T cell responses.  
5.5.2 CD4+ T cells influence the kinetics of AdV transgene product-specific CTLs  
To assess the influence of CD4+ T cells in AdVova-stimulated CTL responses, we 
immunized Iab-/- mice lacking CD4+ T cells with AdVova and analyzed OVA-specific CD8+ 
CTL responses at different time points by flow cytometry. Consisting with previous results (17), 
we found 4 to 6 fold decrease in primary CTL proliferation in Iab-/- compared to WT mice (Fig. 
2a). Furthermore, 90 days after immunization, WT mice showed more than ten-fold better 
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survival rate of CTLs compared to Iab-/- mice. Although primary CTLs in Iab-/- mice (unhelped) 
expanded less efficiently, they still appeared to show some degree of functions, such as IFN-γ-
secreting ability (Fig. 2b) and cytotoxic functions (Fig. 2c). Owing to relatively prolonged 
persistence of AdVova in the body, it is possible that CD4+ T cells could influence the 
exhaustion AdVova-specific CTLs. To rule out this possibility, we monitored the expression of 
PD-1, a well-established exhaustion marker, on helped versus unhelped CTLs (25). Indeed, the 
poor survival of AdV-specific CTLs in Iab-/- mice correlated well with the presence of 
considerably higher numbers of PD-1-expressing memory CTLs in spleen compared to those of 
WT mice on day 75 post-immunization (Fig. 2d). These results strongly suggest CD4+ T cells 
enhance AdV-stimulated CTL survival by rescuing them from exhaustion by inhibiting PD-1 
expression.    
5.5.3 Molecular mechanisms of CD4+ T cell help in CTL primary responses and survival   
To assess the molecular mechanisms of CD4+ T cell help, we developed an immunization 
protocol with a combination of AdVova immunization and adoptive transfer of cognate OTII 
CD4+ T cells in Iab-/- mice (Fig. 3a). We first optimized the dose of purified monoclonal or 
polyclonal CD4+ T cell requirement for efficient CTL responses (data not shown). A dose of 
polyclonal CD4+ T (~15-20x106) or cognate OTII CD4+ T (~1.5x106) cells was found to be 
efficient in reproducing primary CTL response in Iab-/- comparable to WT mice (Fig. 3b). Since 
Ag-presenting cells (APCs) in these mice lack MHC-II molecules and unable to stimulate 
transferred CD4+ T cells, CD11c+ DCs (~1x106) purified from spleens were also necessary for 
adoptive transfer to initiate AdVova-stimulated CTL responses. The critical roles of CD11c+ 
DCs in AdV immunization have been well demonstrated previously (26, 27). In the presence of 
polyclonal CD4+ T cell help, perhaps due to endogenous levels of precursor CD4+ T cells, the 
primary CTL expansion was considerably increased in Iab-/- mice. Strikingly, in the presence of 
OTII CD4+ T cells, the primary CD8+ CTLs expanded even more efficiently (1.5 fold) in Iab-/- 
than in WT mice, indicating that this immunization protocol can be used to assess the molecular 
mechanisms of CD4+ T cell help, when CD4+ T cells derived from IL-2-,  CD40L- and CD80- 
deficient mice are transferred.  
To address the involvement of specific molecular factors, we reconstituted Iab-/- mice 
with polyclonal or monoclonal (OTII) CD4+ T cells with or without a deficiency in selected 
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genes and with CD11c+ DCs one day prior to the immunization. Once again, the reconstitution of 
polyclonal CD4+ T cells in Iab-/- mice considerably supported primary CTL expansion, compared 
to WT levels, and the CTL response was further increased, when endogenous levels of OTII 
CD4+ T cells were additionally provided (Fig. 3c). Strikingly, the primary expansion was 
severely impaired in the absence of IL-2 signaling by polyclonal CD4+ T cells, strongly 
resembling the situation in Iab-/- mice. In addition, the primary expansion was significantly 
reduced when polyclonal CD4+ T cells lacking CD40L (P<0.01) were transferred, while the 
absence of CD80 did not produce any negative effect, suggesting a potential role for CD40L in 
optimizing the primary expansion. During the memory phase, CTL survival considerably 
decreased in Iab-/- compared to WT mice (P<0.01) irrespective of CD4+ T cell transfer (Fig. 3c, 
right panel), perhaps due to the failure of CD4+ T cells to survive in the MHC-II-deficient 
environment (28). Nevertheless, Iab-/- mice reconstituted with polyclonal CD4+ with or without 
OTII CD4+ T cells had considerably higher frequencies of CTLs, when compared to Iab-/- mice 
alone or to Iab-/- mice transferred with polyclonal CD4+ T cells lacking CD40L or IL-2 (P<0.01). 
Strikingly, the transfer of cognate CD4+ T cells (~1.5x106) supported the primary CTL 
expansion, surpassing the WT levels (Fig. 3d). In contrast, the absence of co-stimulatory 
molecules, particularly CD40L, suppressed the ability of cognate CD4+ T cells to support the 
primary CTL expansion, mimicking the response in untransferred Iab-/- mice. As previously, 
CTLs in Iab-/- mice survived poorly during the memory phase, irrespective of OTII CD4+ T cell 
transfer. Nevertheless, Iab-/- mice reconstituted with OTII cells with or without CD80 had 
relatively higher frequencies of CTLs, when compared to Iab-/- alone (P<0.01) or to Iab-/- animals 
reconstituted with CD40L-deficient polyclonal CD4+ T cells (P<0.05).   
To study the impact of CD4+ T cell signals during priming for functional memory CTL 
responses, the above mice were challenged 120 days later with highly metastasizing, OVA-
expressing mouse melanoma tumor cells. WT, but not Iab-/- animals showed complete tumor 
protection (Table 1). However, Iab-/- mice which received CD4+ T-helper-produced signals 
during priming got protected to various extents, depending on signaling content. Although Iab-/- 
mice with transferred polyclonal CD4+ T cells developed tumors, they had very low tumor 
burdens compared to mice receiving CD40L-deficient or IL-2-deficient polyclonal CD4+ T cells. 
Interestingly, 40% of the challenged Iab-/- mice that were transferred with OTII cells, showed 
tumor protection. In contrast, mice transferred with OTII CD4+ T cells missing CD40L remained 
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completely unprotected. Taken together, these data highlight the importance of cognate CD4+ T-
helper signals in AdV immunization, specifically CD40L and IL-2, in the optimization of the 
primary expansion and functional memory development.     
5.5.4 Naïve polyclonal CD4+ T cells support maintenance of AdV transgene product-specific 
CTLs     
The observed faster decrease in the frequency of CTLs in Iab-/- compared to WT mice, 
even in the presence of reconstituted CD4+ T-helper population during priming, (Fig. 3c and 3d) 
suggests a possible role for polyclonal CD4+ T cell environment in the maintenance of CTLs 
after priming. To examine this possibility, the effector CTLs from B6.1 mice (CD45.1+) were 
purified on day 10 following AdVova immunization and transferred to naïve congenic WT or Iab-
/- mice (CD45.2+) and tracked by the tetramer and congenic marker staining. This approach 
precludes detection of endogenous CTLs stimulated by any residual AdV-infected DCs 
following adoptive transfer. Consistent with our previous observations (Fig. 2a, 2b, 3c or 3d), the 
effector CTLs declined drastically starting from day 7 in Iab-/- mice, while a significantly slower 
decline was characteristical for WT mice (Fig. 4a). In agreement, WT mice showed near 
complete protection against tumor challenge, while Iab-/- remained practically unprotected (Fig. 
4b). Furthermore, memory CTLs purified after 90 days following immunization behaved similar 
to effector CTLs, showing reduced survival rate in Iab-/- mice (Fig. 4c). Again, WT animals 
received much better protection, when compared to Iab-/- mice (Fig. 4d). In sum, these 
observations suggest that polyclonal CD4+ T cell environment may be required for optimal 
maintenance of AdVova-specific CTLs.    
5.5.5 CD4+ T cell signals during priming and recall phase are required for optimal secondary 
responses    
Recent studies in multiple models have shown that CD4+ T cells are essential for optimal 
recall responses (1, 29-31). The results of our experiments (Fig. 3c and 3d) also suggest the role 
for cognate CD4+ T cell signals, partly produced during priming, for functional memory 
responses, thus, supporting previously published data (5, 6). To further elucidate the relative 
importance for CD4+ T cells in priming and/or recall responses, memory CTLs were purified 
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from splenocytes of WT (helped CTLs, TmA) or Iab-/- (unhelped CTLs, TmB) mice after 90 days 
of AdVova immunization and adoptively transferred in equal quantities to the naïve secondary 
recipients, WT or Iab-/- mice (Fig. 5a). Recently, Hutnick et al reported that AdV-stimulated 
memory CTLs can expand even in the presence of neutralizing Abs following boosting with 
similar strain of AdV (32). It appears the approach followed here further facilitated the 
expansion of AdV-stimulated memory CTLs following boosting in naive secondary recipients in 
the absence of neutralization of AdVova by Abs. Following AdVova boosting, helped memory 
CTLs robustly expanded in WT when compared to their expansion in Iab-/- mice (Fig. 5b). 
Curiously, unhelped memory CTLs in WT showed increase in the expansion only slightly above 
the levels observed in WT without Tm transfer. Moreover, unhelped memory CTLs in Iab-/- mice 
failed to expand and showed levels similar to Iab-/- mice without Tm transfer. These results 
suggest possible synergistic role for CD4+ T cell help in both priming and recall responses.    
To further understand the nature of CD4+ T cell helper requirement during recall 
responses, the adoptive transfer technology was employed again in Iab-/- mice (Fig. 6a). Here, Iab-
/- mice, were transferred with CD11c+ DCs and OTII cells, polyclonal CD4+ T cells, or OVA-
specific memory CD4+ T cells after being adoptively transferred with helped memory CTLs (Fig. 
6b) as shown in Fig. 6a. As expected, helped CTLs in the presence of CD4+ T cells produced a 
modest increase in the expansion, but the response was considerably much higher in the presence 
of memory CD4+ T cells (Fig. 6c). On the other hand, Iab-/- reconstituted with OTII cells or 
polyclonal CD4+ T cells  in the absence of memory CTLs showed a response similar to that of 
unreconstituted Iab-/- mice (not shown), suggesting the observed CTL responses were mainly due 
to memory CTL expansion. Overall, these results indicate the importance of CD4+ T helper 
signals provided during the priming and recall phases for optimal AdV-stimulated memory CTL 
responses.          
5.6 Discussion 
In the absence of strong inflammatory signals, CD4+ T cells enhance CTL immunity either 
indirectly by licensing DCs (7, 8), or directly by interacting with cognate CD8+ T cells (10, 21, 
33). Immunity to cancers, allogenic transplantations and autoimmune disorders thus requires 
CD4+ T cells for optimal priming, maintenance and memory responses (1, 6, 33-36). Even in 
some infectious diseases, such as HSV, VSV, viral encephalitis and Vaccinia virus infections, 
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CD4+ T cell help is still crucial for the induction of robust primary and functional memory 
responses (2, 3, 9, 37, 38) though the viral byproducts (such as DNA or double-stranded RNA) 
are capable of inducing inflammation. Interestingly, the present study also demonstrates the 
predominant role of CD4+ T cells in multiple phases of AdVova-stimulated OVA-specific CTL 
responses, including the primary, memory maintenance and recall responses. We demonstrate 
that the cognate CD4+ T cell help during priming is crucial not only for the primary expansion 
and memory CTL survival, but also for the fitness of memory CTLs. We also reveal that the 
differentiation of primary CTLs is considerably impaired in the absence of CD4+ T cell-derived 
CD40L signaling. Similarly, functional primary, but defective memory CTL responses were also 
observed in association with LCMV, Pichinde virus and VSV infections in the absence of 
CD40L signaling (11, 39). It appears IL-2 signaling also represents a crucial event that not only 
supports primary expansion, but also helps in the generation of memory CTLs, providing 
survival advantages. The role of the CD40L and IL-2 factors derived from CD4+ T cells in 
producing optimal primary and memory responses is well described in various models (2, 37, 
40). It was shown that Th1 provide CD40L signals to DCs to induce IL-12 secretion and IL-12, 
in turn, acts on CD8+ T cells to enhance IL-2R expression, thus enabling an efficient utilization 
of the IL-2 cytokine (2). Alternatively, it was shown that Th1 can directly provide CD40L, IL-21 
and IL-2 signals to CD8+ T cells in an Ag-specific manner (10, 21, 33, 40, 41). Interestingly, in 
both direct and indirect mechanisms, cognate CD4+ T cells have been shown to modulate CTL 
responses in a CD40L- and IL-2- dependent manner. In Iab-/- mice, the incomplete maturation of 
DCs without CD4+ T cell signals, and/or absence of direct CD4+ T cell signals might have led to 
poor primary and memory CTL responses since we were able to restore such defectiveness by 
provision of polyclonal or cognate CD4+ T cells, suggesting critical roles for CD4+ T cells in 
AdV-mediated CTL induction.  .       
The enhanced recall responses upon provision of naïve monoclonal or polyclonal, or 
memory CD4+ T cells suggest yet another role for CD4+ T cells in OVA-specific CTL responses. 
It is currently not clear, why memory CTLs required CD4+ T cell environment, while receiving 
helper signals during priming and/or being maintained in polyclonal naïve and/or AdV-specific 
CD4+ T cell environment. It was shown in various models that CD4+ T helper signals operate 
similarly during recall responses (1, 31, 34, 36, 40). For instance, treatment with agonistic anti-
CD40 mAb and IL-2 is known to decrease the expression of PD-1, a potent T cell inhibitory 
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molecule, on memory CTLs (31). Consistent with our present observations, memory CD4+ T 
cells have also shown to enhance the primary responses of naïve and memory CD8+ T cells in 
various models (30). Moreover, direct interactions between memory CD4+ and CD8+ T cells, 
involving CD40L and IL-2 signaling, and leading to enhanced recall responses have also been 
reported (34).  
Considerable attention has been paid to understanding AdV-specific CTL persistency. Due 
to persistent transgene expression (20, 24, 42), the high levels of CTL maintenance for a long 
period of time might originate from reactivation of CTLs by APCs or AdV-transduced non-
APCs (42).  In this scenario, all these CTLs could exhaust over a period of time by losing their 
ability to secrete cytokines and protecting against viral or tumor challenges, as seen with chronic 
viral (LCMV and cytomegalovirus) infections (25). In AdV immunization, we demonstrate a 
drastic decrease of CTL persistency in the CD4+ T cell-deficient environment, which may result 
from a poor activation of CTLs and a lack of CD4+ T cell signals. It appears, in WT mice, both 
endured AdV-stimulated and naïve polyclonal CD4+ T cells contribute to CTL persistency. 
Previously, involvement of nonspecific signals from naïve CD4+ T cells in increasing fitness and 
quantities  of memory CTLs in acute infections have been reported (43). Similarly, effects of 
signals from active polyclonal CD4+ T cells on enhancing CTL survival have also been observed 
(44). On the other hand, cognate active CD4+ T cells were able to support robust CTL priming. 
Perhaps due to the absence of some specific types of CD4+ T helper signals, Iab-/- animals 
demonstrate  2 to 3 fold increase in the PD-1+ CTLs, when compared to WT mice. Recently, in 
Vaccinia virus model, Novy et al reported that CD4+ T cells enhance memory CTL survival by 
providing IL-21 signals (1, 40). These signals were required to activate STAT1 and STAT3 
pathways and subsequent increase of the prosurvival molecules, including Bcl-2 and Bcl-xL 
(40). This possibility could exist in AdV immunization owing to persistency of AdV-specific, 
active CD4+ T cells in AdVova immunization. However, the precise relative contributions of 
transgene and non-transgene AdV-stimulated CD4+ T cells vs naïve polyclonal CD4+ T cells and 
associated molecular mechanisms for memory CTL survival need further investigation. Aubert et 
al demonstrated that CD4+ T cells can rescue exhausted CD8+ T cells during chronic viral and 
Plasmodium parasitic infections (45, 46). Similarly, exhausted CD8+ T cells derived from 
progressive HIV patients underwent proliferation when co-cultured with CD4+ T cells taken from 
acute HIV patients (45, 47), suggesting the provision of CD4+ T helper factors could revert CTL 
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functions in chronic HIV infections. Previously, the use of autologous CD4+ T cells in metastatic 
melanoma patient have also shown to induce prolonged clinical remission (48, 49). These results 
together with ours suggest that the use of supplemental CD4+ T cell therapy or CD4+ T helper 
factors may be beneficial in successful treatment of AdV-immunized patients with chronic 
infections or cancers.   
Due to their efficiency in inducing strong innate as well as adaptive immune responses (50), 
AdVs have recently gained much attention as promising vaccination tools in treating intractable 
diseases such as cancers (51, 52) and chronic infectious diseases (53, 54). However, AdV-based 
vaccines often failed to give protection in clinical trials, partly due to the chronic nature of the 
pathogenic Ags and the associated imbalance in the host immune responses, such as the selective 
depletion or defectiveness of CD4+ T cells in chronic diseases, such as HIV infection (55-58). 
Perhaps due to these reasons, our results could partially explain the failure in AdV-based 
vaccinations against these intractable diseases, warranting the development of novel modified 
AdV vaccines. The feasibility of this approach is further supported by observations 
demonstrating an improved CD4+ T cell-independent CTL responses associated with linking of 
AdV-encoded Ag to invariant chain or β2-microglobulin (18, 59-61) or altering route of 
immunization to certain pathogens (19). 
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5.9 Table 
Table 1. Molecular mechanisms of CD4+ T-helper signals required for functional AdV-
specific memory CTL responses a 
 
AdVOVA immunization 
% Tumor-bearing 
mice 
Tumor metastasis 
grading 
PBS                             8/8 (100)             ++++++ 
WT                                0/12 (0) - 
Iab-/-                           12/12 (100) +++++ 
Iab-/-+polyCD4+ T       10/10 (100) + 
Iab-/-+polyCD4(IL-2-/-)      10/10 (100) +++++ 
Iab-/-+polyCD4(CD40L-/-) 10/10 (100) ++++ 
Iab-/-+polyCD4(CD80-/-) 10/10 (100) ++ 
Iab-/-+OTIICD4+ T     6/10 (60) -/+ 
Iab-/-+OTIICD4(CD40L-/-)   10/10 (100) +++ 
Iab-/-+OTIICD4(CD80-/-)     10/10 (100)                     + 
 
a One day prior to immunization, Iab-/- mice were adoptively transferred with CD11c+ DCs and 
naïve polyclonal or OTII CD4+ T cells with or without designated gene deficiency, as indicated. 
120 days later, all the immunized mice were challenged with BL6-10ova tumor cells. Twenty-
four days after the challenge, lung tumor colonies were counted and graded. The data are 
cumulative of two independent experiments, each comprising five to six mice per group.  
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5.10 Figures 
 
Figure 1 
 
 
AdVova stimulates persistent CD4+ and CD8+ T cell responses. (a and b) Following 
immunization, the AdVova-specific CTLs (a) and CD44+CD4+ T cells (b) in the peripheral blood 
and/or spleen were analysed by flowcytometry at the indicated intervals after tetramer staining, 
and CD44 and CD4 double marker staining, respectively. The values in the figure (left panel) or 
line diagram (right panel) are presented as mean%±SD of OVA-specific CD8+ CTLs in total 
CD8+ T  cell population (a) or of CD44+ CD4+ T cells in total CD4+ T cell population (b), and are 
cumulative of three independent studies with three to five mice per group. (c) Following 
immunization, spleen samples were analyzed for AdVova-specific CD4+ T cells by intracellular 
IFN-γ staining at the indicated intervals. The values (% frequencies) are cumulative of two 
independent experiments with three to four mice per group. *P<0.05, versus matching controls. 
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Figure 2 
 
 
CD4+ T cells impact the kinetics of AdV transgene product-specific CTL populations (a and 
b) Following immunization, AdVova-specific CTLs were analysed in the periphery at different 
intervals by tetramer (a) and intracellular IFN-γ (b) stainings. The values are presented as 
mean%±SD of OVA-specific tetramer+ CTLs (a) or IFN-γ+ CTLs (b) in total CD8+ T cell 
population and are representative of two to three independent experiments with three to four 
mice per group. **P<0.01, versus Iab-/- mice. (c) Ten days following immunization, the 
proportions of CFSEhigh-OVAI-pulsed target cells lysed by effector CTLs were determined in 
spleens by in vivo cytotoxicity assay. The values represent mean %±SD of targets remaining in 
spleens relative to controls and are representative of two independent experiments with three to 
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four mice per group. (d) On day 75, following immunization, OVA-specific memory CTLs were 
characterized in spleen for PD-1 expression by flow cytometry. A representative figure is shown 
on the left. The values in the bar diagram represent the mean %±SD of tetramer+ PD-1+ CTLs in 
total tetramer+ CTL population and are representative of two independent experiments with 3 to 
4 mice per group. 
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Figure 3 
 
 
The molecular mechanisms of CD4+ T cell help in CTL primary responses and survival. (a)  
A schematic protocol. Iab-/- mice were adoptively transferred with monoclonal or polyclonal 
CD4+ T cells with or without designated gene deficiency and supplied with spleen-derived 
CD11c+ DCs. One day later, both Iab-/- and WT mice were i.v. immunized with AdVova 
followed by assessment of CTL proliferation at the indicated intervals. After 120 days (memory 
stage) following the immunization, all the groups were challenged with BL6-10OVA tumor cells 
and assessed for tumor protection. (b) Optimized CD4+ T-cell dose required for optimal CTL 
expansion in Iab-/- mice. Iab-/- mice were transferred with monoclonal (OTII) (~1.5X106) and/or 
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polyclonal (~15-20X106) CD4+ T cells and CD11c+ DCs (~0.5-1.0X106), as shown in the figure. 
One day later, all the groups were immunized and assessed for CTL proliferation by tetramer 
assay. The values represent mean %±SD of OVA-specific tetramer+ CTLs in total CD8+ T cell 
population and are representative of two independent experiments with three to four mice per 
group. (c and d) Molecular mechanisms of CD4+ T cell help. Iab-/- mice were transferred with 
monoclonal (OTII) or polyclonal CD4+ T cells with or without designated gene deficiency and 
CD11c+ DCs as indicated. One day later, all the groups were immunized and subsequently 
assessed for CTL proliferation by tetramer assay. The values represent mean %±SD of OVA-
specific tetramer+ CTLs in total CD8+ T cell population on day 10 post-immunization (left panel) 
or at the indicated time points (right panel) and are representative of two independent 
experiments with five to six mice per group. **P<0.01, versus Iab-/- mice with no adoptive CD4+ 
T cell transfer. 
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Figure 4 
 
 
Polyclonal CD4+ T cells support maintenance of AdVova transgene product-specific CTLs. 
(a) Ten days following immunization, total CD8+ CTLs, containing AdVova-specific effector 
CTLs were purified from B6.1 mice (CD45.1+ background) and adoptively transferred to naïve 
congenic WT and Iab-/- mice (CD45.2+ background). The OVA-specific tetramer+ CTLs were 
tracked after staining peripheral blood samples with tetramer reagent and congenic marker up to 
30 days post-adoptive transfer. The values represent mean %±SD of OVA-specific tetramer+ 
CTLs in total CD45.1+ adoptively transferred T cell population at the indicated intervals (right 
panel) and are representative of two independent experiments with five to six mice per group. 
**P<0.01, versus Iab-/- mice. (b) Forty-five days after adoptive transfer, the above mice groups 
were challenged with BL6-10OVA. Twenty-four days after the challenge, both groups were 
assessed for tumor protection. Images represent distorted pathology of lungs, showing relative 
surface tumor burden. (c) Ninety days following the immunization, total CD8+ T cells containing 
AdVova-specific memory CTLs were purified from WT mice and adoptively transferred into 
naïve WT and Iab-/- mice. The OVA-specific tetramer+ CTLs were tracked in peripheral blood 
samples by tetramer staining. The values represent mean %±SD of OVA-specific tetramer+ CTLs 
in total CD8+ T cell population at the indicated intervals (right panel) and are representative of 
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two independent experiments with four to six mice per group. **P<0.01, versus Iab-/- mice. (d) 
Thirty days after the adoptive transfer, the above mice groups (c) were challenged with BL6-
10OVA and the relative surface tumor burden was assessed 24 days after the challenge as detailed 
above. 
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Figure 5 
 
 
CD4+ T cell signals provided during priming and recall phase are required for optimal 
secondary responses. (a) A schematic protocol. After 90 days of immunization, total CD8+ T 
cells containing memory CTLs were purified from WT (helped CTLs, TmA) or Iab-/- (unhelped 
CTLs, TmB) mice, adoptively transferred in equal numbers into the naïve secondary recipients, 
WT and Iab-/- mice, and assessed for recall potential after boosting. (b) Three days after adoptive 
transfer of helped (TmA) or unhelped (TmB) memory CTLs into naïve WT and Iab-/- mice, all 
the mice groups were boosted with AdVova and monitored for the expansion of memory CTLs 
6.5 days later. The values represent mean %±SD of OVA-specific tetramer+ CTLs in total CD8+ 
T cell population and are representative of two independent experiments with five to six mice per 
group. **P<0.01, versus Iab-/- mice with TmA or TmB.        
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Figure 6 
 
 
 
CD4+ T cell signals delivered during priming and recall phase are required for optimal 
secondary responses. (a) A schematic protocol. After 90 days following immunization, total 
CD8+ T cells, containing memory CTLs were purified from WT (helped memory CTLs) mice, 
adoptively transferred equally to the naïve secondary recipients, WT and Iab-/- mice. The Iab-/- 
mice were additionally reconstituted with different types of CD4+ T cells along with CD11c+ 
DCs. Both groups were boosted with AdVova and assessed for memory CTLs expansion. (b) 
Naïve B6.1/OTII CD4+ T cells were co-cultured with irradiated BM DCova, as detailed in 
material and methods to generate Th cells. Th cells were then transferred to naïve congenic WT 
mice. After 45 days, these cells were triple stained and phenotypically characterized by the 
presence of activation- and memory-specific markers, as shown in this figure. The value in the 
dot plot indicates % of OVA-specific CD4+ T memory cells remaining in total CD4+ T cell 
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population and is representative of two independent experiments with 3 to 4 mice per group. (c) 
Iab-/- mice were adoptively transferred with helped memory CTLs (TmA) with or without 
CD11c+ DCs and with OTII CD4+ T cells, polyclonal CD4+ T cells or OVA-specific memory 
CD4+ T cells together with polyclonal CD4+ T cells. Three days later, all the groups were 
boosted with AdVova and the recall potential of the memory CTLs were assessed 6.5 days later. 
The values represent mean %±SD of OVA-specific tetramer+ CTLs in total CD8+ T cell 
population and are representative of two independent experiments with four to five mice per 
group. *P<0.05 or **P<0.01, versus Iab-/- mice with TmA alone. 
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSIONS 
 Although the discussions specific for Chapters 2-5 have been made, the intent of this 
Chapter is to provide a discussion of the thesis work in its entirety. The overall goal of the 
present work was to understand how CD4+ T helper cells modulate different phases of CD8+ 
CTL responses in order to provide effective anti-tumor immunity. The requirements of CD4+ T 
helper cells for effective CTL responses are known to vary with the type of infections or 
immunizations. Hence, in the present work, two distinct immunization systems were chosen to 
understand the modulatory effects of CD4+ T cells on cellular immunity. These included: 1) non-
inflammatory DC immunization, which fails to provide inflammatory/danger signals; and 2) 
inflammatory AdV immunization, which provides profound inflammatory/danger signals. To 
assess the protective ability of memory CD8+ CTLs developed under the influence of CD4+ T 
help, a highly metastatic melanoma tumor cell line was used in challenge studies. Before the 
inception of the work in Chapters 2 and 3, the concept of a “new dynamic model of CD8+ CTL 
responses via CD4+ Th-APCs,” proposed by Xiang et al. (1) was beginning to be understood. 
Hence, a sincere approach was made to further understand the novel role of CD4+ T cells on 
CD8+ CTL responses using DC immunization model. In Chapter 4, the regulatory roles of CD4+ 
T cells were investigated under different CD8+ T cell PF levels in DC immunization model. In 
Chapter 5, the study was focused on understand the behavior of cellular immune response under 
the influence of CD4+ T cell signals following AdV immunization.   
The immunologists’ perception of the participation of CD4+ T cells in various phases of 
CTL responses has changed over time. The role of CD4+ T cells in modulation of CD8+ CTL 
responses was observed originally in in vivo allograft rejection and in vitro studies of allogeneic 
mixed lymphocyte reactions (2). However, this notion of interaction between CD4+ and CD8+ T 
cells for effective CTL responses was again questioned when two recent reports showed the 
absolute CD4+-independent CTL-mediated clearance of acute viral infections (3, 4). This finding 
led to the concept that CD4+ T cell help is needed for generating primary CTL immunity to non-
infectious Ags (such as minor histocompatibility Ags, tumor Ags or protein Ags) (5-7) and not 
for acute infections caused by live virus or bacteria (8). Live microbes were thought to directly 
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license the DCs to mature such that DCs acquire the ability to activate naïve CD8+ T cells 
directly. Subsequently, the concept of pathogenic-mediated DC maturation/licensing and 
subsequent CTL responses was again subjected to skepticism. In the absence of CD4+ T cells, it 
has been shown that the protection of the same virus or bacterial infection impairs during 
memory stage, and even during priming, the infection at high doses can persists without getting 
cleared from the body (9, 10). These findings suggest that CD4+ T cells might play a crucial role 
in the survival/expansion of functional CTLs till the clearance of Ag occur (11, 12). Later, it was 
confirmed that, even in acute infections, CD4+ T cell help is required for optimal memory CTL 
responses (4, 13, 14), suggesting they play a prime role in the memory phase irrespective of type 
of Ags (infection or noninfectious). For memory CTL responses, while these reports suggested 
the involvement of cognate CD4+ T cell help during priming periods, a recent study implicated 
polyclonal CD4+ T cells’ role during memory maintenance phase (3). Based on the above 
observations, it appeared that the timing and nature of CD4+ T cell’s requirement was 
Ag/immunogen type dependent, providing the basis for choosing both inflammatory and non-
inflammatory immunization models in the present work.  
Although their involvement is much appreciated, CD4+ T cell’s conditional requirement 
for different CTL phases remains a long-standing paradox in cellular immunology. Previously, 
two models on how CD4+ T help for CD8+ CTL responses have been proposed. These include: 
1) the passive model of three-cell interaction (5, 15); and 2) the dynamic model of sequential 
two-cell interactions by APCs (6). As reviewed in Chapter 1 (literature review), these two 
models do not convincingly explain how extremely rare number of CD4+ and CD8+ T cells, 
and/or Ag-presenting DCs interact simultaneously or sequentially, an event that has extremely 
low probability. Subsequently, Behrens et al (16) addressed this scarcity caveat partially in a 
diabetic model where they reported that CD4+ T helper cells can convert the tolerogenic CD8+ T 
cell response into one capable of causing destruction of the pancreatic islets which is in contrast 
to finding that help is only important for CTL memory (4, 13, 17, 18). They demonstrated that 
CD40 signaling on DCs is very important for generating effector CTLs. They also reported that 
Th cells, once activated, do not need recognize Ag on the same DCs they license and even may 
not require DC trafficking to LN. Rather, they will interact with various other DCs through 
CD40 signaling even without going for second cognate interactions (i.e. without awaiting second 
TCR signal via pMHC). In this way, the immune system can achieve efficient and rapid means 
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of amplifying CTL responses. Although one or several of these possibilities could exist in vivo, 
“new dynamic concept of Th-APCs” could solve the puzzle of long-standing paradox in cellular 
immunology. Contrary to CD8+ T cells, CD4+ T cells contact DCs multiple times (Ag 
persistence) to undergo activation and differentiation (19). As a result they are known to remain 
for longer periods in lymphoid organs and possibly acquire more and more pMHC-II as well as 
bystander pMHC-I complexes in addition to other APMs. Consequently, Th-APCs with 
relatively more number of pMHC I complexes can readily scan and activate rare number of 
cognate naïve CD8+ T cells in addition to DCs, partially solving scarcity caveat of cellular 
interaction in cellular immunology. The work in the Chapter 2 and 3 further confirmed these 
observations.  
Chapter 2 elucidated key regulatory events mediated by CD4+ T cells that could 
physiologically occur following infections or immunizations. In different experimental systems, 
the multifaceted roles of CD4+ T cells have been shown. In line with these observations, the 
work in Chapter 2 showed how CD4+ T cells participate not only in augmenting CTL-mediated 
immune responses perhaps during early phase, but also in regulating/suppressing cellular 
immunity perhaps during later phase. Furthermore, it showed that Th-APC-stimulated CD8+ T 
cells are more prone to become TCM and the stimulation is mainly mediated via CD40L, IL-2, 
and acquired pMHC I signaling. The study also showed that Th-APC-stimulated CD4+ T cells 
behave like Th cells in function, augmenting overall magnitude of CTL responses. Thus, these 
results greatly enhance our understanding of regulation of cellular immunity and could impact 
vaccine development. The cooperative role of Th and effector CTL have been frequently 
observed in adoptive CTL therapy of cancers, yet how synergistic response occurs from these 
two cells interaction is less understood. The work in the Chapter 3 partially explained how Ag-
experienced Th cells can modulate CTL responses, such as apoptosis, survival, and functional 
memory CTL development, showing additional role of Th-APCs. This study could explain how 
millions of copies of effector CTLs generated in vivo destined to undergo death by apoptosis or 
their minute fractions develop into memory CTLs. This knowledge is particularly relevant in the 
context of adoptive CTL therapy of cancers and chronic diseases. From the current data, a 
successful adoptive CTL therapy should include the provision of Th help to effector CTLs. One 
of the greatest challenges associated with trogocytosis in immunological studies is the translation 
of in vitro findings to in vivo ones (20). So also here, although all these works performed 
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basically derived from a combination of in vitro and in vivo experiments and used transgenic 
mice systems, there remains to be determined the physiological relevance and in vivo 
implications of this concept.  
The natural differences in the size of Ag-specific CD8+ T cell precursors influencing the 
magnitude of primary and memory CTL responses in various types of disease conditions, 
including cancers, autoimmunity, infections and graft rejections, have attracted immunologists to 
investigate whether altered PF modifies requirement of regulatory factors for CTL responses. 
Several recent seminal reports published in high-rated journals suggested that, by increasing 
CD8+ T cell PF, one could achieve CD4+ T help- and CD40-40L-signaling-independent primary 
CTL responses even in immunity involving non-inflammatory conditions (21-25). However, how 
higher PF impact CD4+ T-helper signal requirements for functional memory responses and its 
therapeutic usefulness are not understood. Hence, the work presented in the Chapter 4 addressed 
these issues using combined adoptive transfer technology and various KO systems in a non-
infectious DCova immunization model. The key findings were: 1) At increased PF, CD4+ T cell 
help and its CD40L but not IL-2 signal become dispensable for primary CTL responses; and 2) 
even at higher PF, memory CTL responses, perhaps both survival and functionalities require 
CD4+ T cell signals, largely in the form of IL-2 and CD40L. Strikingly, CD4+ T cell-independent 
primary CTL responses last of longer period. This phenomenon could be exploited in enhancing 
therapeutic efficacy of DC immunization protocols, which at present particularly failing in the 
treatment of cancers due to tumor-induced tolerance (26). Thus, these results could impact the 
development of immunotherapies for cancers, chronic diseases and autoimmune disorders, 
whose pathogenesis is determined in part by CD4+ T cell helper signals and altered CD8+ T cell 
PF. Previously, Marzo et al. reported that higher PF controls memory lineage development in 
infectious models, favoring the generation of the inter-convertible TCM vs TEM cells (27). In line 
with these results, the work of Chapter 2 also showed that DC-stimulated Th with acquired Ag-
presenting machineries can stimulate naïve CD8+ T cells, which in turn prone to become TCM (1, 
28), possibly explaining why skewing of TCM generation occurs at higher-PF. Although these are 
possible speculations, future works should focus on understanding how Th-APC modulates TCM 
generation under physiological conditions.   
Having studied CD4+ and CD8+ T cell interactions in depth, the work in Chapter 5 was 
primarily focused at understanding CMI responses in the context of AdV immunization 
 196
protocols. Due to their exceptional ability to induce higher and sustained levels of transgene 
product-specific CD8+ CTL responses (29, 30), Currently, AdV vectors are at the forefront of 
vaccine development against cancers and chronic diseases, such as HIV infection, where 
humoral immune response was shown to be less effective. However, how CD8+ CTL responses 
are modulated by CD4+ T cells is currently less defined area although such an understanding is 
very critical for successful designation of AdV vaccines. Hence, here an adoptive transfer system 
was undertaken in WT and CD4-deficient Iab-/-mice, and various KO and transgenic mice were 
exploited to investigate the CD4+ T helper requirements for CTL responses. The key findings 
were: 1) without CD4+ T help, both primary and memory responses were greatly reduced; 2) the 
transfer of Ag-specific CD4+ T cells to CD4+ T-deficient mice considerably restored primary and 
memory survival and recall responses, and such help was specifically mediated through CD4+ T 
cell-derived IL-2 and CD40L signaling; 3) adoptive transfer of helped or unhelped effector or 
memory CTLs to naïve CD4+ T-deficient mice revealed the additional role of polyclonal CD4+ 
T-environment for AdV-specific CTL survival, partially explaining protracted CTL contraction 
phase; and finally 4) during recall phase, CD4+ T-environment, particularly with memory CD4+ 
T cells, greatly enhanced not only helped, but also unhelped, memory CTL expansion. In 
contrast to other infectious and noninfectious models, the present study in AdVova immunization 
model demonstrated the participation of both cognate CD4+ T cells during priming and 
polyclonal CD4+ T cells during maintenance phase. A similar synergistic response was also 
observed in DC immunization model (data not shown). Whether such CD4+ T cell’s requirement 
occurs synergistically in other disease conditions, such as cancers and intracellular infections, 
needs further investigation. Collectively, these results provided new dimension to our knowledge 
on CD4+ T helper cells as an important modulators of cellular immunity in AdV vaccination 
procedures, and could partially explain certain failures in AdV-based immunization trials against 
cancers, and chronic diseases that are often associated with reduced CD4+ T cell functions. 
Furthermore, these results warrant the development of novel modified AdV vaccines having 
ability to induce CD4+ T cell-independent CTL responses.  
Conclusions  
Despite technological advances, including flow cytometry, knockout and transgenic mice, 
gene arrays, pMHC tetramer reagents and two-photon microscopy, our knowledge on cellular 
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and molecular mechanisms behind CD8+ CTL responses only began to be understood in the last 
few decades. The requirements of CD4+ T cells and molecular mechanisms for optimal CTL 
responses have puzzled immunologists for years. In the present thesis work, a sincere approach 
was followed to delineate the critical roles of CD4+ Th cells in different stages of CTL responses 
and anti-tumor immunity using advanced technologies. The results presented here will 
significantly advance our current understanding of immunity to cancers, autoimmunity and 
chronic infections since pathogenesis of these diseases is largely determined by CD4+ T helper 
functions. As most immunization procedures use the principle that is based on functions of 
memory T cells, the knowledge gained from this work will also have a major impact on 
designing vaccines against intractable diseases, including cancers and chronic infections such as 
hepatitis and AIDS. Moreover, in advanced tumors, vaccines developed using this knowledge 
may act synergistically with other cancer treatments such as irradiation, chemotherapy and 
microsurgery, minimizing their side effects and prolonging the lives of patients. 
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